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ABSTRACT 
INTEGRATING MEAL AND EXERCISE INTO PERSONALIZED GLUCOREGULATION 
MODELS: METABOLIC DYNAMICS AND DIABETIC ATHLETES 
 
 
Sofie W. Schunk, B.S. 
 
Marquette University, 2015 
 
 
 Diabetes affects nearly 26 million Americans, according to the American 
Diabetes Association, with as many as three million Americans who have Type 1 
Diabetes (ADA, 2015). Type 1 Diabetes (T1D) is autoimmune and characterized by 
little to no insulin production whereas Type 2 Diabetes (T2D) concerns insulin 
resistance and inability to use produced insulin. Factors contributing to current 
diabetes management and regulation include exercise type, daily movement 
activities, and distinct tissue compartment metabolism, each challenging to model in 
a robust and comprehensive manner. Past models are highly limited in regard to 
exercise and varying glucose fluctuations dependent on type, intensity, and 
duration. Modeling could greatly enhance factors that contribute to diabetes 
management—currently, T1D is managed with a pump and/or injections, informed 
by constant blood glucose monitoring.  
This thesis addresses knowledge gaps in the management and etiology of 
diabetes through development of a novel dynamic mathematical model informing 
controller design and implementation (artificial pancreas, continuous glucose 
monitors, and pumps). Diet and meal content on the basis of varying glycemic index 
and on the effects of activity and exercise, with lifestyle habit implications are a 
main focus.  Emphasis is placed on model personalization with a T1D athlete 
example. The following model and case study implement specific aims: 
 10th order model designed in Matlab with 4 interrelated sub-models to 
integrate meal diversity, exercise activities, and personalized body composition. 
o 3-State Glucose Compartmental Model 
o 2-State Control Mechanisms: Insulin and Glucagon 
o 2-State Digestion Model 
o 2-State Exogenous Insulin Control 
o Skeletal Muscle Model with Mitochondrial State 
o Nonlinear relations including Hill Functions 
    A 2 Phase Case Study, IRB approved for a Type 1 athletic 23-year-old 
female to evaluate and develop the model.  
Results illustrate effects of meal type (slow vs. fast glycemic index) and 
exercise/activity based glucose-glycogen consumption on blood plasma glucose 
predictions and hormonal control action for both non-diabetic and diabetic model 
versions. Current challenges are addressed with model personalization, providing 
input flexibility for body mass, muscle ratio, stress, and types of diabetes (T1D, T2D) 
informing artificial pancreas design and possible sports performance applications.
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GLOSSARY 
 
 
AP, Artificial Pancreas 
AT, Anaerobic Threshold 
BG, Blood Glucose 
bpm, Beats Per Minute 
CGM, Continuous Glucose Monitor 
CHO, Carbohydrate 
Cgm, Glucagon Control Parameter, Muscle Tissue Gain, scaled to pg/dl (Cgb in code) 
Cgnm, Glucagon Control Parameter, Non-Muscle Tissue Gain, scaled to pg/dl (Cga) 
Cinm, Insulin Control Parameter, Non-Muscle Tissue Gain (Cia in code) 
Cim, Insulin Control Parameter, Muscle Tissue Gain (Cib in code) 
ECF, Extracellular Fluid 
FFA, Free Fatty Acid 
GI, Glycemic Index 
GLC, Glucagon 
GLUT2, Non-Muscle Glucose Transporter 
GLUT4, Muscle Glucose Transporter 
Gefff, Non-Linear Hill Controller for Rate of xd entering xg (Gabs  in code) 
Geffs, Non-Linear Hill Controller for Rate of xds entering xd path (Gslow in code) 
Gexer, Blood Glucose Loss with Muscle Demand Gradient (Gmgrad in code) 
Gex-Total, Total Aerobic Exercise Glucose Consumption (kcal/hr) 
Gmetm, Basal Metabolic Elimination Rate to Muscle Tissue, Scaled by wm (g/hr) 
Gmetnm, Basal Metabolic Elimination Rate to Non-Muscle Tissue, Scaled by wnm (g/hr) 
HR, Heart Rate (bpm), inputted as u5 
kgreft, Reference Threshold for BG for Non-Muscle Flux Direction (mg/dl) 
IMTG, Intramuscular Triglyceride  
kfast, Meal GI Parameter (Scale of 0-100) 
ks-ds, Half-Way Value for Hill Control, Slow Digestive Pathway (Rising) 
rattype1i, Ratio of T1D (Decimal Percent, Remaining Insulin Production) 
rattype1g, Ratio of T1D (Decimal Percent, Remaining Glucagon Production) 
RER, Respiratory Exchange Ratio 
T1D, Type 1 Diabetes 
T2D, Type 2 Diabetes 
u1fast, Input Representing Fast Absorbing Carbohydrate Path, in kcal/hr 
u1slow, Input Representing Slow Absorbing Carbohydrate Path, in kcal/hr 
u2, Input Representing Insulin Injection 
u3, Input Representing Aerobic Exercise (same as uexer), in kcal/hr 
u4, Input Representing Anaerobic Exercise (same as udaily), in kcal/hr 
u5, Input Representing External Heart Rate Data, in bpm 
ucarb, Input Representing Proportion of Carbohydrate (fraccarb in code)  
udaily, Input Representing Daily Activity (same as u4), in kcal/hr 
uexer, Input Representing Aerobic Exercise (same as u3), in kcal/hr 
ufast, Input Representing Fast Carbohydrate (u1fast in code), in kcal/hr 
uinj, Input Representing Insulin Injection (same as u2) 
xi 
 
 
 
uslow, Input Representing Slow Carbohydrate (u1slow in code), in kcal/hr  
uHM, Input Representing Hormonal Action as a Stress Ratio (stressor parameter)  
VO2max, Maximal Aerobic Capacity  
wbm, Scaling  Parameter of BG to Glucose Muscle Tissue (wratm in code) [g/kg muscle] 
wbt, Scaling Parameter of BG to Glucose Non-Muscle Tissue (wratt in code) [g/kg] 
wm, Muscle Mass (kg) 
wmito, Mitochondrial Mass, as a Ratio of Muscle Mass (ratmito) (kg) 
wnm, Non-Muscle Mass (kg) 
xd, State Representing Glucose Digestive Forward Flow Final Path (g/hr) 
xds, State Representing Low Glycemic Index (Slow) Forward Glucose Path (g/hr) 
xg, State Representing Blood Glucose (mg/dl) 
ẋg, State Representing Blood Glucose Derivative (mg/dl) 
xgn, State Representing Endogenous Glucagon Control Action in Blood Plasma (pg/dl) 
xi, State Representing Endogenous Insulin Control Action in Blood Plasma (mU/dl) 
xinj-nm, State Representing Exogenous Insulin Delivery: Non-Monomeric (mU/hr) 
xinj-m, State Representing Exogenous Insulin Delivery: Monomeric (mU/hr) 
xm, State Representing Muscle Tissue (g/kg) 
xmito, State Representing Mitochondria (g/kg) 
xnm, State Representing Non-Muscle Tissue (g/kg) 
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1. INTRODUCTION 
 
 
It can be argued that glucose, in its many forms, is the most important 
substrate in the body, providing energy for human organ functions and all 
processes. Hence, a thorough mechanistic and quantitative understanding of blood 
glucose (BG) regulation would help provide insight into those factors that 
contribute to diabetes. Further, predictive modeling algorithms can predict BG 
effects of various lifestyles. Clinicians and diabetes educators need to be able to 
quantitatively explain effects of diet choice, athletics, and activity level—currently, 
as seen with many diabetic patients, it is trial and error as to controlling influences 
of lifestyle factors. Factors include exercise variants, daily movement activities, 
tissue compartment metabolism, level of athleticism, and meal type distinction and 
diet habits. Models could aide in predicting athletic performance for all individuals, 
not just those with disease and/or diabetes.  There is a need for a robust and 
comprehensive lifestyle model, as current models reviewed throughout Chapter 2 
are limited, or fail to recognize the importance of, modeling all influential factors.   
A novel nonlinear 10-state lumped compartmental model is presented in 
Chapter 3 that aims to address these challenges, and is designed to provide 
flexibility for variable body mass, muscle ratio, mitochondrial volume, body 
composition, metabolism and Type 1 and Type 2 diabetes. The model is intended for 
both research and clinical use, particularly diabetes educators, and to inform 
delivery design of current artificial pancreas mechanisms, as well as develop 
continuous glucose monitor (CGM) feedback and prediction based on current 
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activity and/or diet. It is motivated by the concept that a diabetic should be able to 
manage BG with exercise, diet, and dual-hormonal control based on algorithm 
feedback of a personalized model, similar to that of machine learning mechanisms.  
Chapter 4, which takes an important step towards extending the general BG 
regulation model of Chapter 3 to a new personalized version, particularly for trained 
athletes with Type 1 diabetes. Chapter 3 remains innovative in regard to digestive 
and non-muscle/muscle compartmental storage dynamics. 
Chapter 4 is innovative in creating a multidisciplinary model of mass and 
energy flow dynamics (common to mechanical engineering mechanisms) of the 
novel glucose model combined with concepts of exercise physiology. When daily 
choices become habitual, a lifestyle body type is present—for example, one could be 
athletic, lean, overweight, inactive, or active.  Exercise physiologists are able to 
quantify metabolic differences in basal metabolism properties of various body 
types, which could inform a personalized model. Chapter 4 uses an athletic Type 1 
female as an example for future adaptive modeling and device learning mechanisms. 
Mechanisms involve an additional state to enhance skeletal muscle dynamics in the 
form of mitochondrial consumption. Additionally, a stressor parameter and input 
associated with elevated intensity and exercise stress allows for improvement for 
certain types of exercise modeling, such as high intensity interval training (circuits) 
or sprints. 
Future directions and applications for clinical use are found in Chapter 5. The 
ultimate goal is to better inform clinicians to educate people with diabetes 
appropriately in regard to glucose regulation on the basis of lifestyle choices that 
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may become habitual. This is possible with better understanding of lifestyle types in 
hope that a library of personalized adaptive models can be created. It is intended 
that current device technologies will become robust in that each can ‘learn’ its user 
to eliminate guesswork of bolus corrections, often used for appearance of hypo- and 
hyperglycemia. Such models can inform CGM ‘trends,’ or inform a patient where 
their BG is headed, based on causation effects of lifestyle inputs. A particular user 
profile, if robust, could drive overall trends and baselines with instantaneous inputs 
(i.e. meal GI, stress, and/or exercise) affecting immediate BG.  
 
2. BACKGROUND  
 
2.1 Overview of Disease 
 
 
 Tight regulation of BG is required for adequate metabolic function in 
humans. Common target BG ranges have included a tight range of 80-120 mg/dl that 
is ideal for organ performance and brain function, requiring ~130 g/day of glucose 
(ADA and National Academy of Sciences, 2005). A high BG, or hyperglycemia, results 
in long-term complications and defines the concept of diabetes: elevated fasting BG 
levels.  On the other hand, hypoglycemia, or low BG <60 mg/dl, can occur in all 
individuals with lack of carbohydrate intake and/or exercise, but is especially 
dangerous for people with diabetes relying on exogenous sources. Glucoregulation 
modeling allows for concise predictive BG algorithms, based on controller design 
and an understanding of human physiologic pathways and hormonal control. A 
broader ‘acceptable’ glucose range of 70-180 mg/dl is suggested for modeling 
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because of undesirable side effects of too tightly regulating BG, especially for active 
people with diabetes and minimal model based insulin devices that fail to recognize 
that increased insulin sensitivity and glucose consumption are dependent on 
activity type (Macdonald, 1987 and McDonald, 2013). Non-diabetic comparisons of 
BG response can help inform proper control via insulin and/or other solutions for 
BG control: exercise, diet, and other lifestyle activities. The imperative need for 
regulation is best explained by lack of regulation as common to those with a 
disability, such as Type 1 or Type 2 Diabetes. 
2.1.1 Type 1 and Type 2 Diabetes 
 
 
 In the process of medical device development, particularly those that replace 
(either partially or completely) a lost biological function, it is imperative to 
understand the physiology behind control mechanisms involved and the underlying 
cause. According to the American Diabetes Association (ADA), Diabetes affects about 
9.3% (29.1 million) of the U.S. population in 2012 and is on the rise; however, it is 
important to note that only 5% of the 9.3% (1.25 million Americans) have Type 1 
diabetes (T1D). People with Type 1 diabetes fail to produce insulin, or at a reduced 
amount. People with Type 2 diabetes (T2D) produce insulin (usually in excess) but 
do not use insulin properly, or have developed insulin resistance. Other key 
differences in regard to model purposes include reduced glucagon action in T1D, 
body weight differences (T2D particularly), and resting basal insulin, blood, and 
tissue glucose levels. Treatment includes continuous monitoring and insulin 
administration and/or pills to prevent long-term health complications such as skin 
5 
 
 
 
and eye degeneration, neuropathy, ketosis, and foot complications and short-term 
hypo- and hyperglycemia.  
 
2.2 Historical Literature Review: Response Data and Older Models 
 
 
Many models focus on varying aspects of blood plasma glucose regulation. 
Typically BG concentration is the main dynamic model compartment, with models 
ranging from very simple (2 total compartments) to complex. All have their 
advantages and disadvantages, but from the present perspective, lack some key 
states and processes.  This section reviews past modeling strategies, and provides a 
context for the proposed improvements, as such models help address knowledge 
gaps in the etiology of people with Type 1 and Type 2 diabetes, often informing 
controller design. Table 2.1 outlines current BG regulation models as an 
evolutionary process.  
One of the most cited original models, focusing on simplification, results from a 
classic 3-state “Bergman minimal model” with two states including insulin dynamics 
and glucose (Bergman, 1981). Bergman quantified insulin sensitivity with 3 
compartments representing plasma insulin, remote insulin and plasma glucose 
concentrations. The model focuses on the insulin-dependent patient, assuming all 
insulin is infused exogenously and then promotes uptake of plasma glucose into the 
hepatic (liver) and periphery tissues, using the form of ordinary differential 
equations, multiplicative states, and about 7 known parameters. Extensions of the 
Bergman minimal model include a minimal exercise model adding a critical 
threshold value (on the basis of VO2max) that drives hepatic glucose production 
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and glycogenolysis during exercise characterized by intensity and duration (Roy, 
2007). These changes are reflected with added terms of the plasma glucose equation 
of the Bergman minimal model. Further, in a review of various differential equation 
approaches, Makroglou et al. (2006) presents delay modeling approaches including 
those by Sturis et al. (1991), integro-differential equations, and partial differential 
equations (Makroglou, 2006). The integro-differential equation approach is key for 
modeling intravenous glucose tolerance test dynamics after recognizing the widely 
used minimal model is improper in qualitative behavior, as the base parameter is 
equal to the basal glucose level. A more realistic delay and dynamic model is needed, 
recognized by many (i.e. Li, 2001 or Mukhopadhyay, 2004) and can also be 
improved with Hill Kinetics, particularly Michaelis-Menten, as used in the Chapter 3 
model structure of this thesis (Gesztelyi, 2012). These additions will address 
fundamental limitations with added states to further insulin dynamics and the 
particular need to recognized delays and oscillations (Makroglou, 2006).   
Core compartmental improvements to Bergman’s model (other than diet and 
exercise) include a 5-state model adding insulin (in liver) and added glucagon states 
(Sorensen, 1985 and Northrop, 2000). Sorenson, as an integral part of a chemical 
engineering Ph.D. dissertation, implemented a mass balance model taking into 
account blood flow, compartmental exchange (with a focus on organs), and 
metabolic processes adding and removing glucose, insulin, and glucagon of a 70 kg 
non-diabetic individual. Clinical studies informed model parameters and estimation 
curves, partially shown Figure 2.1a-b below. Key insights include the modeling of 
glucagon in the form of an ordinary differential equation (ODE) with 
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characterization as a result of an extensive series of rat studies. In addition to 
Sorenson, Northrop also proposed a model for glucoregulation in an Introduction to 
Complexity and Complex Systems (Northrop, 2011). This nonlinear model does not 
address exercise, but has a main focus of various hormonal factors, such as Leptin, 
insulin, and glucagon (GLC). GLC production is modeled as a simple, first-order loss 
kinetics with a static, nonlinear function providing the GLC rate input to the GLC loss 
dynamics ODE. The mathematical modeling of the three main sources of glucose 
(diet, gluconeogenesis, and the breakdown of stored liver and muscle glycogen to 
glucose) is a strong point of this model. Northrop, 2011, particularly focuses on 
hormone kinetics, separating cells into insulin-sensitive and non-insulin sensitive 
(see Figure 2.1c-d), with hepatic glucose flux that depends on insulin, GLC, leptin 
and other regulatory hormones, not only BG. However, it fails to decipher between 
types of glucose input, which will be a focus of the Chapter 3 model in addition to 
modeling complexities in a simplified manner. These glucagon models are compared 
to and validate the Schunk-Winters glucagon model in Section 3.5.3. 
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Figure 2.1: Sorenson (1985) and Northrop (2000) Blood Glucose Regulation Block Diagrams 
and Glucagon Plots. Upper Plots (a,b): Adapted from Sorenson (1985) blood glucose regulation 
model (left) and associated plot of normalized rate of glucagon release as a function of normal 
arterial glucose concentration (right). Lower Plots: From Northrop (2000) blood glucose regulation 
block diagram model (left) with glucose loss rates in urine, into insulin-sensitive cells, into non-
insulin-sensitive cells, and a hepatic glucose flux that depends on hormones insulin, glucagon, and 
leptin.  Normalized glucagon secretion as a function of steady-state plasma glucose concentration is 
shown on the right with half-life of glucagon is 10 minutes.   
 
 
Higher-order models were developed that similarly utilized Bergman mass-
flow relations but instead utilized logistic complexities and Bernoulli-Langevin 
expressions for hepatic glucose production and characterizing exogenous insulin 
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profiles and delays, respectively (Neelakanta, 2006 and Sankaranarayanan, 2012).   
Neelakanta et al., 2006, clinically validates hepatic glucose production on the basis 
of plasma glucose and hepatic insulin concentration. A University of Colorado group 
added and characterized insulin infusion profiles under necessity to characterize 
infusion risks (Sankaranarayanan, 2012). A variety of potential hypoglycemic 
scenario events were modeled including taking an excessive amount of insulin or 
taking a bolus too early in regard to glucose ingestion (also, miscalculation of CHO 
content or GI considerations). Potential hyperglycemic scenarios tested included 
meal-bolus discrepancy and discrepancy between a meal’s predicted GI and actual 
GI (i.e. higher than expected). It was concluded that planned meal times vs. actual 
meal times indicated the highest risk for hypoglycemia, when patient’s seemed to 
take a bolus far in advance of actually consuming foodstuff. This ideology that 
insulin must be taken sufficiently in advance of a meal (15 minutes suggested by 
clinicians, but should vary with GI) indicates an insulin absorption delay. Li and 
colleagues, 2006, denote two explicit time delays: insulin secretion from beta cells 
as a series of complex processes including inherent delays of GLUT2, potassium 
channels, etc. on the range of 5-15 min and a time lag of the effect of hepatic glucose 
production with a magnitude of half-maximal suppression between 11 to 22 
minutes and half-maximal recovery between 54 to 119 minutes (Li, 2006). Perhaps 
more importantly are the sigmoidal shapes of associated functions, f1-f4, informed 
by literature and similar to nonlinearities present in the Schunk-Winters model. 
These shapes are shown in Figure 2.2 below. 
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Figure 2.2: Li (2006) Function Shapes. Function shapes of respected states are plotted against BG 
concentration indicated by f1: insulin production simulated by glucose concentration, f2: insulin-
dependent glucose consumers, dependent on BG alone, f4: insulin-dependent glucose uptake, and f5: 
glucose production controlled by insulin concentration (from Li, 2006).  
 
 
Time delays are found amongst many of the other models as well, not only in 
regards to insulin action and injections, but with digestive absorption and energy 
and mass conservation pathways and will be discussed in Sections 2.3.1 and 2.3.2. 
Most models idealize diet as a single glucose input source, ignoring the 
‘quality’ of carbohydrates.  Once filtered through the digestive system, there is a rate 
of appearance of glucose into the bloodstream.  Newer models utilize 2-3 states to 
capture this digestive process, but fail to distinguish between carbohydrate type and 
varying absorption rates (Dalla Man, 2014, and Hernandez-Ordonez, 2008). Leading 
up, in 2007, Cobelli and colleagues developed an advanced 12-state model for 
studying the effects of carbohydrates (meal) an extension approved by the FDA as a 
preclinical trial tool for controller design used extensively (Cobelli, 2009 and 
Kotachev, 2010).  More recently, the addition of glucagon control action resulted in a 
16th-order model with 7 additional parameters (Dalla Man, 2014). The model 
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implements simulations representing a diversity of “virtual” users.  This work 
evolved into a FDA approved simulator for evaluating controllers for T1D 
management (Kotachev, 2010 and Dalla Man, 2014). One significant limitation is 
that it is still intended for a single meal implemented as a bolus dose of 
carbohydrates.   
The transient dynamics of glucose appearance is strongly influenced by 
foodstuff composition, with measures such as glycemic index (GI) to document the 
reality of peak glucose influx ranging from minutes to hours after ingestion (Monro, 
2008).  Low glycemic foodstuff results in a slower breakdown (less of the “sugar 
high” spike in BG). The  “sugar high” idea is long-standing and is characterized as a 
strong blood insulin influx in response to high glycemic foods, triggering a sudden 
“crash” in BG owing to increased flux into tissues for storage (mostly in liver and 
muscle and adipose) and via energy conversion pathways into fats (Jenkins, 1981, 
Wolfe, 1998, and Walsh, 2014). Only one group (Yamamoto, 2014) addressed the 
need for deciphering between a food’s GI, which is well known to effect the rate at 
which foodstuff is absorbed (Mohammed, 2004). In modeling meal absorption, 
Yamomoto (2014) addresses glycemic index and associated insulin effect based on 
replicated literature curves. A state-space representation form is used for the 
carbohydrate metabolism subsystem, which distinguishes between rapidly 
absorbing glucose (RAG) and slowly absorbing glucose (SAG). It is determined that 
95% of RAG is absorbed within 20 minutes, with SAG between 20-120 minutes. 
Therefore, SAG utilizes a 20-minute time delay, with a time constant of about 21 
minutes (vs. 4.2 for RAG). There is also a first-order gastric emptying delay related 
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to the time required to pass from the stomach to the duodenum.  However, this 
particular model is limited in its other ‘lifestyle’ inputs such as exercise and utilizes 
only the Bergman minimal insulin model for subcutaneous insulin (Bergman, 1981 
and Shimoda, 1997). Figure 2.3 below shows the comparison to ‘staple’ foods with 
known glycemic index values—the glucose-equivalent value takes into account fiber 
content and the known glucose relative (GR) function, with white bread as the 
reference food and expressed as a percentage with respect to 50 grams of glucose. 
This is important for simulation, as 50 grams of each staple food was used. 
 
 
 
Figure 2.3: Yamamoto (2014) Meal Simulation Model with Insulin.  Left: Simulation of four 
staple foods with the proposed model compared to clinical data from Mohammed et al., 2004 
(Yamamoto, 2014). Right: Simulation of subcutaneous insulin effect, as compared to clinical data 
used for Bergman model verification purposes (Yamamoto, 2014). 
 
 
Neelakanta et al., 2006, used early Cobelli theoretical formulations and 
clinical data to form simulated results based on the modified and adapted complex 
systems approach outlined in their model (Neelakanta, 2006 and Cobelli, 1985). The 
main focus of this model is on hormonal controllers, specifically insulin and 
glucagon, to indicate statistical bounds on BG concentration and the rate of 
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appearance of glucose in the blood plasma (Neelakanta, 2006). The improvements 
by Cobelli’s group are implemented in a simulation model of the glucose-insulin 
system in normal life conditions for use in diabetes research (Dalla Man, 2007 and 
Cobelli, 2009). The general model consists of 12-13 states, with an emphasis on 
compartmental insulin kinetics and uni-directional glucose stomach states 
implemented in MatLab and Simulink. Advantages of the Cobelli model include 
accurate experimental parameter values and the use of Hill kinetics, introducing a 
realistic non-linearity approach of parameters and states.  
Exercise as an input to the models is only recent and has been kept as a 
simple and single input. In fact, 3 different exercise models were proposed and 
implemented in silico (Cobelli, 2009). This 2009 version by the Cobelli group 
implemented three additional ‘test’ inputs for exercise, outlined in Models A-C. 
Model A assumed that exercise causes a rapid on-and-off increase in insulin-
independent glucose clearance and a rapid-on/slow-off effect on insulin sensitivity. 
Model B relaxes the assumption that exercise causes a rapid on-and-off increase in 
insulin-independent glucose clearance. Model C is similar to model A, but also 
assumes that insulin action is increased in proportion to the duration and intensity 
of exercise. It was determined, in assessment of quality of each prediction model, 
that Models A and B predict different levels of exercise (based on heart rate) have 
the same effect on glucose utilization and Model C predicts a reasonable glucose 
infusion rate during euglycemic-hyperinsulinemic clamp simulations for both mild 
and moderate exercise. However, other literature suggests that exercise intensity, or 
different levels of exercise, does in fact have implications on glucose utilization and 
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therefore Models A and B are limited compared to the Schunk-Winters exercise 
model (i.e. Brooks, 1994). Heart rate (HR) is also debatable as an accurate measure 
of exercise level, as HR tends to fluctuate with other factors and is intrinsic to an 
individual. Hence, most exercise physiologists use factors such as percent of aerobic 
capacity. That being said, HR can be an accurate predictor if an anaerobic threshold 
and/or VO2max stress test has been performed and correlations between HR and 
particular training zones have been determined. It can help better inform exercise 
activity level and effort, as well as stress. This is further discussed in Chapter 4.  
Perhaps the first model to successfully demonstrate the importance to model 
exercise, as a function of working tissue uptake, plasma insulin, and hepatic glucose 
release, was Roy (2007). However, the model is limited in that hepatic production is 
the only additional means by which glucose is available with exercise and the insulin 
model is minimal. Hernandez-Ordonez (2007) furthered exercise model validation 
at low and moderate intensities and the redistribution of blood flow but do not seem 
to address the effect of meals and/or varying metabolic properties of individuals. 
Duun-Henrikson (2013) used a linear, three-compartment insulin model and simply 
varied absorption rate as a function of exercise intensity and duration.  
In 2013, a group associated with Cobelli and colleagues modified the in silico 
2009 Padova type 1 simulator (Cobelli, 2009) to incorporate the effect of physical 
activity after demonstrating a doubling of insulin activity (Schiavon, 2013). Subjects 
were allocated into two groups: one in the absence of and one with different degrees 
of reductions and durations of basal insulin infusion rates—it was shown that an 
effective strategy is to reduce basal insulin by 50% 90 minutes prior to exercise and 
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30% during exercise to avoid hypoglycemia. However, this is not possible in regard 
to current artificial pancreas design, and exercise type and intensity are not 
accounted for, both of which my further adjust what changes need to be made in 
insulin dosing before, during, and after exercise. This will be a partial focus of 
Chapter 4, after exercise and the metabolic properties associated with muscle 
demand are modeled and able to predict proper BG control.   
        Originally, a 4th/5th classroom model formed by Dr. Jack Winters for a biocontrol 
systems course (BIEN 3301) starting in 2012 forms the basis of the 9th/10th  order 
Schunk-Winters model proposed in this thesis. The original model contains 4-5 
states, and included breaking tissue into separate muscle and non-muscle 
compartments, the typical BG compartment, a simple 1st-order stomach glucose 
filter, an insulin state viewed as a controller, and an optional 5th state for 1st-order 
dynamics for exogenous insulin delivery (could be external for people with 
diabetes). Advantages of this model include, but are not limited to, a basic 
component for sensitivity to exercise via a glucose input sink, which acts as a 
forefront for future modeling. This model is successful in modeling the severe 
effects that are common to most people with diabetes; distinct parameter changes 
are used to separately model Type 1 and Type 2 diabetes. Disadvantages included 
lack of non-insulin control and other key hormonal regulators of BG including 
glucagon, GLUT4 and GLUT2. Exercise is also limited to a subjective intensity scale. 
Meals are limited to only magnitude and duration as input parameters.  
 In summary, models tend to move from utilizing simplified compartment 
‘minimal models,’ such as Sorensen (1978) focusing on nonlinear organ glucose 
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demand and Bergman (1981), the first base compartmental insulin model, to those 
that exist as a system, or multiple states involving dual-control and/or separate 
volume-based compartments with varying metabolic properties. Wilinska (2005) 
performed an extensive study evaluating and validating insulin models, including 
acceptable linear models (Shimoda, 1997), more complex and nonlinear 
compartmental models (Hovorka, 2004), and those using Michaelis-Menten kinetics 
which form a strong core componentry of the Chapter 3 and 4 insulin compartment 
structure. Many of these are shown in Table 2.1. Other models focus on the effect of 
metabolic variations and compartment loss/fluxes due to temperature, thyroid 
hormones, urine loss, and mechanical workload (Northrop, 2000).  
 The Schunk-Winters model addresses significant knowledge gaps in terms of 
digestive absorption pathways and exercise characterization, which are limited in 
most models above (e.g., Cobelli, 2009, Dalla Man, 2014, Yamamoto, 2014, and Roy, 
2007).
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Table 2.1: Evolutionary Summary of Glucoregulation Models (NL = Nonlinear, L = Linear) 
Source Model Structure Strengths Limitations Relevance 
Cobelli Group 
Cobelli et al, 
1985 
 5 State  
 Glucose Subsystem (first order): 
production and utilization (L) 
 Glucagon Subsystem (first order): 
secretion, distribution and 
metabolism(NL-rate) 
 Insulin Subsystem (3rd order): 
distribution and metabolism of portal 
and peripheral infusion by input to 
liver and plasma compartments (NL) 
 Dynamic model of the 
glucose regulation system 
enabled minimal insulin 
profile with peripheral 
insulin infusion to be 
computed.  
 Not adaptable to all types of 
normal and diabetic 
subjects.  
 Meal input is limited to 
single carbohydrate source 
as digestive dynamics lack.  
 Provides basis for 
minimal insulin 
model and Cobelli 
group development. 
Dalla Man et al, 
May 2007 
 12 State 
 Glucose Subsystem: insulin-
independent utilization and insulin-
dependent utilization 
 Insulin Subsystem: liver and plasma 
 Stomach: solid phases, and gut 
 Adipose and Muscle (NL) 
 Glucose-Insulin model 
graphical interface 
 Insulin control at 
organ/tissue and whole 
body levels 
 Type 1 and Type 2 
Recognition 
 Does not account for 
varying metabolic 
properties across tissues 
 Meal input limited to simple 
carbohydrates.  
 No input for 
exercise/activity 
 Matlab/Simulink 
simulation parameters 
and graphs for a 
normal, type 2, type 1 
subject  
 Meal input and both 
open and closed loop 
controls available. 
Dalla Man et al, 
October 2007 
 16th Order adding digestive dynamics 
(ingestion and absorption) based on 
concentration and flux 
 Same compartments as Dalla Man, 
May 2009, with 36 parameters 
(normal and type 2) 
 Meals into quasi-model sub-
systems: Glucose, Insulin, 
Muscle and Adipose, Gastro-
Intestinal 
 Mixed Meal 
 
 Not performed for Type 1; 
only Type 2, normal 
 Muscle and Adipose Tissue 
are in one compartment 
 Stress hormone/ glucagon 
not considered 
 
 Rate of appearance 
parameters are similar 
and provides rate of 
appearance and 
production graphs for 
comparison. 
Dalla Man et al, 
2009 
 Utilizes 16th order (2007) model at 
rest 
 Exercise dynamics: 8 parameters, key 
being hepatic glucose effectiveness 
and hepatic insulin sensitivity 
 Addition of physical activity 
via 3 models in steady and 
non-steady (after a meal) 
state 
 
 Only short term exercise 
and do not properly 
characterize intensity 
 
Some useful exercise 
parameters on the basis 
of heart rate are 
provided; comparative 
curves (validation 
lacking) 
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Kovatchev et 
al, 2009 
 Computer simulation environment: 
glucose-insulin model (Cobelli et al, 
2009), In Silico  Sensor, In Silico 
Insulin Pump, Controller 
 In silico testing of control 
algorithms linking CGM and 
insulin delivery 
 
 Computer simulation only 
 Only insulin delivery 
method model is FDA 
approved  
 Insight into AP 
methods and 
comparative graphs 
provided for 24-hour 
plus simulations. 
Kovatchev et 
al, 2010 
 Testing of model-predictive control 
(MPC) algorithm in conjunction with 
CGM for 300 virtual subjects 
 Closed and Open Loop control 
comparison 
 Extended 2009 in silico 
testing to include closed-
loop control (better 
regulates at night) 
 Improved accuracy 
 Only focus on type 1 
diabetes 
 Useful parameters 
and comparative 
graphs provided, 
especially using CGM 
data 
Dalla Man et al, 
2014 
 New additions from 2007 Model 
(2009 Simulator): counterregulation 
updates (liver, muscle, and adipose 
tissue), new alpha cell and glucagon 
kinetics and delivery (3 additional 
compartments) (NL) 
 Addition of glucagon 
 New rules for insulin to 
carbs ration and correction 
factor 
 Dual-Hormone control (vs. 
2009 version) 
 Results only show for a 
single meal and no exercise 
input capability is apparent  
Glucagon secretion and 
following glucose 
appearance kinetics 
parameters; graphs for 
comparison 
Other Models 
Sorenson, 
1978 
 Nonlinear, ~ 19 Variables 
 Additional Compartments: Brain, 
Vascular, Kidney, Renal and 
Peripheral Systems 
 Glucagon (GLC) modeled as 
ODE 
 Mass-balance modeling 
approach focusing on 
compartmental exchange 
(organs) 
 Parameters estimated from 
rat clinical trials (GLC is 
known to behave differently 
in humans) 
 
 Glucagon modeling 
insights for validation 
 Incorporates 
compartments and 
blood flow similar to 
Schunk-Winters 
Bergman, 1981  3 States, 7 parameters 
 2 Insulin Compartments: plasma and 
interstitial 
 1 Glucose Compartment: plasma and 
basal levels 
 Glucose effectiveness and 
sensitivity.  
 Basic Insulin Model  
 Minimal model  Basis of many glucose 
regulation models in 
literature.  
 Minimal model that 
can be built off of.  
Sturis et al 
(1991) 
 6 states 
 Negative feedback loops: insulin 
effect on glucose utilization and 
production and the effect of glucose 
on insulin secretion 
 Introduction of insulin 
degradation time constants 
and time delays 
 Separates liver, brain and 
nerves, muscle and fat 
 Lumps muscle and fat 
together in terms of 
delays—no way to separate 
exercise demand  
 Understand 
oscillations via delays 
in feedback loops 
 Shape delay curves 
and inform time 
constants for various 
compartments 
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Shimoda, 1997 
(from 
Wilinska, 
2005) 
 3 Compartment Insulin, Linear 
 Depot (2 compartments) and Plasma 
Insulin 
 Saturable absorption rates and 
disappearance 
 Michealis-Menten Kinetics 
similar to our model 
 Simplified  
 No adaption to outside 
influential factors 
 Minimal 
 Simplest form, with 
saturable effects 
while keeping a linear 
model; used by 
Yamamoto 
Northrop et al, 
2000 
 7 State 
 Glucose Compartment: loss urine 
(Linear) into ISCs (1st order linear) 
and NISCs (1st order Linear), hepatic 
glucose flux (hormone dependent) 
 Glucose Input from diet (bimodal, 
Linear) 
 Glucagon Production (NL-rate 
provides input to 1st order loss 
kinetics) 
 Portal Insulin (2 states, Linear and 
NL-saturated) 
 Metabolic rate constant as a 
function of temperature, 
thyroid hormone 
concentration, epinephrine 
and mechanical work load if 
the cells are muscle.  
 Separate glucose sinks into 
insulin vs. non-insulin 
sensitive cells 
 Bimodal glucose input rate 
 Validation and 
implementation 
 Limited in direct application 
to exercise 
 Hormonal importance 
in regard to non-
insulin mediated 
pathways, key during 
exercise and 
increased workload 
Hovorka et al, 
2004 
 ~11 Variables;  
 Endogenous glucose production and 
renal filtration 
 Evaluated using 15 clinical 
experiments in subjects 
with Type 1; strong glucose-
insulin sub model 
 Main focus is correcting 
during fasting conditions 
and overnight; no full day 
simulations 
Insulin model useful for 
when depletion occurs 
with comparative plots 
Li et al, 2006  Core: Two Delay Differential 
Equations for glucose 
production/utilization and insulin 
production/clearance 
 Time delays of insulin using 
mas conservation 
 Oscillation replication of 
glucose and insulin 
 Only for type 1 and lacks a 
bit on meal input dynamics 
and glucose/energy 
homeostasis understanding 
Comparative plots, 
especially regarding 
mass conservation and 
time delays 
Neelkanta et al, 
2006  
 4 Glucose Sinks: Insulin-Sensitive 
Cells (ISCs), Noninsulin-sensitive cells 
(NISCs), kidneys (urine loss), liver or 
muscle (storage) 
 Glucose Input: diet, stored 
fat/protein, glycogen 
 Insulin secretion is NL 
 Three Subsystems: 
 Glucose Subsystem: 5 NL rates 
 Insulin Subsystem: 5 quantity terms 
 Liver glucose production 
based on glucose and insulin 
concentrations  
 Mass-Flow Model 
 Validation and 
Implementation  
 Pertinent to predicting 
and quantifying the 
effect of hepatic 
gluconeogenesis based 
on current 
concentrations 
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 Glucagon Subsystem: 2 quantities, 1 
rate 
Roy et al, 2007  Take three-compartment Bergman 
model and add exercise 
 Insulin dynamics adds circulatory 
removal, 
 Glucose uptake and hepatic glucose 
production (exercise induced) added 
 Modeling exercise effects 
based on uptake of working 
tissue, plasma insulin, and 
hepatic glucose release 
 
 Do not fully understand 
hepatic glucose 
production—this is the way 
exercise effects are modeled 
via increase/decrease which 
is not the case 
 Data from literature 
 Provides insight that 
there is a need to 
model exercise 
 Experimental data 
from literature 
 
Hernandex-
Ordonez, et al, 
2007 
 23rd order nonlinear dynamical 
system 
 
 Validate low and moderate 
intensity exercise on 
existing glucose-insulin 
model; extrapolate for high 
intensity  
 Redistribution of blood flow 
with exercise 
 Meal simulation is limited 
and not addressed 
  Stress hormones and 
trained vs. untrained 
parameters not present 
Insight into glucose 
production 
segmentation: 50% 
glycogenolysis, 30% 
hepatic, and 20% renal; 
comparative plots 
 
Duun-
Henrikson et 
al, 2013 
 Linear Three-Compartment Insulin 
Model: subcutaneous layer, deep 
tissues, and plasma 
 Three-compartment 
artificial pancreas model 
 Absorption rate as a 
function of exercise 
intensity and duration 
 Need validation for insulin 
appearance during exercise 
 Only focus on normal, but 
recognize Type 1 
implications 
Combine exercise idea 
into artificial pancreas 
application 
Yamamoto et 
al, 2014 
 3 Compartments: Carbohydrate 
metabolism, subcutaneous insulin, 
glucose-insulin metabolism 
 Slowly Available Glucose: 2nd order 
delay system 
 3-Compartment (Shimoda) Insulin 
Model 
 Bergman Minimal Model 
 Model of digestion and 
absorption from 
carbohydrates based on the 
Glycemic Index 
 Do not provide exercise and 
some error in regards to 
control algorithm discussion 
and state-space equations 
Direct comparison to 
meal compartment 
model; type 1 
applications 
Sankaranaraya
nan et al, 2012 
 Integration of 3 Models 
 Meal Absorption 
 Insulin Infusion Pump 
 Insulin-Glucose Regulation Model 
(Hovorka, Cobelli, Sorensen) 
 Insulin infusion pump risks 
modeling and varying 
insulin curve shapes 
 Case-study only 
 Assume food ingested has a 
single carbohydrate source 
with fixed high GI 
Insulin infusion plots 
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2.3 Need for a Lifestyle Model  
 
2.3.1 Lifestyle Influenced Modeling: Foodstuff Consumption 
 
 
Foodstuff and varying absorption properties of foods are recognized throughout 
the nutrition community particularly in regard to glycemic index (GI). Yet, glucose 
compartmental models often have a single carbohydrate input source, with other 
mixed meal components assumed negligible in regard to BG effect (Dalla Man, 2007, 
Roy, 2007, and Kovatchev, 2010). One group does capture the kinetics behind GI, 
applying bioavailability concepts into rapidly and slowly available glucose 
(Yamamoto, 2014). Their model is implemented in a way to ‘test’ known GI foods 
and was recreated for comparison to the Schunk-Winters digestive compartment, 
outlined in the Chapter 4 case study. Clinical data is presented in regard to BG 
increment after ingestion of foods partitioned by GI and clinically prescribed insulin 
dosages—however, limitations still exist, especially in regard to starting states 
(Mohammed, 2003 and Sekigami, 2004). Similarities exist in transient response for 
varying glycemic index (i.e. blood sugar ‘spike’ for high GI vs. gradual to steady 
state) and insulin response effect—oftentimes, there is ‘overshoot’ in correction for 
low GI carbohydrate meals due to accommodation of fast insulin dynamics and time 
delay. Due to the simple fact one type of insulin is used for any CHO ingestion and 
varying digestive absorption paths, problems arise due to insulin delay and timing, 
which is investigated in Chapter 3.  
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Both models (Yamamoto, 2015, and Schunk-Winters, 2012) use a summing 
technique for the final digestive absorption state as seen in Figure 2.3 above. 
Glycemic impact curves, or “the weight of glucose inducing a glycemic response” on 
BG concentration are well documented for a variety of foods (Monro, 2008) and 
described in glucose forward flow implementation of Chapter 3 below. The 
motivation behind modeling GI ties into the need to model in conjunction with the 
subject’s other habitual lifestyle habits. For example, by experience, a T1D individual 
can actually keep one’s glucose within a target range solely by eating a low GI diet 
and exercising, although also dependent on whether or not the individual still 
produces some insulin. It was determined that lower GI foods are typically 
associated with higher fat and protein content (if overall caloric intake is kept 
consistent) and could aide in ‘tight’ BG control of the patient based on absorption 
properties (Jenkins, 1981) if known to the predictive algorithm.  
The Dalla Man/Cobelli meal simulator model is used as additional reference and 
comparison to how most models simulate diet (Dalla Man, 2007). For the purpose of 
comparison and that models (other than Schunk-Winters) only display capability 
and literature curves for a defined carbohydrate bolus, all use the same input of 50g 
carbohydrate ingestion typically with an unknown GI (other than Kotachev, 2010), 
thereby making model replication somewhat limiting. Other studies, using a similar 
bolus (~50 g carbohydrate) demonstrate significantly reduced area (i.e. lower BG 
levels) under the BG curve post-prandial after a low-glycemic meal vs. a high-
glycemic meal (Parillo, 2011). 
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2.3.2 Lifestyle Influenced Modeling:  Integrating Diet and Physical Activity 
 
 
 Diet preference and lifestyle choice can influence substrate preference and 
utilization during exercise (and also rest) due to availability. This is particularly 
keen for adaptive modeling—if an individual eats a largely low GI diet (hence, most 
likely incorporating more fat and protein), bioavailability of CHO and glycogen 
stores are most likely decreased. However, a factor of adaptability must also be 
taken into consideration as if the person is also trained, CHO oxidation is decreased 
in general and glycogen ‘sparing’ occurs. This phenomenon suggests a low GI diet 
may be sufficient to avoid hypoglycemia due to increased fat oxidation and 
mitochondrial biogenesis in adapted and trained individuals (Kiens, 1993 and 
Hurley, 1986). On the other hand, a high carbohydrate and high GI diet will increase 
insulin production (possibly decrease sensitivity) and influence BG concentration 
and uptake flux into tissues (especially non-muscle if no muscle demand exists). 
 Glucose mass flow and direction is highly dependent on varying types of 
energy and tissue demand, particularly in regards to anaerobic vs. aerobic exercise, 
as well as daily activity. Substrate for work comes from four main sources of stored 
energy: muscle glycogen, free fatty acids (intramuscular, and via triglyceride 
breakdown from mostly adipose sites), liver glycogen, and in some cases muscle 
proteins (Powers, 2014). A catalyst, pyruvate dehydrogenase (PDH) has entered the 
research field as a key catalyst for the entry of CHO and its subsequent oxidation, in 
addition to the extensively studied relationship of oxygen uptake and carbon 
dioxide production as a fuel consumption estimate (CHO vs fat) (ACSM and Powers, 
2014). Biochemically, fat requires more oxygen for oxidation (23 O2 vs 6 O2).  
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Greater activation (and hence CHO oxidation) occurs with increasing the glycolytic 
flux and rate of pyruvate production, either by increasing muscle glycogen prior to 
exercise or with higher epinephrine concentration. Similarly, myoplasm calcium 
increases muscle activation and (indirectly) carbohydrate oxidation as it is released 
from the sarcoplasmic reticulum during skeletal muscle contraction (Harmer, 2013).  
Maximal oxygen uptake and the respiratory exchange ratio aid in characterizing the 
point at which FFA vs CHO utilization turnover occurs, and can influence an 
individual’s basal metabolic parameters (Brooks, 1994). Variation in basal 
metabolic rate explicitly demonstrates another need for a personalized adaptive 
model, and in addition, it is imperative that glycolysis is understood in all forms. 
Anaerobic glycolysis represents an integral component of CHO utilization at high 
intensity contractions, yet the associated catalytic enzymes can be altered in regard 
to physiological adaptations especially in regard to trained individuals (Ohlendieck, 
2010). Aerobically, fuel oxidation assumes a mix of CHO and fat metabolism, thereby 
directly requiring understanding prior to modeling the glucose regulation system. 
Values such as Respiratory Exchange Ratio (RER) are direct measures of 
characterizing fuel utilization if maximal oxygen uptake and ventilation parameters 
are measured. An RER of 0.7 corresponds to fat oxidation while an RER of 1.0 or 
higher directly correlates glucose oxidation, particularly at high intensity exercise 
(Melzer, 2011). It appears trained individuals, or those who have underwent 
submaximal training for extended periods of time, have a lower RER and hence 
higher degree of fat utilization in addition to a higher capability to utilize muscle 
triglycerides (Boyadjiev, 2004). Other mechanisms include an increased number of 
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mitochondria and GLUT4 translocation in muscle cells, as well as increased enzyme 
activity and decreased catecholamine effect (Boyadjiev, 2004, and Holloszy, 2011).  
Effects of training are discussed further in Chapter 4.  
 Formation of dynamic insulin modeling systems and associated absorption 
properties into the tissue and/or blood has been an intensive evolutionary process, 
core to most diabetic technology systems today. There are inherent time delays 
associated with insulin type, body composition, and environment (Walsh, 2014). For 
example, if one with high body fat content were to inject insulin into the abdomen 
vs. a slim athlete injecting insulin into the leg prior to physical activity, clearly the 
athlete would absorb and utilize insulin at a much faster rate.  In fact, it is well 
documented that anything involved in increasing blood flow will increase insulin 
absorption rate, such as hot temperatures or any form of muscle activity (Walsh, 
2014). This is in addition to time delays associated with dissociation and 
monomeric vs. non-monomeric absorption properties of insulin, and, changing 
pharmacodynamics of insulin action depending on the size of bolus if above a 
certain level (Walsh, 2014). It appears that if injected in a large proportion, there is 
a saturation factor and some insulin may be lost or not fully absorbed. Both issues 
can be taken into account while modeling insulin with the use of Hill and Michaelis-
Menten kinetics—particularly if exogenous insulin is involved. In terms of modeling, 
it is proposed that the different types of insulin (injection) will take paths based 
peak timing and implemented as slower non-monomeric or faster monomeric (Li, 
2006 and Diabetes Services, Inc.). If a subject is insulin-independent, a time delay is 
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still present and may vary due to anticipatory effects (or lack of) of diet, exercise, or 
any other factor affecting BG.   
 Physical activity increases the rate at which insulin effects occur, known as 
insulin sensitivity. It originally was hypothesized, although now currently debated, 
that tissue compartments could remain hypersensitive up to 48 hours post-exercise 
(MacDonald, 2006). This is a dangerous issue in regard to late-onset hypoglycemia, 
which could occur at night when the patient is unaware. However, there are other 
mechanisms of compensation, as typically diet is increased with intense exercise, 
and insulin sensitivity becomes an adaption of trained individuals, or routine, as fat 
oxidation increases therefore sparing glucose (Befroy, 2008). Maarbjerg, 2011, and 
colleagues outline many stimuli contributing to increased insulin signaling and 
sensitivity (hence, glucose uptake) including increased GLUT4 translocation in 
active muscles and fat cells dependent on the phosphorylation of protein TBC1D4, 
as well as decreased glycogen levels (Maarbjerg, 2011). As recently supported, these 
phenomena are present up to 4 hours after exercise, unlike the previously cited ’48.’  
 Hormones, particularly catecholamine’s epinephrine and norepinephrine, 
along with amylin and leptin, influence glucose energy flow amongst compartments 
and are not modeled mathematically, only recognized as influences in literature 
(Aronoff, 2004, and ACSM). Epinephrine has been known to cause bouts of 
hyperglycemia, characteristic of the ‘fight or flight’ response—glucose will flood into 
the bloodstream, aiding in the concept of an ‘adrenaline rush.’ This concept is 
difficult to model, and also occurs during exercise, especially in a high intensity or 
race setting (Tonoli, 2012). For that reason, studies have been done altering the 
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order of anaerobic/resistance training and aerobic training to decrease the effect of 
a BG ‘spike’ prior to the decrease in BG due to an aerobic session (Yardley, 2012). 
Training, particularly long endurance, also decreases catecholamine action in 
general, indicating a need for a personalized model. Amylin, also synthesized in 
beta-cells as with insulin, acts to suppress glucagon secretion and slow gastric 
emptying, thereby aiding in glucose appearance and disappearance in circulation 
(Aronoff, 2014). This complementary effect of amylin to insulin acts through the 
central nervous system and may prove to be important for diabetic modeling 
purposes. Leptin acts to regulate the amount of excess dietary calories stored as fat 
in fat cells versus the amount of glucose stored as glycogen in the liver and muscles 
(Northrop, 2011). Although not clearly associated with immediate glucose 
dynamics, leptin plays a role in fat accumulation based on an excess of 
carbohydrates, important for long-term modeling simulations.  
 Clinically, it does not yet seem possible to predict BG regulation of a diabetic 
athlete—diabetic athletes must discover themselves what is needed and when but 
with no real clinical guidance, only suggestions based on community tips and trial 
and error. For that reason, an algorithm intended to incorporate non-insulin (and 
glucagon) mediated physiologic mechanisms would be highly beneficial.  
 
2.3.3 Lifestyle Influenced Remodeling: Types 1 and 2 Diabetes 
  
All of the above mechanisms are occurring within a living biosystem that is 
inherently changing based on its use history, which reflects lifestyle.  Thus various 
tissues of the body can remodel in structure and composition, including in response 
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to lifestyle behavior and/or clinical interventions.  This in turn needs to be 
considered in clinical disease management.  Two common examples are reviewed.   
The current diabetes epidemic taking priority today involves obesity and its 
direct risk factor of Type 2 Diabetes. This is an example of remodeling: lifestyle 
choices lead to a change in body type, composition, and overall metabolic 
implications which can turn into insulin resistance, and hence disease. 
Accumulation of excess glucose in the blood due to over-eating and lack of exercise 
eventually (over a long-term period) leads to an over-production of insulin but the 
inability to utilize insulin properly, as glucose can no longer enter cells due to 
excess. Buildup often results in conversion to fat, an external remodeling symptom, 
and insulin resistance as an internal remodeling symptom. A lifestyle model, if 
performed for months, could predict implications of BG buildup with proper 
thresholds, tissue volume accumulation, and summation over a significant period of 
time. It has been proven that physical activity is a means of prevention and 
treatment for T2D; a remodeling back to a healthy lifestyle, practically reversing 
insulin resistance, is possible with increased skeletal muscle capitalization, 
increased muscular GLUT4 levels, hexokinase, and glycogen synthesis of chronic, 
daily aerobic exercise (Yavari, 2012). With informed models and predictors of these 
effects—particularly concerning tissue metabolism changes, GLUT4 flux, and 
decreased body mass—it is possible to inspire T2D to make these changes, as it is 
possible to decrease glucose accumulation and levels in general. Exercise-induced 
insulin sensitivity has attracted recent attention for designing effective lifestyle 
changes for T2D (Maarbjerg, 2011). With lifestyle models, this effect could be 
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demonstrated and would inform treatment plans and options useful in a clinical 
setting.  
 Similarly, an athlete, especially if exercise habits are 6 (or greater) days per 
week for extended time periods, will experience body composition remodeling. 
Trained individuals have vastly different metabolic properties and substrate 
utilization during rest and physical activity. Glucose is a key player—oftentimes, an 
athlete relies more on fat oxidation than glucose oxidation while at lower intensities 
of exercise and at rest. This involves changes such as increased mitochondrial 
content, all of which are outlined in Chapter 4. It is important to note modeling 
changes that would occur for a diabetic athlete—reliance on fat (vs. glucose), 
increased muscle mass tissue volume, increased glycogen stores, and importance of 
varying exercise intensity on substrate utilization (Melzer, 2011).  
 
2.3.4 Artificial Pancreas Predictive Applications 
 
 
It is recognized that there is a current need for innovative BG regulation models 
correlating to the current diabetes epidemic. Many factors, mostly related to 
treatment options, manipulate the basis for modeling approaches—diet, exercise, 
and interventional technologies, such as insulin injection, pumps, continuous 
glucose monitors (CGM’s) and the recent concept of an artificial pancreas (AP).   
Recently the AP system has evolved towards a two-sensor system, using two 
Dexcom, Inc., glucose sensors (for comparative proportional error calculations) with 
two pumps for independent delivery of insulin and glucagon controlled by a laptop 
running a custom glucoregulation control model (Jacobs, 2011).   In this pilot 
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strategy, delivery occurred on the basis of weight, Hemoglobin A1C (HbA1C), meals, 
and carbohydrates, all of which factor into an estimation of insulin sensitivity and 
dependent on proportional error from target glucose levels. HbA1C is a common 
measure for how well-controlled one’s BG has been for the previous 2-3 months, as 
it reflects average levels and whether or not red blood cells have become “glycated.”  
  Further, Dexcom, a forerunner in the CGM technology field, has an initial AP 
design that is using BG models, such as the Cobelli et al. 2009 version as seen in 
Table 2.1(Garcia, 2013).  
  The concept of using BG dynamic models for AP controller algorithms makes 
considerable sense.  The challenge is using models that are robust enough to capture 
the diverse events in life that affect BG, including forms of exercise.  The models 
outlined in Chapter 3 and 4 of this thesis, particularly for personalized adaptation of 
an athlete in Chapter 4, possess capability of further informing AP technology for 
unique individuals. However, this is only possible by increasing the algorithm 
accuracy of trend prediction, possibly beginning with integrating extensive user 
profiles. An extensive user profile, that incorporates metabolic parameters (resting 
metabolism, body composition, exercise data to correlate heart rate, etc.) would 
generate a generic algorithm for a particular individual that then can be informed by 
instantaneous events (stress, exercise, foodstuff consumption).  
  Only in recent clinical studies has the need to adapt dual-hormone AP designs 
in regard to lifestyle, particularly exercise and trained individuals, been addressed 
(Haidar, 2013). In a recent clinical study, closed loop delivery guided by advanced 
algorithms was shown to improve short-term glucose control, shown with 15 T1D 
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adults who underwent a 24-hour simulation with 30 minutes of exercise (Haidar, 
2013).  However, this still is not sufficient to predict and inform a habitual lifestyle 
and parameter set of trained individuals (see Chapter 4). Limitations often involve 
instability of glucagon at room temperature; however, it is known that there are 
other non-hormone dependent pathways that aid in glucose and energy utilization 
during exercise.   
Studies have demonstrated a need for adjusting basal insulin infusion rate prior 
to and during exercise—however, this has resulted in only a general suggestion, 
rather than personalized, for AP adaptation by an insulin reduction of about 50% 
(Shiavon, 2013). Clinicians typically advise people with diabetes, for ease, to stop 
insulin altogether during exercise. This may help avoid post-exercise late-onset 
hypoglycemia due to increased insulin sensitivity for long-term duration if exercise 
was of high caliber (MacDonald, 2006). However, as another AP application, a 
patient should not have to completely stop insulin (unless they are experiencing 
hypoglycemia) with a personalized model fine-tuned to individual metabolic 
parameters. It seems that insulin sensitivity is only a small implication of exercise 
and late-onset hypoglycemia; stress hormones and other contraindications as a 
result of training are other causes, especially if a ‘false high’ is accounted for at the 
beginning of exercise. For example, at the onset of exercise, as discussed, BG can 
elevate. If an AP device corrects for this, oftentimes a hypoglycemic episode ensues 
with the result of BG declining due to exercise demand in conjunction with an 
insulin bolus effect. Additionally, a group used the basic 3-compartment insulin 
model best suggested by Wilinska, 2005, and attempted to model the absorption 
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rate between subcutaneous and deeper tissue as a function of exercise intensity, 
realizing this was a major challenge to the current AP (Duun-Henriksen, 2013). 
However, their methodology is limited to two levels of exercise intensity, and does 
not address the influence of diet as another lifestyle parameter.  
Heart rate is an easily obtainable metric and is well known to inform effort (if 
different than perceived) during exercise and also often elevates during various 
high-stress or active events. In the case of the proposed model, HR (if available) will 
be used to inform exercise and stress (hormonal) inputs, but will not be fully relied 
upon, mainly due to heart rate variability and interpersonal variations that must be 
quantified in order to deem HR accurate.  
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3. NOVEL MODELING APPROACH METHODOLOGY 
 
3.1 Introduction 
 
 
Modeling of the blood glucose regulation system will better inform diabetes 
management on the basis of predicting trends characterized by model inputs. 
Clinicians and diabetes educators need to be able to quantitatively explain effects of 
diet choice, athletics, and activity level, and how these relate to drug delivery 
choices.  Exercise type, daily movement activities, tissue compartment metabolism, 
level of athleticism, meal type distinction and diet habits play a key role in BG 
prediction algorithms. There is a need for a robust and comprehensive model that 
simulates lifestyle choices, as current models are limited and fail to recognize 
importance of modeling all influential factors.   
A goal of the model relates to improved BG prediction so that a particular 
individual has confidence in respective management.  As personally seen with many 
diabetic patients, it is trial and error as to controlling influences of lifestyle factors—
for example, physical and mental stress become task-dependent and can elicit vastly 
different responses amongst individuals. Similarly, a marathoner will treat a two-
hour run as a ‘walk in the park,’ whereas another individual could experience 
physical and mental stress. 
A novel nonlinear 10-state lumped compartmental model is presented that 
aims to address knowledge gaps that go beyond those addressed by other models, 
including the ability to provide flexibility for lifestyle choices, variable body mass, 
muscle ratio, and more logical parametric approaches for representing people with 
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Type 1 and Type 2 diabetes. The model is intended for both research and clinical 
use, particularly diabetes educators, and to inform delivery design of current 
artificial pancreas mechanism with a dual-hormone delivery, as well as develop 
continuous glucose monitor (CGM) feedback and prediction based on current 
activity and/or diet. It is motivated by the concept that a diabetic should be able to 
manage BG with exercise, diet, and dual-hormonal control based on algorithm 
feedback of a personalized model, similar to that of machine learning mechanisms.   
3.2 Background  
 
 
Many models have been proposed, focusing on varying aspects of blood plasma 
glucose (BG) regulation. Typically BG concentration is one of the compartments in a 
dynamic model, with models ranging from very simple (2 total compartments) to 
complex. Models tend to move from utilizing simplified compartment ‘minimal 
models,’ such as Bergman (1981), the iteration of a compartmental insulin model, to 
those that exist as a system, or multiple states involving dual-control and/or 
separate volume-based compartments with varying metabolic properties- Sorensen 
(1978) presents a complex model focusing on nonlinear organ glucose demand. 
Wilinska (2005) performed an extensive study evaluating and validating insulin 
models, including acceptable linear models (Shimoda, 1997), more complex and 
nonlinear compartmental models (Hovorka, 2004), and those using Michaelis-
Menten kinetics, which form a strong core componentry of the proposed model. 
Other models focus on the effect of metabolic variations and compartment 
loss/fluxes due to temperature, thyroid hormones, urine loss, and mechanical 
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workload (Northrop, 2000). In addition to Sorenson, Northrop et al. implemented a 
system producing the hormone glucagon (GLC) as a simple, first-order loss kinetics 
with a static, nonlinear function providing the GLC rate input to the GLC loss 
dynamics ODE.  Northrop particularly focuses on hormone kinetics, separating cells 
into insulin-sensitive and non-insulin sensitive, with hepatic glucose flux that 
depends on insulin, GLC, leptin and other regulatory hormones, not only BG.  
The classic 3-state “Bergman minimal model” with two states including insulin 
dynamics and glucose (Bergman, 1981) is one of the most widely used core models. 
Bergman quantified insulin sensitivity with 3 compartments, representing plasma 
insulin, remote insulin and plasma glucose concentrations. Extensions to this model 
include a minimal exercise model adding a critical threshold value (on the basis of 
VO2max) that drives hepatic glucose production and glycogenolysis during exercise 
characterized by intensity and duration (Roy, 2007). These changes are reflected 
with added terms of the plasma glucose equation of the Bergman minimal model. 
Further, in a review of various differential equation approaches, Makroglou et al. 
(2006) presents delay modeling approaches including those by Sturis et al. (1991), 
integro-differential equations, and partial differential equations (Makroglou, 2006). 
The integro-differential equation approach is key for modeling intravenous glucose 
tolerance test dynamics after recognizing the widely used minimal model is 
improper in qualitative behavior, as the base parameter is equal to the basal glucose 
level. A more realistic dynamic model is needed, recognized by many (i.e. Li, 2001 or 
Mukhopadhyay, 2004) and can also be improved with use of Hill kinetics, including 
the special case of Michaelis-Menten, reviewed in Gesztelyi, 2012. These additions 
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will address fundamental limitations with added states to further insulin dynamics 
and the particular need to recognized delays and oscillations (Makroglou, 2006).   
Hepatic glucose production and release is a large part of many models, often 
as a mildly-delayed dynamic response due to depleted glycogen stores and/or low 
BG levels. For example, Neelkanta (2006) proposed 4 glucose sinks: insulin-
sensitive cells (ISCs), noninsulin-sensitive cells (NISCS), kidneys (urine loss) and 
liver or muscle (storage). It is possible to model liver storage and stimuli for glucose 
production when needed by using a lumped glucose/glycogen model and glucagon 
control, respectively. It becomes clear that liver can be modeled as a part of the non-
muscle tissue compartment for the purposes of the Schunk-Winters model. Non-
muscle tissue releases glucose mainly on the basis of glucagon-dependent (state-
dependent) flux, or glycogen-to-glucose conversion particularly in regard to the 
liver. Glucagon directly modulates liver delivery rate.  
Most models idealize diet as a single glucose input source, ignoring the 
‘quality’ of carbohydrates.  Once filtered through the digestive system, there is a rate 
of appearance of glucose into the bloodstream.  Newer models utilize 2-3 states to 
capture this digestive process, but fail to distinguish between carbohydrate type and 
varying absorption rates (Dalla Man, 2014 and Hernandez-Ordonez, 2008). By 2007, 
Cobelli and colleagues developed an advanced 12-state model for studying the 
effects of carbohydrates (meal) an extension approved by the FDA as a preclinical 
trial tool for controller design used extensively (Cobelli, 2009 and Kotachev, 2010).  
More recently, the addition of glucagon control action resulted in a 16th-order model 
with 7 additional parameters (Dalla Man, 2014). The model implements simulations 
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representing a diversity of “virtual” users.  This work evolved into a FDA approved 
simulator for evaluating controllers for T1D management and has made its way 
extensively into the modeling field today, forming a strong sense of nonlinear 
control in regard to insulin response for both T1D and T2D, as well as more recent 
additions of glucagon and exercise (Kotachev, 2010 and Dalla Man, 2014). One 
significant limitation is that it is still intended for a single meal implemented as a 
bolus dose of carbohydrates.   
The transient dynamics of glucose appearance is strongly influenced by 
foodstuff composition, with measures such as GI to document the reality of peak 
glucose influx ranging from minutes to hours after ingestion (Monro, 2008).  Low 
glycemic foodstuff results in a slower breakdown (less of the “sugar high” spike in 
BG). The control actions of insulin in response to high glycemic foods generates a 
strong blood insulin influx, and trigger a sudden “crash” in BG owing to increased 
flux into tissues for storage (mostly in liver and muscle and adipose) and via energy 
conversion pathways into fats (Walsh, 2014, Wolfe, 1998, and Jenkins, 1981). Only 
one current group (Yamamoto, 2014) appears to have addressed the need for 
deciphering between a food’s glycemic index (GI), which is well known to effect the 
rate at which foodstuff is absorbed (Mohammed, 2004). In modeling meal 
absorption, Yamomoto (2014) addressed glycemic index and associated insulin 
effect based on replicated literature curves. A state-space representation form is 
used for the carbohydrate metabolism subsystem, which distinguishes between 
rapidly absorbing glucose (RAG) and slowly absorbing glucose (SAG). It was 
determined that 95% of RAG was absorbed within 20 minutes, with SAG between 
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20-120 minutes. SAG was modeled as a 20-minute time delay plus a time constant of 
about 21 minutes (vs. just a time constant of 4.2 min for RAG). There was also a 
first-order gastric emptying time constant related to the time required to pass from 
the stomach to the duodenum.  However, this particular model is limited in its 
‘lifestyle’ inputs such as exercise and utilizes only the Bergman minimal insulin 
model for subcutaneous insulin (Bergman, 1981 and Shimoda, 1997). Absorption 
dynamics are represented by critically-damped second-order plus delay system of 
the following form (Figure 3.1).  
 
 
 
Figure 3.1: Yamamoto (2014) Glucose Absorption Equations. From Yamamoto, 2014, 
representing rapidly-absorbing glucose (RAG), xRAG, and slowly-absorbing glucose dynamics), xSAG,  
with time-constant T parameters of 4.22 min for RAG and 21.1 min for SAG with a 20-minute time 
delay for 95% total absorption. Values were obtained in vitro. Design specifications for RAG 
absorption include complete glucose absorption for an impulse food between 0-2o minutes and the 
area-under-the-curve of RAG glucose absorption equal to the glucose equivalent for the RAG 
regardless of the amount and GI of the food ingested. 
 
 
3.3  Need for a New Lifestyle Model 
 
 
It is evident that four major contributions need to be incorporated into novel 
BG models: glycemic index (GI) and digestive dynamics, glycogen/glucose lumped 
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into compartments, a muscle compartment that includes the effects of exercise and 
activity, and hybrid-control compartmental energetic model. Fast and slow 
nonlinear pathways, as informed by meal GI, should demonstrate a ratio of 
carbohydrates to protein and fat with respective Hill saturation dynamics affecting 
both absorption rate and substrate availability (Gesztelyi, 2012). Unlike many 
models, glycogen and glucose can allow to be lumped into compartments as one 
entity since the focus is on energy flux and storage. Glucagon and control-sensitive 
flux rates allow for a new and innovative way of accessing glucose without an 
additional state, particularly the liver. GLUT4 and GLUT2 pathways become 
particularly important, with glycogen stores following mass-conservation 
throughout all tissues and glucagon as the controller mechanism.  
The separation of tissue into a non-muscle and muscle compartment allows 
accommodation for demand-based muscle metabolism, and different from constant 
glucose sinks of non-muscle.  Not included under non-muscle is a steady glucose 
energy sink, particularly related to brain consumption.  
The addition of a muscle compartment allows for varying muscle mass and 
body composition of individuals, and type and duration of exercise. Similarly, the 
addition of the internal muscle mitochondrial consumption state allows for ATP 
production on the basis of the amount of mitochondria present, as this is a 
parameter known to vary amongst individuals.  
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3.4 Methods 
 
3.4.1 Model Structure 
 
 
The overriding model design objective was an inherently robust model of the 
human glucoregulation system, using the minimal set of state variables 
(summarized in Figure 3.2) and parameters necessary to simulate diverse scenarios 
with adjustability to composition variation and T1D and T2D. Appendix 7.1 lists all 
flux input/output parameters and terms. 
 
 
 
Figure 3.2: Schunk-Winters Compartmental Model Block Diagram and Structure. Thick lines 
represent material flow with storage and control action as unidirectional signals informed by rate 
parameters and oftentimes, nonlinear, by either Hill kinetics or multiplicative states. Dashed lines 
represent exogenous control, via injection or other external device. Nonlinear relations include both 
flux terms and heuristics that change fitting equations based on different state or input signal ranges.  
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3.4.2  Four Major Novel Contributions 
 
 
The Schunk-Winters model addresses knowledge gaps found in literature, 
focusing on four major contributions including both simplifications and 
developments of past models: glycemic index and digestive dynamics, lumping 
glycogen and glucose, addition of a muscle compartment and regulatory action, and 
opportunity for a hybrid control-compartmental energetic model.  
3.4.2.1  Glycemic Index and Digestive Dynamics 
 
 
The inputs to this sub-model are rate and amount of oral ingestion of 
foodstuff, with the carbohydrate fraction separated into ‘fast’ and a ‘slow’ inputs, as 
informed by the estimated GI of meal components, available from many sources  
(e.g., Monro, 2008 and Yamamoto, 2014). About 88-98% of carbohydrate is 
absorbed (highest for pure high-GI carbohydrate ingestion, lowest for low-GI) 
(Monro, 2008 and Yamamoto, 2014). Also inputted is the ratio of carbohydrate to 
the total consumed energy including fat plus (especially) protein content in a meal 
which can (mildly) influence rate of absorption and carbohydrate availability (as is 
widely documented, and that Meal GI, universally, is a weighted sum of meal 
constituents and associated food GI and carbohydrate (CHO) amount (Monro, 
2008): 
𝑀𝑒𝑎𝑙 𝐺𝐼 =  
(𝐺𝐼𝐹𝑜𝑜𝑑𝐴𝑥 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂𝐹𝑜𝑜𝑑𝐴)+ (𝐺𝐼𝐹𝑜𝑜𝑑𝐵𝑥 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂𝐹𝑜𝑜𝑑𝐵)+⋯
𝑇𝑜𝑡𝑎𝑙 𝑔 𝑎𝑣𝑎𝑖𝑙 𝐶𝐻𝑂
    [3.1] 
 
The slow (low GI) signal enters a separate, slower digestive pathway that is 
assumed to be first-order, but nonlinear in that the rate adjusts with the amount of 
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carbohydrate and overall material.  The material flow state from this pathway 
converges (sums) with the direct “fast” pathway to a final first-order digestive-
absorption process. This approach appears novel, although the concept of 
mathematically distributing carbohydrate into rapidly and slowly available glucose 
based on GI has been published recently, but with a different (linear) strategy, with 
equations outlined in Figure 3.1 above, similar to Yamamoto et al, 2014 (Monro, 
2008).  Meals are inputted in regard to total carbohydrate content (kcal/hr with 4 
calories per gram of carbohydrate) and proportion of fast, high GI, carbohydrate 
content. Other parameters include a term for dietary thermogenesis (i.e. heat lost 
during digestion, assumed a function of the slow pathway) and digestive 
effectiveness ratios for fast (~98% absorption) and slow (~88% absorption) 
digestive inputs due to food loss during digestion in the intestine and stomach, as 
well as fiber and other foodstuff that is not fully absorbed (particularly for slow 
CHO).  
In regards to the calculation of GI, and for purposes of model validation, fiber 
content should be subtracted in order to obtain the amount of ‘available 
carbohydrates.’ Cooking and reheating food tends to raise GI, and this must be 
controlled for to obtain a particular GI.  
3.4.2.2 Glycogen/Glucose Lumped  
 
 
Glucagon and control-sensitive flux rates, specifically GLUT2 (non-muscle 
glucose transporter) and GLUT4 (muscle glucose transporter), represent a new and 
innovative way of accessing glucose in the model without the need for an additional 
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state, typically liver. Both tissue compartments assume that glycogen is the compact 
storage form of glucose and represented throughout the mass-conservation system 
in all tissues assumed in the model—liver, muscle, adipose, etc. Unlike past models, 
there is no state explicitly associated with hepatic production and glycogenesis; 
however glucagon plays the role of control action as a function of non-muscle 
storage (along with the associated flux) resulting in a ‘lumped’ modeling approach. 
That being said, training can alter relative glycogen storage levels, particularly in 
muscle, indicating glycogen stores will start higher and sparing often occurs 
(Holloszy, 1984). It seems necessary to delineate between muscle and non-muscle 
tissue as opposed to adding a liver state, as hepatic glycogenolysis and 
gluconeogenesis can still be modeled with glucagon and GLUT2 action.  
3.4.2.3 Muscle Compartment and Regulatory Action 
 
 
Muscle is often lumped into the tissue compartment of most models, such as 
‘Muscle and Adipose Tissue’ or ‘Periphery’ (Dalla Man, 2009 and Roy, 2007), 
proposing significant limitations. Others simply use exercise as a glucose ‘sink’ and 
decrease in BG (typically non-linear), increase in hepatic gluconeogenesis, storage, 
and flux, and increase in insulin sensitivity (Northrop, 2000, and Neelkanta, 2006). 
The proposed model addresses this knowledge gap by recognizing metabolic 
differences of muscle vs. non-muscle tissue, and treating muscle as a separate 
compartment. 
 Muscle glycogen storage can alter with diet and training, and act as an 
immediate source of glucose for short-term, contraction-based activity. Storage 
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capacity of muscle glycogen in a healthy, non-obese, 70 kg male subject is about 350 
grams, or at most 2% of total body volume (Holloszy, 1982).  However, muscle 
requires mass flow from BG, especially if a burst of anaerobic activity or high 
intensity, >60% VO2max aerobic exercise, as glycogen stores are limited.  
Contractions stimulate processes including phosphocreatine (PCr) shuttling, Ca2+ 
flux from the sarcoplasmic reticulum, and GLUT4. Metabolism using PCr as fuel is a 
glycolytic process particularly important in the first 3 minutes of ATP need and/or 
demand (i.e. exercise or daily, anaerobic, activity). The delivery of glucose parallels 
the activation of contraction (Gastin, 2001).  
Plasma epinephrine, a powerful stimulator of cyclic AMP formation at the 
onset of exercise as well and is primarily responsible for the onset of glycogenolysis 
at exercise >80% VO2max (Kjaer, 1989), is not explicitly modeled as its own entity.  
However, it is indirectly modeled through the nonlinear subtraction of fat in the fuel 
demand mix.  
Fat metabolism is another energy fuel source, and is often a factor of training 
level as related to mitochondrial volume increase, which often occurs with aerobic 
endurance training (Holloszy, 2011).  Maximum proportion of fat fuel consumption 
occurs at low to moderate intensity exercise (Holloszy, 1996). This concept results 
in the nonlinear subtraction (as a reciprocal Hill function) for both tissue glucose 
states. When fat is being utilized, glucose consumption will be reduced until 
intensity or anaerobic activity increases or substrate availability is altered (Hurley, 
1986).  
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The GLUT4 gradient and production of fuel mix (fat) are both modeled by 
nonlinear Hill kinetics on the basis of fat utilization curves found in literature 
(Brooks, 1994). Total aerobic exercise consumption is defined as subtracting the 
total fat fuel mix consumption from the total exercise input. The model assumes by 
default that fat oxidation has a maximum of 30% of total aerobic capacity, although 
with training, this could increase (Brooks, 1994). Total anaerobic exercise 
consumption is assumed by default to be 50 kcal/hr before switching to 
mitochondrial and aerobic.  GLUT4, Ca2+, and liver glycogenolysis are key regulators 
and pathways for glucose access during exercise without hormonal control (i.e. 
glucagon and insulin), although there is an important catecholamine effect as well.  
 Often exercise intensity fluctuates, and it would be useful to have a method 
for informing the model about fluctuating levels of muscular demand for glucose. 
Heart rate data from a smart watch and/or other form of continuous monitor, of 
available, can help inform exercise and activity input signals, helping sculpt 
perceived energy rate input pulses given in kcal/hr (u3 and u4). 
Various measurements of fitness level and correlation between substrate 
utilization, fat vs. carbohydrate fuel, during exercise of varying duration and 
intensity exists and will be further examined in Chapter 4 (i.e. Yardley, 2012). Other 
model capabilities involve individual fitness parameters and will be developed for 
model personalization features (Chapter 4). For example, knowing anaerobic 
threshold and VO2max of an individual allows characterization of heart rate ‘zones’ 
1-5 ranging from ‘light, recovery’ exercise (zone 1) to above anaerobic threshold 
(zone 5). Often used in exercise physiology, zones can be correlated with respiratory 
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exchange ratio (RER) in which an RER = 0.7, often during zones 1-2, is mainly fat 
utilization while zone 5, or RER > 1.0, is mainly glucose utilization with a fuel mix in 
between (Knoebel, 1984). Zones are often used in regard to exercise planning and 
training, as they can be adjusted as one becomes trained, typically favoring higher 
fat utilization at elevated heart rates and shifting zones upward (Millan, 2014).  
 There is the possibility that long durations of circuit training and/or 
anaerobic exercise can elicit fuel mix responses as well; however, this is a current 
debate. Heart rate (HR), assuming steady state, can be a rough crude indicator of the 
amount of fat consumption, if HR zones are known and can provide an accurate 
sense of intensity—further discussed in Chapter 4 as an additional external input. 
3.4.2.4 Hybrid Control-Compartmental Energetic Model 
 
 
 A hybrid model enables the ability to have more realistic inputs than most 
models. Inputs are all scaled to kcal/hr (exercise and activity) or g/hr (digestive 
input, insulin) with easy conversion between each. Body composition data is easily 
incorporated and scales various parameters that are influenced by body mass or 
muscle/non-muscle compartment mass.  Additionally, various types of insulin 
resistance and type 1 effect scale the model. Lifestyle inputs also demonstrate the 
need for GLUT2 and GLUT4 action, as many activities and scenarios allow even a 
type 1 diabetic to be ‘OK’ without experience hypo- or hyperglycemia. For example, 
a type 1 diabetic often can eat a low GI snack or exercise at a low intensity for an 
extended duration without deviating from the target range due to other external 
non-insulin, non-glucagon based pathways.  Hill relations allow for maximum 
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saturation at known quantities and limits, as well as allow tuning for rate changes 
due to a particular concentration without need for conversion, and are reviewed by 
Gesztelyi, 2012.  
  
3.4.3 Nonlinear Hill Kinetics for Saturating Rates and Signal Magnitudes 
 
The model makes use of classic Hill saturating kinetics for rates and in some 
cases signal magnitudes, and is reviewed by Gesztelyi, 2012:  
𝐹ℎ𝑖𝑙𝑙(𝑥, 𝑘𝑚𝑎𝑥 , 𝑘𝑠, 𝑛) =  
𝑘𝑚𝑎𝑥𝑧
𝑛
𝑘𝑠
𝑛+𝑥𝑛
   [3.2] 
where x is a state, kmax  and ks are maximum saturation and half-way x values, the Hill 
coefficient n is 1 (Michaelis-Menten kinetics), 2, 4 or 6 (each with soft saturation at 
both ends), and z = x for rising and z = ks for falling curves (Hovorka, 2002).  
For hormonal P-action signals where 10% rather than 50% of max helps design 
resting values, we map:  
                                                   ks = [9mkn]1/n                          [3.3] 
where k=0.1 (10%) is the basis for hormone “reference” parameters, m = 1 for 
rising, m = -1 for falling. 
Nonlinearities of glucagon and insulin controllers (with added time delay for 
insulin), meal absorption (slow and fast stomach states), tissue intolerance, and BG 
loss muscle demand gradient all utilize Hill kinetics. Figure 3.3 demonstrates Hill 
effects on BG based on insulin and glucagon controllers. In equations that follow, 
Hill functions are seen throughout the following state equations, with values defined 
in Appendix 7.1. 
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Figure 3.3: Insulin and Glucagon Hill Controllers.  Insulin (solid) and glucagon (dashed) vs. blood 
plasma glucose concentration as implemented with Hill based controllers. 
 
 
3.4.4 Glucose Compartmental Flow 
 
 
A 3-compartment “process” model for glucose distributes most of body tissue 
volume (other than plasma glucose) into two compartments: skeletal muscle (~35-
45% body weight (BW)) and non-muscle (~35-40% of BW). The non-muscle 
compartment represents unique features of tissues with specific glucose flux 
pathways within blood and/or storage capacity, including liver, adipose, cardiac and 
digestive.  It does not include the volume of brain or blood erythrocytes (which are 
assumed to provide steady flux sinks), or extracellular fluid (ECF, the volume of the 
third compartment, “blood plasma/ECF”).    
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Interface parameters based on relative mass are used to assure that states 
and fluxes are scaled appropriately between compartments.  Appendix 7.1 provides 
non-muscle and muscle parameters influenced by respective BM contributions.   
Glucose compartmental relations of states 𝑥𝑔, 𝑥𝑚 𝑎𝑛𝑑 𝑥𝑛𝑚 are represented by each 
flux and mass balance/flow term below with most terms nonlinear via use of Hill 
kinetics for rates or magnitudes, and multiplicative control action. A state-
independent steady unidirectional glucose loss flux of (by default) 120g per day is 
used to represent the energy requirements of brain and erythrocytes, based on 
work by Roy (2002) and Melzer (2011). Additionally, there are two types of 
specialized fluxes that are a direct function of insulin or glucagon control action: a 
relatively small non-muscle flux sink associated with the slower-digestion pathway 
(developed below), and potentially much larger fluxes associated with muscle 
workload activities such as exercise (also developed below).   The Schunk-Winters 
model scales to each person by BW ratios relative to defaults for BW (70 Kg), with 
similar ratios for non-muscle and muscle (see Appendix 7.1 Table for affected 
parameters). Muscle mass is also composed of mitochondrial mass, defined by a 
ratio parameter of percent muscle. This value becomes increasingly important with 
training and as discussed in Chapter 4. 
 The addition of a mitochondrial consumption state within the muscle 
compartment is motivated by the remarkable variation in energy demand and 
consumption during exercise and activity.  This allows for varying rates between 
conversion pathways on the basis of total mitochondrial amount and fiber type 
distinction. Type 1 muscle fibers (slow oxidative) have high mitochondrial content 
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and are able to generate more work with less ATP utilization whereas Type 2 
muscle fibers (fast glycolytic) require more immediate glucose as energy and have a 
lower mitochondrial content (Holloszy, 2011). Mitochondrial volume increases with 
endurance-trained individuals, as can energy transport capacity. For instance, one 
study found that a 2-fold increase in GLUT4 expression results in a 2-fold increase in 
glucose uptake at the same insulin concentration (Holloszy, 2011). This concept 
relates the idea that oftentimes walking, or simple daily activity, is beneficial for 
diabetes management, including those experiencing insulin resistance. For the 
purposes of our model, for the x10 state, mitochondrial use of glucose only (despite 
mitochondria’s important role in fat oxidation) is modeled to keep consistency with 
mass glucose conservation and kcal/hr inputs.  The Kreb’s cycle, which takes place 
in the mitochondrial matrix, is a precursor for oxidative phosphorylation and 
efficient generation of ATP from glucose fuel. We assume this process is most fully 
associated with aerobic exercise, the u3 input of our model. On the other hand, 
anaerobic exercise and daily activity (u4) tend to use a less efficient ATP generation 
in glycolysis, or immediate glucose consumption in the cytoplasm. Any exercise 
involving fast-twitch glycolytic muscle fibers (often ‘bursts’ of activity) will utilize 
glycolysis. However, especially with long-lasting activity and/or anaerobic exercise, 
mitochondrial action will continue to take place as a more endured energy source 
but at a reduced proportion (parameter kprop).  
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Figure 3.4: Skeletal Muscle and Tissue Compartmental Model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.4.1 Blood Plasma Glucose State (mg/dl) 
 
𝑑𝑥𝑔
𝑑𝑡
=  𝐾𝑏𝑑𝑥𝑑 − [(𝐶𝑖𝑛𝑚 (
𝑘𝑚𝑥−𝑛𝑚𝑘𝑡𝑖𝑛𝑡𝑜𝑙
𝑘𝑡𝑖𝑛𝑡𝑜𝑙+𝑥𝑛𝑚
)
8
+  𝐶𝑖𝑚 (
𝑘𝑚𝑥−𝑚𝑘𝑚𝑖𝑛𝑡𝑜𝑙
𝑘𝑚𝑖𝑛𝑡𝑜𝑙+𝑥𝑚
)
8
)] 𝑥𝑔𝑥𝑖 + (𝐶𝑔𝑛𝑚 + 𝐶𝑔𝑚) 𝐾𝑔𝑡𝑥𝑔𝑥𝑔𝑛 −
[(
𝑘𝑚𝑥−𝑒𝑥𝑢𝑒𝑥𝑒𝑟
𝑘𝑠−𝑒𝑥+𝑢𝑒𝑥𝑒𝑟
)
1
(𝑥𝑔 − 𝑥𝑚)] −
𝐾𝑏
𝑤𝑛𝑚
− (
𝑘𝑔2𝑚𝑎𝑥𝑥𝑔
𝑘𝑔𝑟𝑒𝑓𝑡+𝑥𝑔
)
2
(𝑥𝑔)                                         [3.3] 
 
 
where influxes are digestive (stomach) glucose (𝒙𝒅) and glucagon controller 
(𝒙𝒈𝒏, mostly via liver and controlled rates), with outfluxes of exercise loss (𝑢𝑒𝑥𝑒𝑟), 
insulin (𝑥𝑖 , to tissues), brain consumption (𝐾𝑏), bi-directional GLUT2 loss (liver, 
intestines, etc.), muscle demand consumption.  
Below is a key for Equation 3.3. Equations 3.4- 3.12 follow a similar scheme, 
with terms and parameters defined in the Glossary and Appendix 7.1. In particular, 
Hill parameters are denoted by ks or kmx, referring to half-way saturation and 
Skeletal Muscle and Tissue Compartmental Model 
u
m-activity    
: Daily Activity Muscle Input (kcal/hr) 
u
m-exer-Ana 
: Anaerobic Exercise Muscle Input (kcal/hr) 
u
m-exer-Aer 
: Aerobic Exercise Muscle Input (kcal/hr) 
fat_Aer: Aerobic Fat Consumption (out of total exercise input) (kcal/hr) 
AerCap: Maximal Aerobic Capacity (kcal/hr) 
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maximal saturation, respectively. Other subscripts inform on the basis of state or 
parameter. For instance, a subscript ‘m’ refers to muscle, or kgreft refers to the 
parameter greft. Current state concentrations are denoted by x terms. The units of 
each state are provided after each subheading or in the Glossary and Appendix 7.1.  
 
 
 
 Inputs u1-u4 are in kcal/hr, consistent with an energy flow model. For 
glucose, 4 Kcal of energy is assumed to have a one gram mass equivalent (1 g CHO = 
4 kcal). Thus for rates, 1 g/hr of glucose flux maps to 4 Kcal/hr of glucose energy 
flux. Any quantity that has units of kcal/hr will be divided by 4 in order to convert to 
grams/hr.  
 
𝑑𝑥𝑔
𝑑𝑡
, Rate of Change in BG vs. Time (hr) [mg/dl] 
𝐾𝑏𝑑 , Conversion of Digestive Mass Flow (g/hr) into ECF (BG + interstitial) scaled by blood 
volume (in dl)    and with mass converted from g to mg  
xd, Glucose Digestive Forward Rate Path [g/hr] 
Cinm, Insulin Control Parameter, Non-Muscle Tissue Gain [unitless] 
𝑘𝑚𝑥−𝑛𝑚, Maximum Saturation for Non-Muscle Tissue Intolerance [/hr] 
𝑘𝑡𝑖𝑛𝑡𝑜𝑙 , Reference Threshold for Non-Muscle Tissue [mg/dl] 
xnm, Non-Muscle Tissue State [g/kg] 
𝑘𝑚𝑥−𝑚, Maximum Saturation for Muscle Tissue Intolerance [/hr] 
𝑘𝑚𝑖𝑛𝑡𝑜𝑙 , Reference Threshold for Muscle Tissue [mg/dl] 
xm, Muscle Tissue State [g/kg] 
xi, Endogenous Insulin Control Action in Blood Plasma (mU/dl) 
𝐶𝑔𝑛𝑚, Glucagon Control Parmeter, Non-Muscle Tissue Gain [unitless] 
𝐶𝑔𝑚, Glucagon Control Parmeter, Muscle Tissue Gain [unitless] 
𝐾𝑔𝑡 , Basal Tissue Elimination Rate, Scaled to Grams (for Glucagon) [/hr] 
xi, Endogenous Glucagon Control Action in Blood Plasma (pg/dl) 
𝑘𝑚𝑥−𝑒𝑥 , Maximum Saturation for Muscle Tissue Gradient [/hr] 
𝑘𝑠−𝑒𝑥 , Half-Way Saturation for Muscle Tissue Gradient [g/kg] 
𝑢𝑒𝑥𝑒𝑟 , Aerobic Exercise Input, u3 [kcal/hr] 
𝑘𝑏 , Blood Glucose to Steady Consumption Sink (mostly brain) [g/hr]*, scaled by kbd conversion 
to mg/dl 
𝑤𝑛𝑚, Non-Muscle Mass [kg] 
𝑘𝑔2𝑚𝑎𝑥 , Maximum Rate, GLUT2 Flux [/hr] 
𝑘𝑔𝑟𝑒𝑓𝑡 , Reference Threshold of BG for Non-Muscle Flux Direction [mg/dl] 
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3.4.4.2 Non-Muscle Tissue State (g/kg) 
 
𝑑𝑥𝑛𝑚
𝑑𝑡
= [(
𝑘𝑔2𝑚𝑎𝑥𝑥𝑔
𝑘𝑔𝑟𝑒𝑓𝑡+𝑥𝑔
)
2
(𝑥𝑔) + 𝐶𝑖𝑛𝑚 (
𝑘𝑚𝑥−𝑛𝑚𝑘𝑡𝑖𝑛𝑡𝑜𝑙
𝑘𝑡𝑖𝑛𝑡𝑜𝑙+𝑥𝑛𝑚
)
8
𝑥𝑔𝑥𝑖 − 𝐾𝑔𝑡𝐶𝑔𝑛𝑚𝑥𝑔𝑥𝑔𝑛] 𝑤𝑏𝑡 −
[𝐺𝑚𝑒𝑡𝑛𝑚+(𝐾𝑐𝑎𝑟𝑏𝑥𝑑𝑠)]
𝑤𝑛𝑚
   
[3.4]  
where influxes are insulin-regulated BG delivery, brain requirement, bi-directional 
GLUT2 gain (liver, intestines, etc.), and outfluxes are basal metabolic tissue loss and 
glucagon-regulated delivery.  Some are scaled by wbt, based on blood volume and 
non-muscle mass.  
 Scaling and conversion is similar to that of Equation 3.3. Parameter wbt is 
used for compartmental flux conversion with BG concentration (in mg/dl) 
converted to amount in grams by using BG volume, then is normalized to the mass 
of the segment (thus g/kg of non-muscle). 
 
3.4.4.3 Muscle Tissue State (g/kg) 
 
𝑑𝑥𝑚
𝑑𝑡
= [
(
𝑘𝑚𝑥−𝑒𝑥𝑢𝑒𝑥𝑒𝑟
𝑘𝑠−𝑒𝑥+𝑢𝑒𝑥𝑒𝑟
)1 (𝑥𝑔−𝑥𝑚)]
𝐺𝑚𝑏
+ 𝐶𝑖𝑚 (
𝑘𝑚𝑥−𝑚𝑘𝑚𝑖𝑛𝑡𝑜𝑙
𝑘𝑚𝑖𝑛𝑡𝑜𝑙+𝑥𝑚
)
8
𝑥𝑔𝑥𝑖 − 𝐶𝑔𝑚𝑥𝑔𝑥𝑔𝑛] 𝑤𝑏𝑚 −
𝐺𝑚𝑒𝑡𝑚
𝑤𝑚
−
[𝑢𝑑𝑎𝑖𝑙𝑦+𝐺𝑒𝑥𝑒𝑟(𝑢𝑒𝑥𝑒𝑟)]
4𝑤𝑚
− 𝑟𝑎𝑡𝑚𝑖𝑡𝑜𝑥𝑚𝑖𝑡𝑜                                                [3.5] 
 
 
where influxes are insulin-managed BG delivery (scaled to this compartment) and 
exercise-demanded BG delivery (scaled), and the outfluxes are basal metabolic 
muscle loss, exercise-demanded muscle glucose consumption, and daily activity 
related muscle glucose consumption. 
Scaling and conversion is similar to that of Equation 3.3. Parameter wbm is 
used for compartmental flux conversion with BG concentration (in mg/dl) 
54 
 
 
 
converted to amount in grams by using BG volume, then is normalized to the mass 
of the segment (thus g/kg of muscle). 
3.4.4.4 Mitochondrial State (g/kg) 
 
 
𝑑𝑥𝑚𝑖𝑡
𝑑𝑡
= [
𝑘𝑚𝑢𝑠𝑐(𝐺𝑒𝑥−𝑇𝑜𝑡𝑎𝑙+𝑘𝑝𝑟𝑜𝑝
𝑢𝑑𝑎𝑖𝑙𝑦
4
−𝑥𝑚−𝑥𝑚𝑖𝑡)
4∗𝑤𝑚𝑖𝑡
   ]                                    [3.6] 
 
where influxes are total exercise (anaerobic + aerobic) glucose consumption 
demand as a Hill function and daily activity and outfluxes are loss to muscle tissue 
(demand based) and mitochondrial consumption. 
3.4.4.5 Glycogen Storage Approach 
 
 
It is well known that glucose is stored as glycogen in almost all tissue 
compartments, with amount dependent on a variety of factors including habitual 
(and recent) diet (i.e. high carbohydrate vs. high protein and/or fat), health and 
athletic training status, as well as instantaneous demand of exercise. High dietary 
carbohydrate is a key reason for glycogenosis within the liver and muscle, the 
largest storage sites.  
During high stress triggering events, whether it be a form of exercise 
requiring glucose or the ‘fight-or-flight’ mechanism elicited for another external 
stimulant, glycogenolysis typically occurs in the liver as shown in most models. 
Despite lack of an explicit liver state, the same effect is achieved with on-muscle 
demand contributing to a rise in BG on the basis of increased HR input (u5) and/or 
glucagon controller response.  
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3.4.5 Glucose Forward Mass Flow 
 
 
This sub-model is 2nd-order, with its output state being a mass flow rate of 
appearance of glucose into the blood plasma/extracellular fluid compartmental. The 
proportion of carbohydrates entering into the fast vs. slow absorption path is 
dependent on meal glycemic index (kfast) and the total amount of carbohydrates 
inputted.  There is a maximum saturation on how fast glucose can enter (if 
extremely high GI, absolute path, kmax or kabs) and a limit on how much can be 
absorbed based on the filling and/or gastric emptying of the stomach in grams (slow 
path kmin value). Absorption is modeled with use of saturating Hill kinetics.  
 
 
Figure 3.5: Digestive Lumped Compartmental Model 
 
 
 
Digestive Lumped Compartmental Model 
u
1-fast*   
: Fast Carbohydrate (High Glycemic) Glucose Input (kcal/hr) 
u
1-slow*
: Slow Carbohydrate (Low Glycemic) Glucose Input (kcal/hr) 
Kfoodloss: Food Input Not Absorbed (Fiber, etc.) (Decimal Percent) 
Ksink: Foodstuff Lost Prior to Stomach Absorption (Intestines, etc.) (Decimal Percent) 
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3.4.5.1 Low Glycemic Index (Slow) Forward Glucose Path (g/hr) 
 
𝑑𝑥𝑑𝑠
𝑑𝑡
= [𝐾𝑢𝑔𝑠 + (
𝑘𝑢𝑔𝑠𝑥𝑑𝑠
𝑘𝑠−𝑑𝑠2+𝑥𝑑𝑠
)
4
] 𝑢𝑐𝑎𝑟𝑏𝐺𝑒𝑓𝑓𝑠 (
𝑢𝑠𝑙𝑜𝑤
4
) − 𝑥𝑑𝑠                                                  [3.7] 
 
 
where influxes are glucose input and slow stomach glucose state, and outflux is the 
slow path that enters the final stomach path that follows. It is important to note that 
scaling occurs by a factor of 4, as for glucose 1 g of CHO = 4 kcal.  
 
3.4.5.2 Glucose Digestive Forward Flow Final Path (g/hr) 
 
𝑑𝑥𝑑
𝑑𝑡
= [𝑢𝑑 [(
(𝑘𝑢𝑔𝑓/2)𝑥𝑑
𝑘𝑠−𝑑+𝑥𝑑
)
4
+ (
(𝑘𝑢𝑔𝑓/2)𝑥𝑑
𝑘𝑠−𝑑2+𝑥𝑑
)
4
] 𝐺𝑒𝑓𝑓𝑓 (
𝑢𝑓𝑎𝑠𝑡
4
) + [𝐾𝑢𝑔𝑠 +
(
𝑘𝑢𝑔𝑠𝑥𝑑𝑠
𝑘𝑠−𝑑𝑠2+𝑥𝑑𝑠
)
4
] 𝐺𝑒𝑓𝑓𝑠𝑥𝑑𝑠 − 𝑥𝑑]                                                 [3.8] 
 
 
where the influxes are the glucose input (fast component) and the pre-filtered slow 
component, each sculpted for lower rates outside of their respective digestive mid-
ranges, and the outflux is the output of the digestive process, i.e., the rate of glucose 
entering the bloodstream.  
 
3.4.6  Glucose Bio-Controllers 
 
 
It is well known that xg is regulated to reach homeostatic bounds of about 80 
to 120 mg/dL (sometimes higher, if diabetic) largely through hormonal control 
action. Endogenous insulin production within the pancreas and secretion into the 
blood increases with high glucose concentration. Glucagon is a counter regulatory 
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hormone to insulin with similar mirroring dynamics for when xg is low. Glucagon 
supplements the simplified hepatic glucose production process of this model.  
Insulin and glucagon are implemented as nonlinear Hill controllers with n=4 
to best replicate known literature curves (Sorenson, 1985, Northrop, 2000, and 
Duun-Henriksen,2013) and resting levels of about 10% of maximum.  These can be 
viewed as nonlinear proportional action (P-action) controllers.  Additionally, the 
insulin biocontroller is mildly delayed, and also includes implementation of a 
derivative action (D-action) control component (see Dalla Man, 2007, for former, 
Dalla Man, 2014, for latter).  
Relative blood flow acts as an indirect controller in the fact that both glucose 
delivery from blood to different tissues and exogenous insulin delivery can both be 
affected. The rate of absorption of glucose into tissues from the blood is dependent 
on external factors that increase (or limit) blood flow, as well. Anything increasing 
blood flow to a certain tissue, such as heat or muscle activity, will increase glucose 
uptake rate into that type of tissue, of which insulin works as a signal. This mostly 
reflects changes in blood flow.  For instance, with endurance exercise, there is 
redistribution of glucose towards muscle, heart, and skin if external temperature is 
increased, with internal organs can see a decrease. For example, during a long race, 
it is harder to digest foodstuff (the creation of ‘gels’ ensued) as flow becomes 
demand-based, with decreased flow for digestive processes. With higher flow 
perfusion to muscle and other glucose sources needed (i.e. liver), both insulin-
dependent and non-insulin dependent fluxes should be up.  
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In another example, absorption may also be affected by excess tissue or an 
extremely large bolus within a short time frame, may result in limited or lowered 
absorption. This is modeled by adjusting the ratio of forward-rate parameters of the 
non-monomoric (slow) to monomeric (fast) parallel insulin pathways. Table 3.1 
below outlines appropriate parameter adjustment. The addition of a Hill saturation 
controller accounts for high dosage boluses in a short time window—linearity is 
preserved at low dosages before becoming saturated (Figure 3.6).  
 
 
Table 3.1: Factors Influencing Insulin Absorption Rate 
  Increase Ratio 
(Reffect) 
Decrease Ratio 
(Reffect) 
Increase 
Overall 
Magnitude 
(Kd) 
Decrease 
Overall 
Magnitude 
(Kd) 
Effect Slower absorption; 
non-monomeric 
absorption 
Faster absorption; 
monomeric 
absorption 
Faster 
Dissociation  
Slower 
Dissociation  
Physiologic 
Reasoning 
Injection into excess 
tissue (i.e. abdomen), 
large bolus, Slow-
Acting Type 
Hot environment, 
muscle activity, 
lean tissue, Fast or 
Regular Insulin 
Type 
  Large bolus 
Range of 
Value 
0.6-1.0 0.1-0.6 0.02-0.1 0.005-0.02 
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Figure 3.6 Effect of Dose Size on Insulin Pharmacodynamics. (Top): From Walsh, 2014: dose size 
changes pharmacodynamics of insulin. (Bottom) Recreated exogenous insulin saturation effect as 
bolus size increases (mainly due to predicted tissue absorption).  
 
 
 
Exogenous insulin, particularly injections, can be of three types with varying 
peak effect and time delays—fast, regular, and long acting (Diabetes Services, Inc). 
Injection modeling here uses half sine waves to account for varying effects. Dosage 
depends on a clinically based sliding scale accounting for current xg level and food 
GI.  Peak rates and times used for curve shaping are as follows in Table 3.2.  
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Table 3.2: Action Times for Insulin (adapted from Diabetes Services, Inc) 
Insulin Starts Peaks Ends Low Most 
Likely At: 
Usage 
Humolog/Novolog/
Apidira 
10-20 min 1.5-2.5 hr 4.5-6 hr 2-5 hr Designed to peak, 
covers meals, and 
lowers high BG’s Regular 30-45 min 2-3.5 hr 5-7 hr 3-7 hr 
Lantus 1-2 hr 6 hr 18-26 hr 5-10 hr Designed for flatter 
and longest action, 
basal insulin action 
for keeping BG flat 
when fasting 
Levemir 1-3 hr 8-10 hr 18-26 hr 8-16 hr 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Exogenous Insulin Model 
 
 
 
 
 
Insulin ‘Black Box’ Model 
Reffect: Ratio of Non-Monomeric to Monomeric Insulin 
Rtissue: Tissue Absorption Factor  
Rtype: Insulin Type Factor 
Rflow: Blood Flow Factor 
Kd: Rate Constant of Insulin Dissociation 
αM: Rate Constant of Monomeric Insulin Absorption 
αNM: Rate Constant of Non-Monomeric Insulin Absorption 
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3.4.6.1 Endogenous Insulin Control Action in Blood Plasma (mU/dl) 
 
𝑑𝑥𝑖
𝑑𝑡
= 𝐾𝑎2𝑥𝑖𝑛𝑗−𝑚 + 𝐾𝑎1𝑥𝑖𝑛𝑗−𝑛𝑚 + [𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 (
𝐺𝑟𝑒𝑓𝑖𝑥𝑔
𝑘𝑠−𝑖𝑛𝑠+𝑥𝑔
)
4
+ 𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 𝐾𝑖𝑑𝑥?̇?] −  𝐾𝑖𝑥𝑖    
[3.9] 
 
 
3.4.6.2 Endogenous Glucagon Control Action in Blood Plasma (pg/dl) 
 
𝑑𝑥𝑔𝑛
𝑑𝑡
= 𝐾𝑔𝑐 [𝑟𝑎𝑡𝑡𝑦𝑝𝑒1𝑖 (
𝐺𝑟𝑒𝑓𝑔𝑥𝑔
𝑘𝑠−𝑔𝑛 +𝑥𝑔
)
4
−  𝑥𝑔𝑛]                                         [3.10] 
 
3.4.6.3 Exogenous Insulin Delivery by Injection: Monomeric 
Absorption (mU/dl) 
 
𝑑𝑥𝑖𝑛𝑗−𝑚
𝑑𝑡
= 𝐾𝑑(𝑥𝑖𝑛𝑗−𝑛𝑚 − 𝑘𝑎2 ∗ 𝑥𝑖𝑛𝑗−𝑚)                          [3.11] 
 
3.4.6.4 Exogenous Insulin Delivery by Injection: Non-Monomeric 
Absorption (mU/dl) 
 
𝑑𝑥𝑖𝑛𝑗−𝑛𝑚
𝑑𝑡
= −(𝐾𝑑 + 𝑘𝑎1) ∗ (𝑥𝑖𝑛𝑗−𝑛𝑚) + (
ℎ𝑠𝑚𝑎𝑥∗𝑢𝑖𝑛𝑗
ℎ𝑠𝑘𝑠+𝑢𝑖𝑛𝑗
)
1
               [3.12] 
3.4.6.5 Exogenous Glucagon 
 
 
Exogenous glucagon would be an additional state, imperative to artificial 
pancreas function. A counter regulatory hormone to insulin must exist in order for 
AP technology to be possible. It is important to note that one limitation in including 
Glucagon in AP design is its short shelf life (Jacobs, 2011). New artificial pancreas 
(AP) research solutions (Jacobs, 2011) include one rather complex model 
(Neelkanta, 2006). Due to lack of data and substance instability as a part of current 
AP design, exogenous glucagon delivery is not included as a state in the Schunk-
Winters model. However, if added, its inclusion would be simplified as a (linear or 
nonlinear) 1st-order process, making the overall model 11th-order. Due to glucagon’s 
62 
 
 
 
fast dissociation, exogenous glucagon is indirectly modeled with non-muscle 
compartment action on the basis of hepatic glucose production (Jacobs, 2011).  
 
3.4.7 Additional Hormonal Actions and Methods for Inclusion 
 
 
Primary glucoregulatory hormones include insulin and glucagon, as is 
common to most models. However, it is known that there are other regulatory 
hormones for BG—three are noted here, each including a viable method for 
inclusion (e.g., as a multiplicative functional operating on one or more existing 
model parameters). 
 Amylin suppresses glucagon and works with insulin in circulating glucose by 
decreasing hepatic glucose output following ingestion, as well as slowing gastric 
emptying (Aronoff, 2014). Both insulin and amylin are produced by pancreatic β-
cells, thereby will be absent in people with Type 1 diabetes and limited in Type 2. If 
adopted, a new real-time hormonal controller could naturally modulate the 
digestive rates (e.g., slow path) and thus the Kugf parameter, and perhaps the 
glucagon rate for which glucose is used by tissue (i.e., modulate the Cga parameter).  
 A second additional hormonal controller, also real-time and anticipatory, 
could involve sympathetic nervous system effects. Included would be catecholamine 
action in response to an exercise and/or emotional induced stress that enhances 
sympathetic drive. Enhanced sympathetic drive can result in a variety of measurable 
effects including elevated HR, pupil dilation, and increased blood flow and pressure. 
Oftentimes, an increase in BG is seen, even if brief. An approach for such additional 
control action would be to modulate the GLUT2-mediated flux between the non-
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muscle and BG compartments. Hence, stressorrat, a parameter formed to scale 
added stress other than only HR fluctuation is implemented for high-intensity and 
increased stress training situations by increasing the rate at which glucose leaves xg 
from xnm via the GLUT2 flux pathway in a multiplicative manner. Greft and Kg2Max 
also have an effect as parameters involved in the GLUT2 Hill functional. Stressorrat 
works to inform exercise of additional catecholamine action (and general 
sympathetic neural system drive) that may be present. 
This concept is further developed in Chapter 4, where high heart rate (within a 
context) is proposed as a method to inform controller action.  
The hormone leptin acts to regulate the amount of excess dietary calories 
stored as fat in fat cells versus the amount of glucose stored as glycogen in the liver 
and muscles (Northrop, 2011).  The most significant location for leptin receptors is 
on the pancreatic beta cells that secrete insulin. Leptin plays a role in fat 
accumulation based on an excess of stored carbohydrates, important for long-term 
modeling simulations, greater than 24-hours. The Schunk-Winters model has this 
capability. This type of additional control would act as adaptive management, 
particularly for long-term effects such as excess glucose building in tissues over 
consecutive simulations (i.e. the ending state concentration is higher than first 
initialized), as any longer-term buildup in either of the two tissue compartments is a 
natural indicator of glycogen to fat transfer. 
These new control action modulators are proposed here and developed in 
Chapter 5 as future directions for the model.  
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3.4.8 Muscle State Inputs 
 
 
Inputs to the muscle state relate to glucose fuel consumption associated with 
meeting muscle energy demands, here assumed to be of two forms. Inputs consume 
glucose and amount is scaled appropriately according to Table 3.3 on the basis of 
supply and demand.  
Body composition inputs for the muscular state include muscle mass (out of 
total BW), mitochondrial volume, aerobic capacity, and knowledge of one’s 
anaerobic threshold zones on the basis of a VO2max stress test. The latter is not 
required for the basic model, however, if HR is known, a more personalized and 
refined model input can be estimated. Table 3.3 below shows input variations. 
 
 
Table 3.3: Exercise and Activity Input Characterization 
Input u3 u4 u5 (if obtainable) 
Characterization  Primarily aerobic or 
during long duration 
anaerobic/circuit 
training 
 Continuous  
 HR is ramp-like 
 Can be sustained  
 Sufficient oxygen is 
provided to sustain 
for energy 
 Uses oxygen to burn 
CHO and fat for 
energy 
 Primarily daily 
/training anaerobic-
dominated activity, 
or “sprints” during 
longer exercise 
 Daily Activity, 
Weight Training 
 Fluctuating HR, 
characterize by 
spikes 
 Increase in 
glycolysis 
 Increase in lactic ace 
 Lower Oxygen 
requirement 
 Glucose = fuel 
 
 HR input 
characterized by 
resting (u5 = 0) and 
maximum (u5 = 1) 
difference 
 Fluctuation or 
continuous is key 
to delineate 
between fuel mix 
type 
 Characterize 
anaerobic 
threshold and 
zones with 
VO2max stress 
test 
 
Units kcal/hr kcal/hr bpm 
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3.4.8.1 Exercise (u3) 
 
 
Exercise, dependent on intensity (kcal/hr), duration (hr), and substrate 
availability (i.e. diet and fuel before and during), is inputted as either 1) aerobic or 
2) anaerobic or a combination of both. The u3 input primarily relates to aerobic 
exercise, as shown in Table 3.3. It is important to note that the combination, or fuel 
mix, of exercise is achieved by combining the activity input with aerobic exercise 
input on a scale of aerobic capacity.  
Heart rate may also be inputted to better quantize the (potentially 
fluctuating) aerobic “pulse input” intensity (assuming zones are known), as well as 
characterize activity as anaerobic if HR fluctuations are present. Aerobic exercise is 
often continuous and ramp-like in behavior. Typically, aerobic exercise can be 
maintained, as sufficient oxygen is available for fat and carbohydrate consumption. 
Mitochondrial action is present, especially at low to moderate intensity.   
 
3.4.8.2 Daily Activity (u4) 
 
 
Considering a resting metabolic rate around 0.82, the typical human body 
derives more than half of its energy from fatty acids and the rest from glucose 
(Melzer, 2011); but many tissues (including muscle) can use whatever fuel is 
available. Activities requiring immediate energy typically utilize the 
phosphocreatine (PCr) shuttle and hence (indirectly) glucose utilization—this 
phenomena also is imperative to the onset of exercise. Many aspects of daily activity 
are often characterized as anaerobic, increasing glycolysis and glucose consumption 
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due to a low oxygen requirement (e.g., muscles recruitment that includes fast 
glycolytic fibers).  Examples are certain team sports and work around the kitchen.  
In some cases lactic acid increases, and activity can be characterized as 
demonstrating fluctuating heart rate due to ‘bursts’ of energy demand.  
Circuit training and the end of a long aerobic session may present some 
characteristics of the u4 input.  
Daily activity is inputted in kcal/hr with maximum at around 200 kcal/hr, 
although dependent on aerobic capacity.  
3.4.8.3 Heart Rate (u5) 
 
 
One advantage of our modeling framework is that dietary and exercise inputs 
do not have to be bolus inputs, in contrast to most models (Dalla Man, 2007, and 
Yamamoto, 2015), but are energy rates that can be a function of time.  Most common 
is a pulse input, i.e., an energy rate intensity over a time duration.  Heart rate can be 
inputted into the model to help sculpt the u3 input.  A standard heart rate monitor 
often measures at a frequency of 1/second, using units of beats per minute. This 
quantity is converted into model’s time step, or 100 units/hour (1 unit = 36 
seconds). Heart rate data at steady-state can be used to help quantify exercise 
intensity (and thus, potentially, u3 level), typically on the basis of anaerobic 
threshold zones, and heart rate fluctuations can be used to quantify a sudden 
stressful situation, or the onset of exercise (as well as circuit training or anaerobic 
exercise). Heart rate variability (HRV) due to breathing, etc. is not an issue as the 
time sampling unit is 36 seconds, significantly greater than the duration of HRV. 
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3.4.9 Summary of Default Parameters 
 
For full description of parameters and values refer Appendix 7.1 and 
Glossary.  A majority of the core insulin sub-model was based off of literature curves 
and clinical data from Cobelli (2007), Bergman (1981), Yamamaoto (2014), and 
Hovorka (2004). The digestive sub-model was shaped on the basis of known 
nutritional trends based on GI (Monro, 2008) and modeling approaches used by 
Yamamoto (2014). Since the addition of GI digestive dynamics is new to the 
modeling field, some personal clinical knowledge and data was also used for trend 
shaping.  
3.4.9.1 Parameter Adjustment: Person with T1D 
 
 The following parameters/relations in Table 3.4 are scaled by rattype1i (on a 
scale from 0 to 1, with 0 being no insulin production): 
  
 
Table 3.4: Type 1 Diabetic Parameter Adjustments for Insulin 
Insulin initial state 1.0 mU/dl (default) 
Insulin Controller GCi 
Residual Insulin Storage Controller GCid 
Muscle Flux Gradient Gmgrad 
 
 
 
The following parameters/relations in Table 3.5 are scaled by rattype1g, if 
determined necessary (on a scale from 0 to 1, with 0 being no glucagon production): 
 
 
Table 3.5: Type 1 Diabetic Parameter Adjustments for Glucagon 
Glucagon initial state 70 pg/mL (default) 
Glucagon Controller GCg 
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It is not well-known the extent of diabetes on glucagon production; however, 
many other mechanisms (GLUT2/GLUT4 path, muscle contraction and calcium 
influx, etc.) are redundant with glucagon’s primary actions: stimulating hepatic 
production and allowing glucose to enter the blood, that the effect of glucagon 
depletion is not as apparent as with insulin.  
From personal experience working with a certified diabetes educator (CDE) it 
is often assumed that a T1D maintains normal glucagon production (i.e. rattype1g = 
1.0). That being said, glucagon emergency injection kits are prescribed to T1D’s in 
the case of hypoglycemia as this will be a more concentrated and faster action dose 
than pancreatic produced glucagon action (due to biological sensing time delays and 
potential for delayed hepatic glycogenolysis if BG is already low and no immediate 
glucose source exists). In the model there is opportunity to scale the amount of 
glucagon production present, although a default of 1.0 is used.  
 
3.4.9.2  Parameter Adjustment: Person with T2D 
 
 Modeling insulin resistance would affect the absorption rate of glucose 
entering tissues. Insulin can be assumed to still be fully produced in the quantity 
needed for a given food intake (often excess); however, it will not be properly 
utilized, thereby resulting in elevated BG levels and eventually conversion into fats.  
In the model, some degree of insulin resistance can be related to the GLUT4 and 
GLUT2 gradients, since high tissue levels change this gradient.  One study also 
suggests moderate weakness in select skeletal muscles due to a reduction in 
mitochondrial proteins in insulin-resistant fibers (Ohlendieck, 2010). As discussed 
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in Section 3.4.7, leptin acts to regulate body fat storage, a well-known indication of 
T2D. The potential for an additional hormonal state could incorporate this 
phenomenon, as supported by Northrop (2011) in a study in which exogenous 
leptin has been used successfully to cause obese mice genetically lacking the ability 
to produce leptin to lose weight.  
 General parameter adjustments for T2D simulation (Figure 3.19) typically 
include an increased BW (and most likely non-muscle tissue) as well as decreased 
mitochondrial volume and changes to lifestyle habits—higher caloric intake, high GI 
food intake, decreased exercise and activity, etc. may be present. 
 
3.5 Model Validation: Exogenous Insulin, Digestive, Muscle Activity 
 
 
Section 3.5.1 demonstrates comparative validation of the insulin sub-model. 
Figure 3.8 shows model capabilities of an exogenous insulin bolus only with no 
other inputs. A 4 Unit bolus was compared to the normalized plasma insulin effect of 
3 separate sets of data, with one being clinically based (red dashed in Figure 3.8 
below) with the others being modeling approaches of two validated and 
comprehensive studies (Yamamoto, 2014, and Shimoda, 2004). Figure 3.9 shows 
BG, insulin, and glucagon replication an in silico T1D study by Dalla Man (2007) and 
a variety of parameter variants overplotted (Table 3.6). Focus was on response rate 
and magnitude. Figure 3.10 demonstrates model capabilities to scale based on the 
ratio of remaining insulin production of a T1D and compares non-monomeric vs. 
monomeric insulin injection response as in (Cobelli, 2009). 
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Section 3.5.2 demonstrates model digestive capabilities, particularly in 
regard to time response and magnitude. Some inputs of other models were not 
known, or did not exist, as many models do not account for GI or proportion of 
carbohydrates. However, in this case, an assumption of a mixed meal and moderate 
GI was used. Figure 3.11 highlights three key digestive studies (Dalla Man, 2007, 
Yamamoto, 2014, and Kotachev, 2010) and comparison to the Schunk-Winters 
model.  
Section 3.5.3 compares the Schunk-Winters glucagon model to that of 
Sorenson (1985) and Northrop (2000) in Figure 3.12. 
Section 3.6.5 demonstrates mitochondrial state effects in response to 
exercise input (Figure 15) in Figure 3.13. 
3.5.1 Insulin Validation  
 
Figure 3.8 compares Schunk-Winters insulin model to literature and clinical 
data. Data points were obtained from curves found in literature and overplotted in 
Matlab. Figure 3.9 demonstrates comparative model validation to Dalla Man (2014) 
in which certain parameters were varied over the course of 18 simulation runs, 
according to Table 3.6. Changed parameters (from default) are in bold. Figure 3.10 
demonstrates the effect of varying insulin production and exogenous injection of 
both non-monomeric and monomeric insulin paths as in Cobelli (2007). 
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Figure 3.8: Insulin Submodel Validation and Literature Comparison. Comparative insulin 
validation approach with a constant input amongst all sources of a fast-acting insulin bolus (i.e. 
Lispro in most studies) at t = 0 (1 time unit in the Schunk-Winters model for a duration of 5 time 
units, or 3 minutes) of 80 U/hr, or ~4 Units. Yamamoto and Shimoda plot subcutaneous insulin effect 
(min-1), or normalized so that the maximum peak is ‘1’. Clinical data is adapted from Swan (2009). All 
curves are adapted from picked data points of respective sources and fit using a smoothing spline 
function in Matlab.  
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Figure 3.9: Model Validation with Parameter Adjustment to Dalla Man (2014). Left: Dalla Man 
(2014) simulated plasma glucose, insulin, and glucagon in 100 in silico T1DM adults, adolescents, and 
children. Right: Replication of Dalla Man (2014) using parameter variations listed in Table 3.6 below. 
The upper plot shows plasma glucose with the middle demonstrating effective plasma insulin based 
on exogenous bolus, also separated into monomeric and non-monomeric components (3 states are 
shown). The lower plot depicts Hill rate and magnitude insulin kinetics. Simulations varied mainly by 
BW to simulate adults vs. children with the lower plot showing insulin rate and magnitude 
controllers (Hill functions). The meal input was the same for both Dalla Man and Schunk-Winters, of 
50g of carbohydrates at 8:00 AM (t = 1) and an optimal insulin bolus calculated according to patient’s 
own carbohydrate to insulin ratio. Dalla Man focused on varying insulin sensitivity amongst patients, 
whereas in the left replication, variations focused on changing insulin sensitivity (or level of one’s 
own insulin production) and BW parameters as well as muscle and non-muscle tissue mass.  
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     Table 3.6: Parameter Simulation Variants for Dalla Man (2014) Validation (Figure 3.9)  
Note: The changed simulation parameters (from default) are highlighted in each respective column. Values were 
chosen both above and below the default on the basis of sensitivity.  
*Type 1 ratio refers to the amount of insulin the T1D is still able to produce. A value of 0 = no insulin 
production and a value of 1.0 = non-diabetic production. 
 
 
BM (kg) 
Muscle 
(kg) 
Non-
Muscle (kg) 
Mitochondria 
to Muscle 
Ratio 
Type 1 
Ratio* 
Starting BG 
(mg/dl) 
Insulin Dose 
(U/hr) 
Meal 
Magnitud
e (g CHO) 
70 30 25 0.1 0 130 20 50 
70 35 20 0.1 0 130 20 50 
70 25 30 0.1 0 130 20 50 
50 21.5 18 0.1 0 130 20 50 
90 38.7 32.4 0.1 0 130 20 50 
100 43 36 0.1 0 130 20 50 
40 21 18 0.1 0 130 20 50 
70 30 25 0.2 0 130 20 50 
70 30 25 0.05 0 130 20 50 
70 30 25 0.3 0 130 20 50 
70 30 25 0.1 0.5 130 10 50 
70 30 25 0.1 0.25 130 15 50 
70 30 25 0.1 0 100 20 50 
70 30 25 0.1 0 120 20 50 
70 30 25 0.1 0 150 20 50 
70 30 25 0.1 0 130 15 50 
70 30 25 0.1 0 130 25 50 
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Figure 3.10: T1D Simulations Scaled by Percent Insulin Production.  T1D simulations scaled by 
% remaining insulin production with 50g CHO input and simultaneous injection as in (Cobelli 2007). 
Insulin absorption controllers for exogenous input are shown. 
 
 
3.5.2 Digestive Validation 
 
Figure 3.11 demonstrates meal validation and effects of varying glycemic 
index and carbohydrate ratio as seen throughout literature. Figures in the left 
column compare overplots of digestive input, BG and insulin. The right column 
highlights replicated inputs.  
75 
 
 
 
Model Replication Input and Study Description 
 
3.5.2.1.1.1.1 Replication: 
 78g CHO meal with GI = 50, 50% CHO with duration of 3 minutes 
 BW = 78 kg and x(1,1) = 90 mg/dl 
Dalla Man (2007): 
 Mixed Meal with 1+/- 
0.02 g/kg of glucose 
 204 normal subjects 
 BW = 78 +/- 1 kg 
 Age 56 +/- 2 years 
 Starting BG ~ 90 mg/dl 
 
 
 
3.5.2.1.1.1.2 Replication: 
 50g CHO meal with GI = 83 (potato) and 41 (spaghetti), 60% CHO (potato) 
and 78% CHO (spaghetti) with duration of 3 minutes 
 BW = 78 kg and x(1,1) = 140 mg/dl 
 Fast-Acting Insulin Bolus = 50 U/hr 
Yamamoto (2014): 
 Mixed Meal Staple Foods 
with 50g CHO 
 Clinical data: Mohammed 
(2003), 8 T1D subjects 
 Insulin Lispro: 10 IU at t = 
0 
 Starting BG ~ 140 mg/dl 
 Potato: GI = 83; %CHO = 
0.6 
 Spaghetti: GI = 41, %CHO 
= 78 
 
 
Kotachev (2010): 
 Ensure Plus with 50g 
CHO 
 One subject T1D study  
 Insulin: ~ 4U 
automatically delivered 
via closed-loop control 
 Starting BG ~ 100 mg/dl 
 GI = 44, %CHO = 57 
Figure 3.11: Digestive Submodel Validation and Literature Comparison 
 
 
3.5.3  Glucagon Validation 
 
Figure 3.12 demonstrates glucagon effect curves found in literature vs. blood 
glucose concentration. The top two plots are found in literature, with the Schunk-
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Winters model simulation on bottom. Note that glucagon is plotted vs. BG on the 
right axis.  
 
 
  
 
 
Figure 3.12: Glucagon Submodel Validation and Literature Comparison. Glucagon model 
comparison with Schunk-Winters model (bottom) validated by Northrop (2000) (top left) and 
Sorenson (1985) (top right) glucagon vs. blood plasma glucose plots. Note that the Schunk-Winters 
model plots glucagon (dashed) scaled on the right axis. 
 
 
3.5.4 Mitochondrial State Validation 
 
 
In order to see mitochondrial state effect, Figure 3.13 demonstrates a 2-hour 
aerobic session with and without Xmito present. Exercise input appears to smooth 
out, indirectly validating that the addition allows BG to rise due to increased ATP 
efficiency, particularly during aerobic exercise. The mitochondrial state will be 
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further developed in Chapter 4.  In Chapter 3, the state is relatively conservative and 
sensitivity will be important in regards to athletes (Chapter 4) and increased 
mitochondrial volume.  
 
  
Figure 3.13: Mitochondrial State Validation. Two hour exercise session informed by HR input with 
(left) and without (right) mitochondrial state consumption present (lower plot).  
 
 
3.6 Results: Sensitivity Analysis and Simulation Output 
 
 
Parameter sensitivity analysis was performed for 23 of the 68 model 
parameters, with emphasis on representative parameters for various relations (e.g., 
often 1 of 3 for most Hill functions).  These can be separated into control/rate 
parameters, threshold values, and scaling and maximum flux rates.  Increments of + 
10% were used to scale parameters from the nominal value, with behaviors 
extracted from state trajectories that included peaks and magnitudes at strategic 
times during strategic tasks, including pre- and post-meal, as well as pre- and post- 
exercise.  It is recognized that many forms of sensitivity analysis exist; however, this 
approach was most applicable in that sensitivity of a given behavior (extracted from 
state trajectories) to a particular parameter could be computed. In all cases 
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sensitivity coefficients were obtained using the following equation, defined by 
Lehman et al, 1982: 
(𝐵+−𝐵−)
𝐵𝑜
⁄
(𝑃+−𝑃−)
𝑃𝑜
⁄
.                                                                      [3.13] 
(B+-B_) refers to the change in state behavior of interest (i.e. xg) and normalized to 
make the quantity dimensionless, and (P+-P_) refers similarly to the parameter of 
interest.  Results for the default non-diabetic and Type I diabetic models are 
provided in Appendices 7.6.1 and 7.6.2, respectively, for 4 tasks (see also Tables 3.9-
3.13):  
 nominal steady-state level (u1=u2=u3=u4=u5=0),  
 meal (u1 input only for non-diabetic, also u2 for Type 1 diabetic),  
 snack (also u1, and u2 for Type 1 diabetic), and  
 moderate endurance exercise (u3 input).    
 
 
Table 3.7: Sensitivity Analysis Inputs 
Meal Snack Exercise 
 700 kcal total 
 30 minute duration 
 175 g CHO (GI = 50, 50% 
CHO) 
 Simulation times: 0.3 
hours before, 0.3 hours 
after ingestion, 1 hour 
post-meal 
 60 kcal total 
 6 minute duration 
 15 g CHO (GI = 80, 80% 
CHO) 
 Simulation times: 0.3 
hours before, 0.3 hours 
after ingestion, 1 hour 
post-meal 
 
 600 kcal/hr for 1 hour 
 Aerobic Capacity = 1000 
 Simulation times: 30 min 
before, halfway, 18 min after 
  
 
 
In general, all states exhibited sensitivity to various parameters, but as might 
be expected, it was very task-specific.  For instance, there are several unidirectional 
pathways: digestive submodel parameters would not be expected to influence the 
response to exercise since u1=0, and exogenous insulin submodel parameters 
would never influence non-diabetic model responses since u2=0.  As certain state 
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equations are highly coupled either through compartmental or control modeling 
(e.g., xg, xnm, xm, xi, xgn), it can be expected that all parameters entering into these 
relations will exhibit a degree of sensitivity.  Some of the key results are highlighted 
in Tables 3.9-3.13 (parameters those with threshold of the value being greater 
than 0.4 for a given behavior extracted from a given state trajectory) and Figures 
3.14-3.15. Figure 3.16 includes a chart of overall most sensitive parameters for meal 
and exercise combined.   
      Insensitive parameters, and therefore reaching constant value in our model, are 
outlined in Table 3.8. Key values here for snack and meal are mitochondrial 
associated parameters, as well as ks-ds, the ‘half-way’ Hill saturation value for the 
slow digestive pathway. In regards to exercise, constant parameters include those 
associated with the digestive compartment, as expected, with insulin parameters 
remaining relatively insensitive (see Table 3.13), as glucagon is the main controller. 
 
Table 3.8: Constant Parameters (Sensitivity Consistently < 0.05) 
Meal Snack Exercise 
Ka2* 
Ka1* 
Kd* 
Km-xex 
Rat_ia 
Hs_max 
Hs_rate 
Kprop 
ratmito 
Ka2* 
Ka1* 
Kd* 
Km-xex 
Kse 
Ksds 
Hs_max 
Hs_rate  
Kprop 
ratmito 
Ka2* 
Ka1* 
Kd* 
Kugf 
Kse 
Ksds 
Hs_max 
Hs_rate 
*These parameters are associated with injection and become sensitive when injection is present (i.e. 
T1D) 
 
 
 
It was determined that steady-state levels of certain strategic states such as 
xg (BG) are quite sensitive to certain parameters, especially those that directly or 
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indirectly affect BG, since this is the compartmental conduit through which xg, xnm, 
xm, xi,  and xgn interact.  These important sensitivities are provided in Table 3.10 for 
the T1D model and 3.9 for the non-diabetic model, including both parameters 
associated with compartmental flow rates and with controller signals. 
It was determined that GLUT4 was a main driver along with insulin 
controllers Cia and Cib.  An example of state trajectories with variation in this 
parameter is provided in Figure 3.14.  In another example, during exercise, Kg2max 
was key for stimulating glucagon action, summarized in Tables 3.11-3.13 looking in 
the Xgn column. Other sensitive parameters during exercise include the muscle 
gradient Hill parameter and reference threshold for muscle, kmintol, which also had 
sensitivity during meal as well. Scaling parameters, such as wratt, were also 
sensitive per their corresponding compartment (i.e. xnm). Insulin elimination rate, 
Ki, was sensitive for the BG state in both meal and snack simulations, as expected.  
Sensitivity analysis was also performed for both T1D simulations (Appendix 
7.6.1), with key differences in that T1D show no sensitivity to certain plasma insulin 
controller parameters but have high sensitivity for most states in regard to injection 
parameters: kd (insulin dissociation), ka1 (non-monomeric insulin forward rate) and 
ka2 (monomeric insulin forward rate). Additionally, exercise sensitivity behavior for 
T1D is diminished with Cga, Kgt, ratmito, Kg2Max, and Grefg as the only sensitive 
parameters. Hence, only non-diabetic sensitivity is shown with all sensitivity 
behaviors and simulations in Appendix 7.6 and is more inclusive due to a lower 
threshold (>0.4). 
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Table 3.9: Steady-State Sensitivity Analysis for Non-Diabetic with Basal Glucose Infusion of 50 kcal/hr 
 Xg Xnm Xm Xd Xds Xi Xinj-m Xgn Xinj-nm Xmito 
T = 24 
hours 
Ki 0.321 
Cga 1.336 
Kgt 1.339 
Grefi 0.840 
Grefg 4.653 
Greft 2.726 
Kg2Max -1.144 
 
Ki -0.795 
Cib 0.867 
Cga 0.487 
Kgt 0.472 
Grefi -2.047 
Grefg 1.632 
Greft 0.978 
Gbt 0.772 
Kg2Max -0.412 
Kmxex -0.644 
Kse -0.463 
KMintol 0.677 
 
Ki -2.278 
Cib 2.475 
Cga 1.309 
Kgt 1.267 
Grefi -5.857 
Grefg 4.380 
Greft 2.625 
Kg2Max -1.105 
Kmxex -1.837 
Kse -1.321 
KMintol 1.92 
Ratmito 1.648 
___ ___ Ki 1.878 
Cga -0.890 
Kgt -0.892 
Grefi 4.950 
Grefg -3.091 
Greft -1.816 
Kg2Max 0.763 
 
__ Cga -0.946 
Kgt -0.948 
Grefi -0.595 
Grefg 2.532 
Greft -1.929 
Kg2Max 0.806 
___ __ 
Steady-
State 
Values 
90 mg/dl 5 g/kg 10 g/kg 0 0 1.0*ratType1i 
 
0 0.45*ratType
1g 
0 0 
 
 
 
 
Table 3.10: Steady-State Sensitivity Analysis for T1D* with Basal Infusion of 0.75 kcal/hr and Basal Insulin 0.05 U/hr 
 Xg Xnm Xm Xd Xds Xi Xinj-m Xgn Xinj-nm Xmito 
T = 24 
hours 
Cga 1.194 
Kgt 1.197 
Grefg 4.217 
Greft 2.635 
Kg2Max -1.207 
Gbt 0.819 
Kd 0.436 
Ki -0.640 
Cib 0.642 
Kmintol 0.458 
Kd 1.427 
Ratmito 2.038 
___ __ Ki -1.270 
Ka2 -7.894 
Ka1 0.462 
Kd 2.948 
Ka2 -
9.604 
Ka1 0.462 
Kd 2.948 
Cga -1.109 
Kgt -1.112 
Grefg 2.444 
Greft -2.442 
Kg2Max 1.114 
Ka1 8.843 
Kd 
108.100 
__ 
Steady-
State 
Values 
110 mg/dl 5 g/kg 10 g/kg 0 0 1.0*ratType
1i 
 
0 0.45*ratType1
g 
0 0 
*Rattype1i = 0 
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Table 3.11: Non-Diabetic Meal Simulation Sensitivity Analysis 
 Xg Xnm Xm Xds Xi Xgn 
Xmaxb Ki 1.149 
Cia -0.733 
Kugs 0.578 
Kmintol -0.784 
Wratt 1.068 
Kmintol -0.523 
Cib 0.589 
Kmintol 1.306 
Kugs 
0.662 
Ki -0.796 
Grefi 0.612 
Grefg -1.272 
___ 
XBMc Ki -1.879 
Cia -1.225 
Cib 3.090 
Cga 1.461 
Kgt 1.446 
Grefi -4.317 
Grefg 5.518 
Greft 1.872 
Kg2Max -0.751 
Kmxex -1.233 
Kse -0.921 
Kmintol -4.281 
Ratmito 1.079 
Ki -0.550 
Cib 0.732 
Grefi -1.106 
Grefg 1.267 
Gbt 0.504 
Wratt 0.496 
Kmintol 0.971 
Ki -0.973 
Cib 1.296 
Cga 0.620 
Kgt 0.611 
Grefi -1.952 
Grefg 2.249 
Greft 0.605 
Kmxex -0.665 
Kse -0.500 
Kmintol 1.690 
Ratmito 0.645 
___ Ki -3.031 
Cia -1.147 
Cib 3.129 
Cga 1.311 
Kgt 1.296 
Grefi -4.489 
Grefg 4.857 
Greft 1.726 
Kg2Max -0.707 
Kmxex -1.252 
Kse -0.936 
Kmintol -4.060 
Ratmito 1.083 
Ki -2.472 
Cia -0.857 
Cib 3.297 
Cga 0.768 
Kgt 0.752 
Grefi -5.576 
Grefg 6.373 
 
XDMRd __ Ki -1.311 
Cia -1.131 
Cib 2.198 
Cga 0.796 
Kgt 0.780 
Grefi -2.666 
Grefg 2.966 
Greft 0.894 
 
Gbt 1.486 
Kugf -1.035 
Wratt -0.486 
Kg2Max -1.315 
Kmxex -1.125 
Kse -0.848 
Kmintol 2.995 
Ki -0.845 
Cib 1.201 
Cga 0.533 
Kgt 0.526 
Grefi -1.686 
Grefg 1.939 
Greft 0.522 
Kmxex -0.544 
Kse -0.421 
Kmintol 1.622 
Ratmito 0.506 
Kugs 
0.717 
Kid 0.890 Ki -0.511 
Cga 0.635 
Kgt 0.636 
Grefi -1.025 
Grefg 1.301 
Greft -0.615 
XDMFe Ki 0.546 
Cia -0.431 
Kid -0.402 
Wratt 1.077 
Kmintol -0.456 
Cib 0.649 
Kmintol 1.137 
 
Kugs 
0.600 
 
Ki -1.165 
Grefi 0.455 
Grefg -0.621 
Ki -0.451 
Cga -0.608 
Kgt -0.609 
Grefi -1.002 
Grefg 1.444 
Greft -0.582 
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Table 3.12:  Non-Diabetic Snack Simulation Sensitivity Analysis 
 Xg Xnm Xm Xd Xds Xi Xgn 
Xmaxb Ki 1.380 
Cia -0.618 
Cga 1.197 
Kgt 1.200 
Grefi 1.424 
Grefg 4.366 
Greft 0.991 
___ Ki -0.940 
Cib 1.327 
Cga 0.633 
Kgt 0.625 
Grefi -1.760 
Grefg 2.242 
Greft 0.603 
Kugf 
0.549 
 
Kugs 0.972 Ki -6.047 
Cia -0.487 
Cga 1.927 
Kgt 1.932 
Grefi -8.041 
Grefg 6.924 
Greft 1.307 
___ 
XBSc Ki 0.776 
Cia -0.479 
Cga 0.920 
Kgt 0.922 
Grefi 1.562 
Grefg 3.415 
Greft 0.890 
Ki -0.534 
Cib 0.778 
Cga 0.449 
Kgt 0.444 
Grefi -1.049 
Greft 1.593 
Greft 0.418 
Gbt 0.451 
Wratt 0.549 
Kmintol 0.621 
Ki -1.014 
Cib 1.406 
Cga 0.719 
Kgt 0.710 
Grefi -1.994 
Grefg 2.534 
Greft 0.666 
Kmxex -0.684 
Kse -0.513 
Kmintol 1.126 
Ratmito 0.605 
___ ___ Ki 54.629 
Cia 12.176 
Cib 7.400 
Cga -23.404 
Kgt -23.455 
Grefi 109.876 
Grefg -86.464 
Greft -22.650 
Kg2Max 6.985 
Kmxex -3.746 
Kse -2.814 
Kmintol 8.313 
Ki 0.866 
Cia -0.531 
Cga 1.026 
Kgt 1.028 
Grefi 1.744 
Grefg -2.752 
Greft 0.991 
XDSRd Ki 0.774 
Cia -0.479 
Cga 0.921 
Kgt 0.923 
Grefi 1.559 
Grefg 3.416 
Greft 0.891 
 
 
Ki -0.534 
Cib 0.778 
Cga 0.449 
Kgt 0.444 
Grefi -1.049 
Greft 1.593 
Greft 0.418 
Gbt 0.451 
Wratt 0.549 
Kmintol 0.621 
Ki -1.014 
Cib 1.406 
Cga 0.719 
Kgt 0.710 
Grefi -1.994 
Grefg 2.534 
Greft 0.666 
Kmxex -0.684 
Kse -0.513 
Kmintol 1.126 
Ratmito 0.605 
 
___ ___ Ki 54.629 
Cia 12.176 
Cib 7.400 
Cga -23.404 
Kgt -23.455 
Grefi 109.876 
Grefg -86.464 
Greft -22.650 
Kg2Max 6.985 
Kmxex -3.746 
Kse -2.814 
Kmintol 8.313 
Ki 0.866 
Cia -0.531 
Cga 1.026 
Kgt 1.028 
Grefi 1.744 
Grefg -2.752 
Greft 0.991 
XDSFe Grefi 0.608 
Grefg 1.054 
Ki -0.547 
Cib 0.797 
Cga 0.451 
Kgt 0.446 
Grefi -1.076 
Grefg 1.604 
Wratt 0.535 
Kmintol 0.653 
Ki -1.009 
Cib 1.399 
Cga 0.711 
Kgt 0.702 
Grefi -1.987 
Grefg 2.510 
Greft 0.661 
Kmxex -0.680 
Kse -0.510 
Kmintol 1.152 
__ Kugs 0.887 Ki -0.852 
Grefi -0.985 
Grefg 0.619 
Kugf 0.450 
Kid 0.836 
Grefi 0.510 
Grefg -1.046 
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Table 3.13: Non-Diabetic Exercise Simulation Sensitivity Analysis 
 Xg Xnm Xm Xi Xgn Xmito 
Xmaxb Ki 1.819 
Cia -2.214 
Cib -1.456 
Cga 1.168 
Kgt 1.170 
Grefi 2.091 
Grefg 4.594 
Greft 1.611 
Kg2Max -0.522 
Kmintol -1.315 
Kid -2.706 
___ Ki -0.550 
Cib 0.994 
Cga 1.449 
Kgt 1.440 
Grefi -0.993 
Grefg 4.197 
Greft 0.675 
Kmxex 0.591 
Kse -0.557 
Kmintol 0.692 
Ratmito -1.166 
Ki -2.196 
Cia -0.418 
Cga 0.836 
Kgt 0.839 
Grefi -2.160 
Grefg 2.902 
Greft 0.541 
Kmxex 0.915 
Kid 0.745 
Ki 1.043 
Cia -1.337 
Cib -0.901 
Cga 1.429 
Kgt 1.432 
Grefi 1.412 
Grefg -4.218 
Greft 1.160 
Kg2Max -0.458 
Kmintol -0.789 
Kid -1.682 
Grefg -0.201 
XBEf Ki 0.810 
Cia -0.469 
Cga 0.913 
Kgt 0.915 
Grefi 1.629 
Grefg 3.388 
Greft 0.877 
Ki -0.403 
Cib 0.708 
Cga 0.525 
Kgt 0.520 
Grefi -0.738 
Grefg 1.797 
Greft 0.464 
Wratt 0.602 
Ki -0.941 
Cib 1.404 
Cga 0.772 
Kgt 0.763 
Grefi -1.756 
Grefg 2.582 
Greft 0.666 
Kmxex -0.654 
Kse -0.489 
Kmintol 0.903 
 __ Ki 0.916 
Cia -0.527 
Cga 1.030 
Kgt 1.032 
Grefi 1.839 
Grefg -2.889 
Greft 0.987 
___ 
XDEg Cga -0.951 
Kgt -0.953 
Grefg -2.478 
Kmxex 0.838 
Cib 0.421 
Cga 0.538 
Kgt 0.535 
Grefi -0.460 
Grefg 1.570 
Wratt 0.743 
Ki -0.533 
Cib 0.893 
Cga 0.976 
Kgt 0.969 
Grefi -0.996 
Grefg 2.902 
Greft 0.572 
Kse -0.432 
Kmintol 0.585 
Ki 2.378 
Cga -1.293 
Kgt -1.297 
Grefi 3.298 
Grefg -3.808 
Greft -0.541 
Kmxex 0.475 
Kid -0.911 
Kgt -1.197 
Kgt -1.199 
Grefg 1.085 
Kmxex 0.874 
Grefg -0.135 
XRh Cga 0.838 
Kgt 0.840 
Grefi 0.539 
Grefg 2.788 
Greft 0.470 
Kmxex 0.548 
Kid -0.442 
Cga 0.464 
Kgt 0.461 
Grefg 1.355 
Wratt 0.825 
Ki -0.567 
Cib 0.996 
Cga 1.539 
Kgt 1.529 
Grefi -1.059 
Grefg 4.433 
Greft 0.711 
Kmxex 0.619 
Kse -0.589 
Kmintol 0.673 
Ratmito -1.310 
Ki -0.958 
Cga 0.614 
Kgt 0.616 
Grefi -0.910 
Grefg 2.101 
Kmxex 0.827 
Kid 1.033 
Ki 0.509 
Cga 3.173 
Kgt 3.181 
Grefi 0.890 
Grefg -2.388 
Greft 0.983 
Grefg 0.272 
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Figure 3.14: Non-Muscle Gradient Sensitivity Effect. Sensitivity effect of varying the GLUT2 non-
muscle gradient parameter for a non-diabetic, Kg2Max, with an input of 600 kcal/hr exercise at t = 
3.5 hours and a 700 kcal meal of duration 30 minutes (GI = 50, %CHO = 50) at t = 13 hours.  
 
 
 
 
 
Figure 3.15: Muscle Gradient Sensitivity Effect. Sensitivity effect of varying the gratm muscle-
blood glucose demand gradient parameter for a non-diabetic, with an input of 600 kcal/hr exercise at 
t = 3.5 hours. 
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Figure 3.16: Frequency of Most Sensitive Parameters. Frequency of most sensitive parameters 
using total appearances over all sensitivity trials. The most sensitive in regard to xg (Grefg, Greft, Kg2max, 
and Kg4max) are also shown as a frequency plot.  Bias is eliminated toward foodstuff but only including 
meal and exercise simulations (snack is ignored). Top: Meal and exercise simulations combined 
(overall sensitivity without bias toward meals and/or exercise). Bottom: Xg state sensitivity for both 
meal and exercise combined.
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3.7 Model Predictions for 24-Hour Lifestyle Simulations 
 
 
Section 3.7.1 demonstrates model digestive capabilities of varying GI vs. the 
proportion of carbohydrates in a mixed meal in Figure 3.17.  
Section 3.7.2 demonstrates 24-hour simulation runs and overall model 
capabilities of a non-diabetic to that of a T1D (Figure 3.18) and results of a poor 
lifestyle and reaching T2D implications (Figure 3.19). 
 
3.7.1 Low vs. High GI and Proportion of Carbohydrate Variation 
 
 
 
Figure 3.17: Low vs. High GI Foodstuff Comparison.  Low vs. High GI foodstuff comparisons with 
a) kfast = 0.5 and 90% CHO vs. b) kfast = 0.5 and 20% CHO (blue BG curves) and varying GI with c) 
kfast = 0.9 and 50% CHO vs. d) kfast = 0.5 and 50% CHO vs. e) kfast = 0.2 and 50% CHO. Meal 
constants are for a non-diabetic subject all with 100g CHO input and a duration of 6 minutes. Note 
the black solid lines of the input plot is ‘cut-off’’ due to n input of 4000 kcal/hr for 6 minutes (i.e. 400 
kcal or 100g of CHO).  
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3.7.2 24-Hour Simulation  
 
 
Figure 3.18: Non-Diabetic and T1D 24-Hour Simulations. Four 24-hour simulations: 1) atypical 
T1D with no insulin injection or exercise (BW = 80kg, wmito = 0.1), 2) Healthy T1D with meal rapid-
acting injections and long-acting basal injection (BW = 70, wmito =0.3), 3) same healthy T1D with no 
long-acting insulin, and 4) non-diabetic with similar inputs as (2).  Inputs (top plot) include 3 
meals/3 snacks (black solid, red digestive state), 700 kcal/hr exercise. Muscle and non-muscle mass 
is kept consistent. A Healthy (large exercise, ~2000 kcal/day and mainly low GI meals) T1D shows 
natural regulation (good steady-state BG range) and can get ‘better’ than a non-diabetic with proper 
injection and timing (see second vs. third meal) and basal insulin. With lack of exercise and T1D 
glucose management, there is glycogen accumulation predicted, especially in non-muscle 
compartment. 
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Figure 3.19: T2D Precursor 24-Hour Simulation. Effects of poor lifestyle habits and how, if 
continued over an extended period of time (>3 weeks), body remodeling could occur and be a T2D 
precursor model.  
 
 
3.8 Discussion 
 
 
The model aims to predict BG regulation based on various lifestyle choices and 
diabetes, while using the lowest possible number of states that can provide robust 
and personalized conditions and predictions.   Through its distinct framework, new 
perspectives are possible.  
GI, often promoted as an influential factor in people with diabetes, is predicted 
to have a strong dynamic effect: a low glycemic diet (Figure 3.17) decreases glucose 
spikes while also predicting reasonable insulin control action and storage in muscle 
and non-muscle tissues. Low GI meal content tends to absorb slower, coinciding 
with the idea that whole grains, higher fiber, and unprocessed glucose will keep an 
individual feeling ‘full’ for longer. In the digestive validation section (Section 3.5.2) it 
is demonstrated particularly in the non-diabetic simulation, that there are two 
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peaks due to a separation of fast vs. slow carbohydrate absorption and hence rate of 
appearance into the blood stream (xg)—this is common for mixed meals (i.e. 
fraccarbs <1.0). It is recognized that our model has faster insulin and meal transient 
dynamics than Dalla Man (2007) and Yamamoto (2014) in response to high-GI 
meals; however, on the basis of collected data (Chapter 4) and a variety of 
references supporting both cases (i.e. Dalla Man, 2007, vs. Shimoda, 2000) this is not 
recognized as a limitation. 
 Further, direct validation comparisons were limited in that our digestive 
submodel is more complex than most, with separation of absorption dynamics into 
two states, as well as influences of body composition. This made it difficult for direct 
comparison to Dalla Man (2007), as their ‘mixed meal’ could not be precisely 
replicated in our model without knowledge of glycemic index and fraction of carbs 
(50% was assumed for modeling purposes). The Dalla Man model and parameters 
are used by many others, and resulted in an FDA approved model—particularly for 
insulin, which validates our model in terms of magnitude and rate of increase for 
insulin response (Section 3.6.1). Our model is highly valid for mixed meals known in 
literature, with a slightly faster response to high-GI foodstuff than most, yet most 
models do not have capability of differentiating high-GI. 
A key insight from model validation is that daily activity, exercise, dietary 
choices (GI) and body composition (including mitochondrial volume) are seen to be 
important for BG management. Further, in 24-hour simulations, there were 
frequently upward and downward drifts of glucose (mostly as glycogen) 
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concentration in the tissues which could be associated with lifestyle choices and, for 
people with diabetes, insulin management.  
Steady-state sensitivity analysis (Tables 3.9 and 3.10) shows some high-
sensitivity parameters when inputs (all u) are set to zero, explaining some steady-
state adjustments that needed to be addressed. For example, it was found that due 
to an elevated starting value, glucagon was causing a drifting of BG upwards when 
t<1hr, hence the model was adjusted adding this baseline sensitivity. Insulin and 
glucagon controllers, along with GLUT2 and GLUT4 gradients, were consistently the 
most sensitive parameters at steady-state for a non-diabetic (states xg, xnm, and xm). 
Gref parameters were also sensitive, as expected (xi and xgn), for T1D as well. T1D 
steady-state sensitivity was focused on glucagon controllers (xg, and xnm), as well as 
GLUT2 gradient and basal tissue metabolism. Starting blood glucose value was set 
higher for a T1D at 137 mg/dl vs. 100 mg/dl for non-diabetic.  
Sensitivity analysis (Tables 3.9-3.13) highlights some key aspects of the model: 
high sensitivity to adjustments of reference values for BG-tissue flux pathways 
(Gref’s), especially to hormonal control action (as expected). This is true for BG and, 
importantly, more so for both tissue compartments. Other key sensitivity data 
relates to mitochondrial volume proportion in regards to exercise, and sensitivity to 
basal elimination rates particularly for non-muscle and in regard to insulin (Table 
3.12 and 3.13).  Meal and snack sensitivities (expressed mainly through the xg, xnm, 
xm, xds, xd, and xi states) include mainly insulin control and non-muscle tissue scaling 
in addition to digestive forward rate controllers.  Additionally, it is important to 
recognize that non-diabetics can still have a BG spike at the onset of a meal due to 
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this control (which is contradictory to what one believes) since with endogenous 
insulin production there is no anticipatory effect (Figure 3.18). 
Meal onset and insulin timing has relevance to T1D insulin sensitivity, 
especially with timing:  taking rapid-acting insulin 15 minutes prior to a meal (as 
typically suggested clinically) was beneficial.  However, the model predicts that a 
T1D who does not take any insulin is able to slowly “regulate” BG, perhaps more 
effectively than the experience of many T1D’s; this is a byproduct of our 
implementation of the GLUT2 pathway (and some residual production), which was 
hard to fine-tune because of a lack of experimental data.  T1D can take their insulin 
as early as necessary, and theoretically could have better control than a non-
diabetic. However, that being said, spikes in non-diabetics tend to be brief, as 
endogenous insulin acts much more rapidly than exogenous. T1D sensitivity 
analysis additionally demonstrates exogenous insulin rate effects, particularly with 
ka1, ka2, and kd, the nonlinear fast and slow insulin and dissociation parameters, 
respectively. 
Perhaps the most novel insight from the model is the sensitivity of model 
behavior to parameters associated with the GLUT2 and GLUT4 pathways, denoted 
from Figure 3.14 and 3.15, both of which are known to be influenced by factors 
other than hormonal control, including physical laws (e.g., the blood-tissue glucose 
concentration gradient), and are predicted to influence relative balance between BG 
states and tissue. This is further exemplified by increased sensitivity to Kg2Max 
(Table 3.11) and muscle gradient parameters (i.e. kse). These insights, along with 
manifold predictions of high tissue concentrations with certain lifestyle protocols 
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(including simulations not presented here), suggest new research directions for 
helping understand the complex phenomena called insulin intolerance, and by 
inference, the longer-term etiology of T2D as a function of lifestyle choices.  With 
possible additions of a hormonal state, leptin would help shape glucose mass 
conservation via activation of conversion to fat (if in excess) and further more 
possibilities for personalized lifestyle implications and T2D. 
      In regard to model output limitations, because insulin, glucagon and 
corresponding glucose effect have a high model sensitivity in regard to control 
parameters (i.e. steady-state sensitivity coefficient for Cga is ~1.8 and Cia is ~0.3)—a 
slight input error would have a large effect on BG, decreasing accuracy.   
       Exercise also has a drastic effect and aids in BG control as seen in the 24-hour 
simulations. There is an influx from BG (which decreases) as muscle glycogen 
gradually becomes depleted (Figure 3.18) which in turn activates glucagon control 
(xgn) in order for non-muscle glucose storage (mostly hepatic) to restore BG levels 
via glycogenolysis. Consequently, non-muscle tissue glucose (xnm) decreases. Daily 
activity effects are less drastic as expected, but clearly influence glucose tissue 
stores, especially xm, helping prevent meal-related buildup (Figures 3.18 and 3.19) 
and thus providing a natural form of advantageous glucose management.  
 The addition of a mitochondrial state allows for a smoother dynamic 
response and glucose transfer, particularly during aerobic exercise (Section 3.5.4, 
Figure 3.13), as seen with the ability for BG to rise during long duration exercise (i.e. 
more efficient glycolysis and ATP utilization at moderate intensities) when 
mitochondrial state is present (left of Figure 3.13) vs. when xmito is set to 0 (right). 
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             The antagonistic effects of insulin and glucagon control action are 
documented, important for both transient and steady state behavior. Exogenous 
insulin is affected by flow, body mass, and dose size, as higher saturation tends to 
occur with increased tissue mass and dose (Figure 3.6 from Section 3.4.1).  
T1D simulations (Figure 3.18) depict the differing effects of long-acting, 
rapid-acting, and regular delivery, including timing. T2D is only indirectly modeled, 
through an “intolerance” effect based on excessive (saturating) glycogen storage in 
tissues and indirectly through assumptions of body composition.  However, it 
illustrates how “poor” lifestyle habits can cause gradual glucose accumulation in 
tissue compartments (Figure 3.19). Future directions for simulations could study 
longer time periods (e.g., weeks).  
    With regards to model capabilities and limitations, our model accurately 
depicts the reactive effects of exercise, i.e., those related to utilization of glucose for 
energy with HR as a separate, external input for tuning and validating predicted 
exertion if accessible (Chapter 4 and Figure 3.13, as a part of mitochondrial state 
validation).  Anaerobic exercise elicits spikes via immediate glucose demand and 
hormonal action with higher glucose utilization as intensity increases, while aerobic 
efforts tend to utilize the mitochondrial state and glycolysis efficiency, often relying 
more so on a fuel mix (i.e. fat). Short periods of hyperglycemia may be evident due 
to release in stress hormones before or at the onset of exercise. The latter is 
suggested by case study data during anaerobic exercise in Chapter 4. Along with all 
other models, our model cannot yet predict the “anticipatory” adrenaline effect of a 
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short rise in BG, although with the addition of HR and a hormonal state this is 
possible. 
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4. PERSONALIZED ADAPTED MODEL FOR DIABETIC ATHLETES: 
IMPLEMENTATION OF A FEMALE TYPE 1 CASE STUDY 
 
4.1  Introduction 
 
 
A novel nonlinear 10-state lumped compartmental model was presented in 
Chapter 3 and aimed to provide a robust model with default parameters. 
Furthermore, it was designed to provide flexibility for variable body mass, muscle to 
non-muscle ratio, and Type 1 and Type 2 diabetes. The model is intended for both 
research and clinical use, particularly diabetes educators, to quantify BG effects of 
these lifestyle factors.  The model could help inform delivery design of current 
artificial pancreas mechanism with a dual-hormone delivery, as well as develop 
continuous glucose monitor (CGM) feedback and prediction based on current 
activity and/or diet.  
This chapter is motivated by the concept that a diabetic should be able to 
manage BG with exercise, diet, and for dual-hormonal control based on algorithm 
feedback of a personalized model, similar to that of machine learning mechanisms.  
It takes an important step towards refining the general BG regulation model of 
Chapter 3 to a new personalized version, particularly for trained athletes with Type 
1 diabetes.  
Oftentimes, from personal and peer anecdotal evidence, a highly-motivated 
diabetic keen on health-mindedness or athletic performance will know more about 
their personal adaptation mechanisms than their endocrinologist. This is something 
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that needs to change, if possible, so that diabetes educators and endocrinologists 
can provide quantified feedback to diversified patients.   
 Current diabetes technology devices predict daily choices by varying inputs 
day-by-day. When daily choices become habitual a lifestyle body type becomes 
present—for example, one could be athletic, lean, overweight (indicator of Type 2 
diabetes), inactive, or active.   
Exercise physiologists are able to quantify metabolic changes on the basis of 
body composition (i.e. increased muscle mass and/or basal metabolism) for various 
body types, which could inform a personalized model. Chapter 4 uses an athletic 
Type 1 female as an example for future adaptive modeling and device learning 
mechanisms.  
One key goal is to better inform clinicians to educate people with diabetes 
appropriately in regard to glucose regulation on the basis of lifestyle choices that 
may become habitual. This is possible with better understanding of lifestyle types in 
hope that a library of personalized adaptive models can be created. It is intended 
that current device technologies will become robust in that each can ‘learn’ its user 
to eliminate guesswork of bolus corrections, often used for appearance of hypo- and 
hyperglycemia.  Additionally, such models can inform CGM ‘trends.’  Thus a second, 
longer-term goal is to provide the foundation for an “intelligent system” model 
framework that could directly inform a patient where their BG is headed, based on 
causation effects of lifestyle inputs. A particular user profile, if robust, could drive 
overall trends and baselines with instantaneous inputs (i.e. meal GI, stress, and/or 
exercise) affecting immediate BG.   
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4.2 Background and Motivation 
 
 
It is well accepted that exercise directly influences BG concentration, in 
response to increases in muscle tissue demands for energy (in form of ATP) that 
result in consumption of glucose as a source of fuel.  What needs characterization 
and modeling is the effect of exercise type as combined with an individual’s personal 
metabolic and body composition parameters and current fed or fasting state. Many 
groups characterize exercise on the basis of VO2max and gauge substrate utilization 
(CHO vs. Fat) on the basis of RER and known % of total aerobic capacity. However, 
this is typically only consistent with aerobic exercise performed under conditions 
without other types of stressors (e.g., stress of competition).   
An extensive study by Yardley (2012) that focused on exercise in TID 
attempted to demonstrate the effects of resistance vs. aerobic exercise and the 
timing of each.  As seen in Figure 4.1 below, BG is utilized in general at a much faster 
initial rate during aerobic than resistance exercise (although ultimately about the 
same response is elicited).  This is cause for investigation and seen in other sources.  
Resistance exercise incorporates other stress mechanisms beyond those associated 
with aerobic exercise (also dependent on the individual’s lifestyle), oftentimes 
resulting in a slight ‘spike’ in BG at the onset or prior to a hard exercise training 
(often anaerobic) session. This phenomena has been seen throughout many studies 
(Yavari, 2012,  and Harmer, 2008 and 2013 ) and is what clinicians warn against as 
a ‘false’ high due to catecholamine action and glycogen breakdown with adrenaline, 
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hormones, etc. when the ‘flight or fight’ mechanism normally associated with the 
sympathetic nervous system (SNS) occurs. 
 Heart rate is another means of characterization, and has been used to 
characterize exercise intensity and duration in a basic exercise model for glucose 
utilization, although a lack of research was recognized (Dalla Man, 2007). Most 
conclude that there is heightened insulin sensitivity and increased CHO oxidation, 
glycogen depletion, and hepatic production as exercise intensity increases.  
 
 
 
Figure 4.1: Yardley (2012) Resistance vs. Aerobic Exercise Training. From Yardley (2012) 
demonstrating the effects of performing resistance exercise before aerobic exercise (dark filled 
circle, RA) or resistance exercise after aerobic exercise (open circle, AR) in people with Type 1 
diabetes.  
 
 
 
Another source of glucose during exercise, perhaps more importantly, is 
skeletal muscle glycogen. It has been found that depleted glycogen levels results in 
the inability to sustain prolonged high-intensity exercise and that depletion of 
glycogen stores is dependent on its localization within the muscle cells (Nielsen, 
2011).  
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As shown in Figure 4.2, other proposed contributions to a decrease in blood 
glucose levels (G in Figure 4.2) with prolonged exercise include a decrease in 
glycogenolysis (Ggly), which has been modeled using an equation dependent on 
exercise intensity and duration (Roy, 2007).  
 
 
 
Figure 4.2: Roy (2007) Exercise Modeling. From Roy, 2007: Exercise modeling of BG taking into 
account exercise intensity and duration and effect on hepatic glucose production. Volume of non-
muscle, muscle, and mitochondrial compartments is also accounted for as in the Schunk-Winters 
model. Parameters are defined as: p1, rate at which glucose is removed independent of insulin, Gprod, 
hepatic glucose production induced by exercise, Gb, glucose concentration, Gup, glucose uptake, VolG, 
glucose distribution space, and A(t), the integrated exercise intensity (with critical threshold Ath). 
 
 
Additionally, the dependence of glycogen depletion commencement time 
(tgly) on exercise intensity (u3 in Figure 4.2) is shown in Figure 4.3. Roy, 2007, uses 
an approach correlating glucose utilization with intensity, similar to what our model 
does with VO2max. This is a more robust and accurate approach than relying strictly 
on HR measures, as in Cobelli, 2009. However, HR has informational value, and is 
used to tune the u3 input of our model, comparing to perceived intensity, which will 
be investigated below.  
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Figure 4.3: Roy (2007) Glycogen Depletion vs. Exercise Intensity. From Roy, 2007 plotting the 
muscle glycogen depletion commencement time vs. exercise intensity.  
 
 
 
 Post exercise late-onset hypoglycemia has also been widely documented in 
T1D and interestingly no link was found between those in good or excellent 
metabolic control, or those making the transition from an untrained to trained state 
(MacDonald, 1987); energy is a conservative quantity with consumption that can be 
predicted through tissue compartments, as in Chapter 3.   
A recent review of exercise models describes principal energy substrates as 
muscular glycogen, plasma glucose (including liver production), plasma free fatty 
acids and intramuscular triglycerides with the CHO reserves (1200-2400 kcal) 
localized in the muscle (79%), liver (14%) in glycogen form and in blood (7%) as 
glucose (Derouich, 2002).  This model incorporates early models which recognized 
increased insulin sensitivity with exercise simply by incorporating the lowering of 
glucose concentration during and after exercise and increasing the insulin use by 
cells (Bergman, 1981). In addition to simplified early models, the disappearance of 
glucose from blood to working tissue is dependent on the ability of the exercise to 
accelerate the flow of glucose via a factor that is independent of the increase of 
insulin, and a second factor (insulin sensitivity), which is a function of the increase 
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in insulin (Derouich, 2002). Energy remains conserved, and a variety of factors that 
will be discussed relate to the source of energy and its management. 
In modeling T2D and the effect of exercise type, trends follow a similar pattern 
despite overall VO2max being lower on average. Therefore, the point at which 
threshold is reached and overall emphasis on CHO oxidation efficiency is lower. 
With less mitochondria and fewer capillaries, an unfit individual may burn more 
energy based on a lower oxidative capacity. A combination of both aerobic and 
resistance training led to an improvement in HbA1c and triglyceride content as 
opposed to aerobic or resistance training alone (Yavari, 2012).  Hemoglobin A1C 
(HbA1C), related to oxygen transport capacity, is a common measure for how well-
controlled an individual’s BG has been for the previous 2-3 months, as it reflects 
average levels and whether or not red blood cells have become “glycated.” Another 
recent hypothesis attributes insulin resistance in T2D and obese individuals by a 
deficiency and/or dysfunction of skeletal muscle mitochondria as a result of a 
decreased ability to oxidize fat (Kim, 2008).  Exercise training results in 
improvement in insulin action and mitochondrial volume/function and hence is 
important for all people with diabetes, particularly those with T2D (Holloszy, 2011).  
Exercise appears in later iterations of the Dalla Man (2007) and Cobelli 
(2009) model, and was kept as a simple and single input in the 12-13 state model as 
emphasis was placed on compartmental insulin kinetics. In fact, 3 different exercise 
models were proposed and implemented in silico. The 2009 version by the Cobelli 
group implemented three additional ‘test’ inputs for exercise. Model A assumes that 
exercise causes a rapid on-and-off increase in insulin-independent glucose clearance 
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and a rapid-on/slow-off effect on insulin sensitivity. Note that without separate 
muscle and non-muscle compartments, a possible source for this effect (e.g., flux 
between BG and muscle compartments based on demand-based GLUT4 transporter 
signaling as developed in Chapter 3 and discussed further in Section 4.2.1) could not 
be addressed. Model B relaxes the assumption that exercise causes a rapid on-and-
off increase in insulin-independent glucose clearance. Model C is similar to model A, 
but also assumes that insulin action is increased in proportion to the duration and 
intensity of exercise. It was determined, that Models A and B predict different levels 
of exercise (based on heart rate) have the same effect on glucose utilization and 
Model C predicts a reasonable glucose infusion rate during euglycemic-
hyperinsulinemic clamp simulations for both mild and moderate exercise. However, 
other literature suggests that exercise intensity, or different levels of exercise, does 
in fact have implications on glucose utilization (i.e., Brooks, 1994) and therefore 
Models A and B were recognized as limiting, and motivated the development of the 
Schunk-Winters exercise model (see Chapter 3). Heart rate (HR) is also debatable as 
an accurate measure of exercise level, as HR tends to fluctuate with other factors 
and is intrinsic to an individual. Hence, most exercise physiologists use factors such 
as percent of aerobic capacity. That being said, HR can be an accurate predictor if an 
anaerobic threshold and/or VO2max stress test has been performed and 
correlations between HR and particular training zones have been determined. This 
concept will aide in model personalization. For example, knowing anaerobic 
threshold and VO2max of an individual allows characterization of heart rate ‘zones’ 
1-5 ranging from ‘light, recovery’ exercise (zone 1) to above anaerobic threshold 
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(zone 5). Often used in exercise physiology, zones can be correlated with respiratory 
exchange ratio (RER) in which an RER = 0.7, often during zones 1-2, is mainly fat 
utilization while zone 5, or RER > 1.0, is mainly glucose utilization with a fuel mix in 
between (Knoebel, 1984). Zones are often used in regard to exercise planning and 
training, as they can be adjusted as one becomes trained, typically favoring higher 
fat utilization at elevated heart rates and shifting zones upward (Millan, 2014).  
In 2013, a group associated with Cobelli and colleagues modified the in silico 
2009 Padova type 1 simulator (Cobelli, 2009) to incorporate the effect of physical 
activity after demonstrating a doubling of insulin sensitivity and hence rate at which 
glucose enters cells (Schiavon, 2013). Subjects were put into two groups: one in the 
absence of and one with different degrees of reductions and durations of basal 
insulin infusion rates—it was shown an effective strategy is to reduce basal insulin 
by 50% 90 minutes prior to exercise and 30% during exercise to avoid 
hypoglycemia. However, currently, this is not possible in regard to current artificial 
pancreas design as exercise type and intensity is not accounted for, both of which 
may further adjust what changes need to be made in insulin dosing before, during, 
and after exercise. If type of exercise and relative intensity (which can be tuned with 
HR) and duration is inputted, theoretically a CGM or artificial pancreas design would 
be able to use a personalized model to predict BG fluctuations based on quantifiable 
trends (later shown in Figure 4.10). Reducing insulin during exercise is necessary; 
however, dependent on exercise type the amount of this decrease and timing would 
differ. For example, if a subject was performing high intensity sprint training, insulin 
reduction before exercise may be less than the 50% proposed above due to the 
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typical increase in BG at the onset of high intensity events. On the other hand, 
insulin may be reduced more if exercise is going to be more aerobically based. 
Limitations of current proposed exercise models include exercise energy 
intensity as a function of HR implemented as a square wave – this is only useful for 
steady-state aerobic exercise and varies amongst individuals in terms of threshold 
values and zones. See Table 4.1 below and Figure 4.4 for limitations in using a 
square wave approach. Anaerobic exercise is not accommodated by the 2009 Cobelli 
model.  
 
Table 4.1: Cobelli (2009) vs. Schunk-Winters HR informed Exercise Intensity 
 Cobelli, 2009 
Characterization 
Schunk-Winters HR Data (Phase 2 
Case Study, Section 4.4) 
Baseline HR (bpm) 60 45 
Mild Exercise, 15 min 1.5 x baseline = 90 bpm 128-145 
Mild Exercise, 30 min 1.5 x baseline = 90 bpm 128-145 
Moderate Exercise, 15 min 2 x baseline = 120 bpm 146-169 
Moderate Exercise, 30 min 2 x baseline = 120 bpm 146-169 
 
 
 
  
Figure 4.4: Cobelli (2009) Exercise Modeling Using Heart Rate. Cobelli (2009) simplistic 
approach to modeling exercise with the use of HR.  
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4.2.1 GLUT4 and Mitochondrial Biogenesis 
 
 
An increase in the GLUT4 isoform of skeletal muscle tissue in addition to 
(and perhaps in part in conjunction with) an increase in mitochondrial content with 
endurance exercise results in roughly a linear increase in glucose uptake in 
response to the same insulin concentration. For example, a 2-fold increase in GLUT4 
results in a 2-fold increase in glucose uptake in response to the same insulin 
concentration (Holloszy, 2011). GLUT4 expression is regulated in parallel with 
mitochondrial biogenesis in response to exercise-generated signals in skeletal 
muscle (Rockl, 2010). It is also important to note that GLUT4 has a short half-life 
(t1/2) and the increase in GLUT4 concentration induced by exercise reverses rapidly 
(Richter, 2013).  
4.2.2  Trained vs. Untrained Individuals 
 
  
Skeletal muscle’s glucose needs vary depending on activity level, and the 
glucose flux capacity depends on trained vs. untrained state. Hence, multiple 
mechanisms (other than the strictly insulin-mediated pathways) are available for 
glucose uptake. Particular motivation of a case study involving trained T1D’s, based 
on personal experience and conversations with other elite T1D (DSP, 2015), stems 
from the ability to be carbohydrate/glycogen depleted in an insulin dependent state 
and still manage to avoid hypoglycemia during prolonged exercise.  Despite early 
suggestions that a certain amount of insulin was necessary for muscle glucose 
transport in increase with contractions, it is now apparent that many other signaling 
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pathways are responsible and result in an additive effect on GLUT4 translocation, 
and hence glucose energy uptake of skeletal muscle during exercise (Richter, 2013). 
 Due to variations of fiber type amongst ‘trained’ individuals (i.e. greater 
proportion of slow Type I fibers of an endurance athlete vs. more and larger fast 
Type II fibers of sprinters and power athletes), it is recognized that although 
glycogen storage location may differ, total glycogen content within muscle can 
fluctuate considerably, and depends on diet and recent muscle use history (e.g., 
“carbo-loading” in athletes) (Costill, 1976).  This was seen in Chapter 3, where the 
predicted muscle compartment levels would vary over the course of a 24-hr day, 
such as in Figures 3.17 and 3.18.  
Endurance training effects (i.e. decreased resting HR, increased fat oxidation, 
etc.) generally follow similar trends (Nielson, 2011). However, aerobic endurance 
athletes may not rely on as much CHO oxidation if intensity is kept moderate for 
prolonged periods.  High intensity training (i.e. >70-80% VO2max) requires a 
greater proportion of glucose fuel utilization, usually reached during intense 
interval training, maximal lifting,  sprinting sessions, and in highly-trained athletes 
capable of maintaining such high VO2 and HR levels. A key adaptation is an increase 
in mitochondrial content, and hence oxidation potential in trained individuals 
(Holloszy, 2011). Some studies suggest an increase in mitochondrial demand and 
utilization may represent how exercise training enhances muscle insulin sensitivity, 
and fatty acid oxidation in both resting and exercise states (Befroy, 2008). Factors 
influencing increased insulin sensitivity are important for insulin models and 
clinically informing people with diabetes so that hypoglycemia can be prevented. 
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Summaries of varying adaptations of trained vs. untrained individuals between low, 
moderate, and high intensity exercise is summarized below.  
In studies comparing substrate utilization of untrained vs. trained subjects, a 
variety of methods exist. Ahlborg et al., 1974,  analyzed six healthy untrained 
subjects during prolonged (4 hr) exercise on an upright bicycle at 30% of their 
maximal oxygen uptake, focusing on leg metabolism of substrates including glucose, 
lactate, pyruvate and individual amino acids (Ahlborg, 1974). Wolfe took varying 
exercise intensity of 5 trained subjects and determined peripheral lipolysis, plasma 
rate of appearance of FFA, total fat oxidation, and carbohydrate oxidation (Wolfe, 
1998). The subjects were trained cyclists and performed 30 minutes at 85%VO2max 
and 120 minutes at 25 and 65% VO2max randomized over a course of three days.  
 
 
Table 4.2 Summary of Low Intensity Substrate Fuel Utilization in Trained vs. Untrained 
Subjects 
  Overall Trend Trained Untrained 
Source Characte
rization 
CHO FFA CHO FFA CHO FFA 
Ahlborg, 
1974 
~30% 
VO2max for 
prolonge
d 4 hours  
Contributi
on fell 
from 40 to 
30% 
between 
90 to 240 
min. 
Account 
for 
majority of 
leg muscle 
metabolis
m beyond 
40 min to 
62%. 
__ 
 
__ *Rest: 4.51  
mmol/l 
40 min: 4.57 
90 min: 4.30 
180 min: 
3.53 
240 min: 
3.12 
*Rest: 0.66  
mmol/l 
40 min: 0.78 
90 min: 0.93 
180 min: 
1.57 
240 min: 
1.83 
Wolfe, 
1998 
25% 
VO2max 
__ __ 15 μmol 
glucose/(kg
*min), 
about 36% 
of total fuel  
Total Fat 
Oxidation: 
26.8 μmol 
FA/(kg*min
); 25.8 FFA 
rate of 
appearance 
__ __ 
*Refers to arterial concentration of substrate. 
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While in conflict with other literature that suggests a more proportional 
glucose-intensity relation (e.g., Figure 4.3), this study suggests that at low intensity 
endurance exercise, FFA oxidation is prevalent with only about 10% of total energy 
expended from carbohydrates (Holloszy, 1996). Sources also differ in regard to 
IMTG utilization (Ahlborg, 1974).  
Table 4.3 summarizes studies of fuel utilization for trained versus untrained 
individuals for a moderate-intensity exercise session. Holloszy (1996) studied 
energy expenditure data during 0-30 minutes of exercise at 25, 65, and 85% of 
aerobic power and during 90-120 minutes of exercise performed at 25 and 65% 
VO2max. Confounding factors such as nutritional state, training level, and muscle 
glycogen supercompensation were taken into account for the 5 trained cyclists, 
adapted from the study used by Wolfe, making the studies comparable (Holloszy, 
1996 and Wolfe, 1998). In a separate study, 9 untrained male subjects underwent a 
12-week training program with measurements taken before and after training 
during exercise of 120 minutes at an average of 64% VO2max (Hurley, 1986). In 
terms of duration and intensity, this study is comparable—however, it is important 
to recognize possible confounding factors associated with untrained becoming 
‘trained’ and lifestyle remodeling.  
 
 
 
110 
 
 
 
 
Table 4.3: Summary of Moderate Intensity Fuel Utilization in Trained vs. Untrained 
Subjects 
  Overall Trend Trained Untrained 
Source Characteriza
tion 
CHO FFA CHO FFA CHO FFA 
Hollosz
y, 1996 
50-75% 
VO2max, 2 
hours 
10% 
Plasma 
Glucose, 
20% 
Glycogen 
<50% 
FFA, 20% 
IMTG 
(since 
prolonged
) 
__ Greater; 
IMTG~75% 
of FFA 
oxidized  
__ IMTG 
~50% of 
FFA 
oxidized 
Hurley, 
1986 
64 + 3% of 
VO2max for 2 
hours 
Glycogen 
becomes 
depleted 
quicker 
than BG 
Function 
of 
concentra
tion but in 
trained 
subjects 
FFA 
oxidation 
capacity 
increases; 
rely on 
IMTG 
~415 kcal 
for energy 
from CHO 
after 
training 
~600 kcal for 
energy from 
fat after 
training 
~650 
kcal for 
energy 
from 
CHO 
before 
training 
~390 
kcal for 
energy 
from fat 
after 
training 
Wolfe, 
1998 
65% VO2max __ __ 132μmol 
glucose/(kg
*min) 
Total Fat 
Oxidation: 
42.5 μmol 
FA/(kg*min); 
22.8 FFA rate 
of 
appearance 
__ __ 
*Refers to arterial concentration of substrate. 
 
 
At a moderate exercise intensity, more emphasis is placed on CHO oxidation, 
with total glucose utilization = BG + glycogen (Holloszy, 1996). IMTG utilization 
increases in some trained individuals. According to Hurley et al (1986) and 
calculated from RER, the proportion of caloric expenditure derived from fat 
increased from 35% before training, to 57% after training while keeping relative 
workload constant during exercise. Muscle glycogen utilization was 41% lower. 
 Kiens (1993) attributes the relative proportion of FFA uptake in exercising 
muscle as a saturable process enhanced by training; lower CHO utilization in the 
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trained leg was mainly a function of glycogenolysis reduction. As duration increases, 
FFA uptake increases more rapidly in trained individuals and plateaus in non-
trained after 60 minutes. 
 
Table 4.4:  Summary of High Intensity Substrate Fuel Utilization in Trained vs. Untrained 
Subjects 
  Overall Trend Trained Untrained 
Sourc
e 
Characteriz
ation 
CHO FFA CHO FFA CHO FFA 
Hollos
zy 
>75% 
VO2max up to 
30 minutes 
60% 
Glycogen; 
10% 
Plasma  
10% 
IMTG; 
15-20% 
FFA 
69% of Total Decreasing; 
less release 
from adipose 
75% of 
total 
__ 
Wolfe, 
1998 
85% VO2max __ __ 259μmol 
glucose/(kg*mi
n) 
Total Fat 
Oxidation: 
29.6 μmol 
FA/(kg*min); 
17.0 FFA rate 
of 
appearance 
__ __ 
 
At high intensity, fat oxidation is no longer sufficient as a primary fuel source, 
and carbohydrate oxidation is the dominant mode of most energy expenditure, 
especially in untrained individuals (Ahlborg, 1974 and Kiens, 1993).  
 Sufficient data on the exercise physiology aspects of mass-conservation of 
glucose with exercise allows for model personalization as long as intensity can be 
characterized and inputted. The Schunk-Winters model (Chapter 3) uses an 
approach to input exercise as an aerobic ‘fuel-mix’ demand source (in kcal/hr) or 
from an anaerobic/daily activity standpoint (also in kcal/hr). The addition of a 
mitochondrial demand consumption state allows the separation of muscle tissue 
into multiple supply-demand based compartments to account for effects seen in 
Tables 4.2-4.4 above and with case study results in Section 4.4 below.  
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4.3 Methods 
 
 
The Chapter 3 Schunk-Winters model acts as the base compartmental model 
for Chapter 4 and model personalization. The main augmentations focus on the 
highlighted tissue compartments in Figure 4.5, the general model, and Figure 4.6, 
the skeletal muscle model proposed in Chapter 3. Further parameter 
personalization and an example of application to a T1D athlete are presented in 
Section 4.4 Case Study and Section 4.6, with personal adapted parameters used for 
simulations throughout results outline in Methods 4.3.2. 
 
  
Figure 4.5: Schunk-Winters Model Structure with Exercise Focus. Thick lines represent material 
flow with storage and control action as unidirectional signals informed by rate parameters and 
oftentimes, nonlinear, by either Hill kinetics or multiplicative states. Nonlinear relations include both 
flux terms and heuristics that change fitting equations based on different state or input signal ranges.  
 
Xmito 
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Figure 4.6: Skeletal Muscle and Tissue Compartmental Model with Added Input. 
 
 
4.3.1 Case Study Phases 1 and 2 and Data Collection Protocol 
 
 
Full protocol description, results, and logbook can be found in Appendices 7.2 
and 7.3 for both phases, respectively. The subject completed an IRB-approved Case 
Study Phase 1 in June 2014 and Case Study Phase 2 in June-July, 2015.  
The phase 1 case study was an in silico 24-hour study with the model output 
compared to BG monitoring of a 22-year-old T1D athletic female. 3 protocols and 1 
control protocol were performed on the same day of the week for 4 consecutive 
weeks. BG was collected using the subjects OneTouch Ultra Blood Glucose monitor, 
requiring a finger prick every 30 minutes. Meal content (GI), exercise type, and meal 
timing were variables of interest. Controls included meal magnitude, exercise 
Skeletal Muscle and Tissue Compartmental Model 
u
m-activity    
: Daily Activity Muscle Input (kcal/hr) 
u
m-exer-Ana 
: Anaerobic Exercise Muscle Input (kcal/hr) 
u
m-exer-Aer 
: Aerobic Exercise Muscle Input (kcal/hr) 
fat_Aer: Aerobic Fat Consumption (out of total exercise input) (kcal/hr) 
AerCap: Maximal Aerobic Capacity (kcal/hr) 
 
 
  
DXA Data (body composition) 
and Aerobic Capacity (from 
VO2max testing) 
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duration, activity (time and relative intensity) and insulin injection, based on clinical 
prescription. Outputs mainly resulted in determining a need to differentiate exercise 
type and meal content in modeling. Limitations include inaccuracies due to finger 
pricks and sampling only 2 times per hour and no control for the female’s menstrual 
cycle. This study opened up the need for Phase 2.  
Phase 2 featured the addition of a continuous glucose monitor (CGM, specifically 
Dexcom G4 Platinum) and extended protocol length. The purpose of the study 
phases was to validate known BG trends in regard to particular meals and content 
(i.e. low vs. high GI) as well as differences in exercise type (intensity, duration, 
aerobic, and resistance variations) similar to that of Phase 1, but with longer 
duration to accommodate additions to both meal and exercise simulations. Known 
literature study inputs will be replicated for comparison and are referred to in the 
logbook of Section 6.4. Literature studies replicated include Yamamoto, 2014, 
Kotachev, 2014, and Cobelli, 2007 amongst others.  
 Prior to the primary part of this study of continuously monitoring blood 
glucose levels (Phase 2), clinically standard metabolic and physiological tests 
related to your body composition and baseline fitness levels took place (Phase 2).  
These were performed in several exercise laboratories on the Marquette University 
campus.  An IRB-approved maximal oxygen consumption test (VO2max test) was 
performed on a treadmill. The subject wore a VO2 testing mask and followed the 
laboratory protocol of increasing the treadmill grade by 2% approximately every 2 
minutes until volitional fatigue or the presence of any contraindication to the 
American College of Sports Medicine (ACSM) guidelines. Blood lactate was 
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measured before and after to ensure that the lactate threshold was reached.  Body 
composition parameters and values were obtained with the use of a DXA machine 
and full-body scan (further explained in Appendix 7.5). 
The main part of this research study involved a planned 8-day protocol for meals 
and exercise.   Meal content was planned using glycemic index and load calculations 
to distinguish between “fast” and “slow” carbs.   
4.3.2 Model Personalization  
 
 
Parameters and inputs that shape the personal integration into the Schunk-
Winters model are outlined below, and given in Table 4.5. These values are used for 
all simulations included in Section 4.4.2 results. They will form the basis for all 
future personal integration model parameter and input changes. New parameters 
(in addition to those changed below) are metabolism scaling that will scale both 
non-muscle and muscle tissue loss, and a stressor ratio parameter to inform the new 
additional input uHM, or any hormone effect associated with added stress, i.e. 
eliciting catecholamine action during exercise. This input is time dependent, with a 
default value of 1.0 and scaled by stressrat, or a pulse affecting the GLUT 2 bi-
directional gradient at a given time. For example, in 4.4.2 results, this parameter is 
used to model circuit training. Both metab and stressrat will be defaulted at 1.0, with 
a scale from 1.0-1.5 for higher metabolism or higher stress situations, respectively. 
Stress ratios implemented for model simulations, particularly in regard to circuit 
and sprint training, are displayed in Figure 4.11a. 
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Table 4.5: Model Personalization Parameters 
Schunk-Winters General Model Personal Integration Model 
Parameters 
Body Mass = 70 kg 65 
Muscle Mass = 30 kg 30 
Non-Muscle Mass = 25 kg 20 
Aerobic Capacity = 1000 kcal/hr 1137 
Mitochondrial Volume =  0.1 0.3 
Type 1 Ratio = varies 0.2 
GLUT2 Forward Rate = 6.0 6.0 
Stressor Ratio (i.e. Exercise) = 1.0 1.5 
Maximum Fat Consumption Capacity = 300 kcal/hr 341 
Metabolism Scaling* = 1.0 1.5 
Basal Non-Muscle Tissue Metabolic Loss* = 2.5 g/hr 3.0 (Refer to Appendix 7.5 for body 
composition) 
Basal Muscle Tissue Metabolic Loss* = 1.5 g/hr 2.25 
HR Resting = 60 bpm 45 
HR Maximum = 200 bpm 212 
Inputs 
Exercise Duration and Single Intensity Exercise Duration with Heart Rate 
Informed Intensity 
Activity—Separate Input Activity—Separate Input or During 
Exercise 
Hormonal Input, uHM  = 1.0 Hormonal Input, uHM = 1.0 *(Stressor 
Ratio); time dependent 
* Metabolic Scaling is on the basis of basal metabolism and scales both muscle and non-muscle 
metabolic loss as a multiplicative entity. 
 
 
 
An external heart rate input (if available) from a monitor or smart watch 
augments the exercise input portion of the model. The following code snapshot 
(Figure 4.7) from Matlab demonstrates the theory behind applying a Hill functional 
to map the u3 reference input to the HR u5 reference input. Heart rate is used to 
sculpt u3 when compared to a reference input value to the user. The difference is 
used to add/subtract to u3 to create a new and HR informed u3. HR is first 
normalized.  
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     urelHR(i) = (u(5,i)-HRrest)/(HRmax-HRrest); 
     upredex(i) =(u(3,i)/AerCap); 
     urelHR = upredex;  
     kscale = 500; 
     if urelHR(i) == 0 
         u3new(i) = u(3,i); 
     else  
      deltu3(i) = kscale*(upredex(i) - urelHR(i)); 
      u3new(i) = u(3,i) + deltu3(i); 
     end 
 
Figure 4.7:  Heart Rate Code Snippet. Code snippet from Schunk-Winters model.  
 
 
 Another aspect of the model involves varying a subject’s fat oxidation 
capacity, or the subject’s potential ability to utilize fat as an energy substrate during 
exercise. This often increases with training, along with mitochondrial volume, etc. 
The following curves (Figure 4.8) demonstrate the model subtraction of fat from 
total energy consumption, thereby leaving glucose consumption as the main input 
(in kcal/hr). Although there is not a separate fat consumption state, the model 
accounts for an increase in fat oxidation by a higher magnitude/rate subtraction as a 
fat fuel Hill function  from total energy consumption as seen below (Rynders, 2011). 
This approach automatically adjusts the fuel mix, with fat a relatively higher 
proportion for low-to-moderate and moderate intensity endurance activity, then 
becoming less for high-exertion endurance activities.  For example, the Hill function 
could be adjusted to saturate at a higher value than 300 (~30% if Aerobic Capacity = 
1000 kcal/hr), such as estimated as 341 Kcal/hr for the case study.  For steady 
aerobic exercise, even at higher intensity, this provides a reasonable approach for 
fuel distribution as a function of endurance activity. 
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Figure 4.8: Glucose and Fat Consumption vs. Total Energy Expenditure.  Fat and glucose energy 
consumption (kcal/hr) vs. total energy expenditure (kcal/hr) varying the fat consumption capacity 
from 30% of aerobic capacity (red lines) to 40% (blue lines). Dashed lines indicate glucose 
consumption, the main model input of total expenditure – fat consumption (solid lines). 
 
 
 
 
 Various types of exercise, particularly those similar to high intensity interval 
training, circuit training, and sprint intervals (i.e. repeating high intensity followed 
by rest), can be modeled using both u3  and  u4 inputs thereby simulating both 
aerobic and anaerobic components .  Such high-exertion exercise protocols, 
requiring discipline and concerted focus by the athlete, may be viewed as having a 
stress component outside of exercise stress. In such cases, an additional 
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119 
 
 
 
multiplicative control function operating on tissues on the basis of anticipatory real-
time sympathetic hormone effects  (i.e. see hormone discussion in Section 3.4.7) 
similar to glucagon effect of transferring glucose to blood from non-muscle 
compartments via pathways such as hepatic over-and-above account for 
fluctuations associated with such exercise types as well. Effects are quantified in 
Section 4.4.2, case study phase 2 results.  
 Body composition variations have a large effect in terms of maximum 
saturation of Hill functionals, as limits are placed based on the amount of muscle 
and non-muscle volume (and hence glycogen/glucose storage) available. 
Additionally, a higher muscle volume directly effects mitochondrial volume, with 
both typically increased in a trained individual (can be verified by a DXA scan). In 
this case, aerobic efficiency and hence u3 effects are increased. 
4.4 Case Study Results and Comparative Simulation 
 
 
Section 4.4.1 highlights key Phase 1 results, limited in that Phase 1 was used to 
design Phase 2. Section 4.4. 2 includes Phase 2 results. Phase 2 results are separated 
into an exercise section (Figures 4.9 and 4.10) demonstrating CGM data acquisition, 
analysis, and model simulation replication. Exercise protocols are compared based 
on similar time duration. The following section and Figure 4.11 shows and example 
of a full-day protocol (Day 7), including CGM data and external heart rate input 
(Figure 4.11a), foodstuff logbook and spreadsheet, and Schunk-Winters replication 
(Figures 4.11b and c). 
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4.4.1 Phase 1 Results 
 
 
Examples of useful Phase 1 results are shown in Figure 4.9; however, most 
results were used to design the more extensive Phase 2 study. Timing of insulin 
prior to a meal was a useful insight as well as lingering effects of exercise type. It 
was clear that some hyperglycemia exists with resistance training but could not be 
quantified due to a sampling frequency of every 30 minutes.  
 
  
Figure 4.9: Phase 1 Case Study: Anaerobic vs. Aerobic Exercise and High vs. Low GI Dinner. 
Snapshots from Phase 1. Left: Anaerobic vs. Aerobic Exercise for a 22-year old female T1D. Right: 
High vs. Low GI Dinner. X-axis denotes time in hours. For the right plot, the time scale is over a period 
of two hours—each tick = 30 minutes.  
 
 
4.4.2 Phase 2 Results 
 
All results from the following sources are provided in Section 6.5 and 6.6: 
 
 DXA Scan 
 VO2max Treadmill Test (Bruce Protocol) 
o Excel datasheet is available. 
 CGM Data and Calibrations 
 Garmin Heart Rate (HR) Snapshots 
o Excel HR files are available. 
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 Meals/Snacks 
o Magnitude, GI, proportion of CHO 
o Time/Duration 
o Excel datasheet available.  
 Daily Logbook 
o Activity level/notes 
o Stress level 
o Resting HR 
o Corrections for BG 
 
Figure 4.10 shows the process used for data analysis in a comparison of 
protocol days 4 and 8: long duration exercise. This example compares a long 
duration (~2 hour) anaerobic lifting workout to a long duration (~2.5 hour) aerobic 
run. CGM data is obtained alongside corresponding HR data. HR data is inputted into 
the Schunk-Winters model along with perceived intensity level of exercise (in 
kcal/hr as a proportion of maximal aerobic capacity) and all states are predicted as 
shown in Figure 4.10 (bottom). Figure 4.11 outlines HR variation, CGM data 
acquisition, and model prediction for four different exercise types.  
 
4.4.2.1 VO2max and Body Composition  
 
Table 4.6 and Table 4.7 provide VO2max test results and calculated aerobic 
capacity, as well as training zone characterization of the subject calculated from 
VO2max test results. Table 4.8 shows a general overview of subject body 
composition with all results in Appendix 7.5.  
Other biological factors controlled for included the female menstrual cycle and 
insurance that the diet and exercise protocols would be as normal as possible to the 
subject’s typical training and diet routine as to not affect basic body composition. 
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Table 4.6: VO2max and Aerobic Capacity Calculation 
VO2max (mL/kg/min) 62.65 
VO2max (kcal/kg/hr) 17.9 
Aerobic Capacity (kcal/hr)* 1137 
Anaerobic Threshold Parameters 
VO2 (ml/kg/min) 50.4 
% VO2max 80.4 
Speed @ 1% Grade (mph) 9-9.5 
HR (BPM) at 170 
Maximum HR (BPM)* 212 
Resting HR (BPM)* 45 
Maximal Fat Consumption (kcal/hr) 
Assuming ~30% Aerobic Capacity* 341 
*Denotes Model Inputs 
 
 
 
Table 4.7: Phase 2 Case Study Training Zone Characterization  
Training 
Zones   %AT 
Lower Bound 
(bpm) 
Upper Bound 
(bpm) 
1 Active Recovery 65-74 111 126 
2 Easy Aerobic 75-85 128 145 
3 
Moderate 
Aerobic 86-95 146 169 
4 Threshold 100-105 170 180 
5 Maximal 106- max HR 180 191 
 
 
 
Table 4.8: Subject Body Composition Overview 
Date: 22-Jun-14 
Height (in) 69.5 
Weight (lbs)* 139 
Age 23.2 
Android (% Fat) 20.2 
Gynoid (% Fat) 20.9 
A/G Ratio 0.96 
Total Body (%)* 15.4 
BMI (kg/m^3) 20.2 
Muscle Mass (kg)* 54.3 
Non-Muscle Mass (kg)* 8.806 
*Denotes Model Inputs 
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4.4.2.2 Exercise 
 
 
Section 4.4.2.2 highlights key results pertaining to the Case Study exercise 
sessions, with all data shown in Appendix 7.3. Figure 4.10 demonstrates an example 
of personalized model progression to compare long endurance exercise, taking CGM 
blood glucose clinical data, applying corresponding HR input, and replicating the 
simulation inputs in a personalized version of the Schunk-Winters model so that 
each state is displayed, and exercise physiology and biological glucose flow 
mechanisms can be seen (i.e. mitochondrial consumption, flow to and from tissue 
states, etc.). Heart rate is used to better tune and inform intensity based on taking a 
perceived u3 input and known aerobic capacity with any difference based on HR 
fluctuation above or below this threshold as an added or subtracted entity.  
Figure 4.11a-c compares type of exercise with a constant duration. An 
aerobic tempo run at 60-70% maximum aerobic capacity is compared to circuit 
training, a combined bike and run aerobic session, and sprint training. Circuit 
training is further informed with the personalized parameter stressrat or a stressor 
value of 1.5.  
 
 
Snack at 6:30 AM with 
Long Aerobic in Pink 
(lower curve) and 
Anaerobic in teal.  Aerobic 
Anaerobic 
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Figure 4.10: Phase 2 Case Study: Personalized Model Progression. Example of a personalized 
model progression taking Case Study Phase 2 CGM blood glucose clinical data (Top) for long-
duration (2-2.5 hour) aerobic vs. anaerobic exercise and using corresponding HR data (Middle) to 
inform BG fluctuations and trends in summation with the model prediction(Bottom). If HR is higher 
(or lower) than the predicted exertion (i.e. ~500 kcal/hr for long aerobic and bouts of 800 kcal/hr or 
greater for anaerobic), the exercise and activity input is adjusted. Subject is a 65 kg T1D female with 
an increased mitochondrial content ratio (0.3) due to athletic training level (mitochondrial 
consumption shown in kcal/hr).  
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CGM (BG [mg/dl] vs. Time) Heart Rate (bpm) Additional Input 
Protocol Day 2: Tempo Run 
 
 
Stress Ratio = 1.5 
Starting BG = 97 mg/dL 
Basal Insulin for Simulation = 1.0 U/hr 
Average HR = 162 bpm 
Training Zone 3 
Protocol Day 3: Circuit Training 
  
Stress Ratio = 2.0 
Starting BG = 72 mg/dL 
Basal Insulin for Simulation = 2.0 U/hr 
Average HR = 164 bpm 
Peak HR = 183 bpm 
No Zone Characterization (HR spikes) 
Protocol Day 6: Bike and Run 
  
Stress Ratio = 1.0 
Starting BG = 84 mg/dL 
Basal Insulin for Simulation = 1.5 U/hr 
Average HR = 143 bpm 
Training Zone 2 
Protocol Day 7: Sprint Training 
  
Stress Ratio = 1.8 
Starting BG = 72 mg/dL 
Basal Insulin for Simulation = 2.0 U/hr 
Average HR = 163 (including rest) 
Peak HR = 182 
Training Zone During Sprints = 4 
 
Figure 4.11a: Exercise Type Comparison. Comparison of days 2, 3, 6 and 7 exercise sessions, CGM clinical data and external heart rate.  The additional 
input column is used for Schunk-Winters simulation reference. 
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Protocol Day 2: Tempo Run Protocol Day 3: Circuit Training 
  
 
Figure 4.11b: Exercise Type Comparison. Simulation Comparison of days 2, and 3 exercise sessions. In all cases, the subject had a 15 g CHO snack at 
6:30 AM with exercise beginning at 7:00 AM for 1 hour. Personalized model output is shown with blue-dashed lines, while default model output is 
shown in red solid. 
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Protocol Day 6: Bike and Run Protocol Day 7: Sprint Training 
  
Figure 4.11c: Exercise Type Comparison. Simulation comparison of days 6 and 7 exercise sessions. In all cases, the subject had a 15 g CHO snack at 
6:30 AM with exercise beginning at 7:00 AM for 1 hour. Personalized model output is shown with blue-dashed lines, while default model output is 
shown in red solid.  The parameter stressorrat was used to inform any increased exercise-induced stress, triggering non-muscle to BG flux. 
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4.4.2.3 24-Hour Simulations 
 
 
Figure 4.12 shows an example of a 24-hour simulation and replication. The 
provided example is for Protocol Day 7, which consisted of a track workout at 7 AM 
(4x400, 4x200, 1x400, 1x200, and 4x100) for about 40 minutes estimated at 700 
kcal/hr, 3 meals, and 1 snack. In the simulation run, t =0 is 12:00 AM, as in the CGM 
graph. The subject data is found in Appendix Section 7.5 (23-year old T1D athletic 
female). Table 4.9 and 4.10 provide meal content information, including time, 
duration, and GI. Other full day CGM data and meal content are found in Appendix 
Section 7.4. 
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Figure 4.12: 24-Hour Case Study Simulation: Day 7. (Top) Dexcom Studio CGM plot for 
Protocol 7 (July 7, 2015), indicating CHO intake, insulin, and exercise. BG is plotted vs. Time. 
(Bottom) Model replication of Protocol 7 showing BG, effective insulin (amount produced with 
ratType1i = 0.2 + exogenous), tissue states, and mitochondrial effect.  
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Table 4.9: Protocol Day 7 Meal Content 
Meal 1 Meal 2 Meal 3 Meal 4           
FOOD GI 
Calories 
(kcal) Serving 
CHO 
(g) 
Fiber 
(g) 
Available 
CHO (g) Fat (g) 
Protein 
(g) 
Fiber One 
Protein 30 120 1 bar 17 5 12 6 6 
Banana 60 100 1 banana 25 3.1 21.9 0 0 
Eggs 0 140 2 eggs 0 0 0 8 12 
Bread ,2 
slices  60 140 2 slices 28 3 25 2 2.5 
Peanut 
Butter 14 105 1 tbs 3.5 1 2.5 8.5 3.6 
Grapes/ 
Berries 60 105 1 cup 28 0.5 27.5 0 0 
Yoplait 
Strawberry 35 170 6oz 33 0 33 1.5 7 
Cheese 0 110 1/3 cup 0.5 0 0 9 7 
Turkey 0 60 4 slices 4 0 4 1.5 7.6 
Kashi 
GoLean 
Crunch 55 95 1/2 cup 18 6 12 1.5 10 
Instant 
Potato 83 333.6 67.3 g 50 3 47 12.6 5.6 
Quinoa 53 174.75 3/4 cup 35 4 31 4 8 
Chicken 10 200 4 oz 10 0 10 3 33.3 
Bell 
Peppers 27 50 300g 8.4 3 5.4 0.6 3.6 
Red Wine 15 130 1 glass 5 0 5 0 0 
TOTALS   2033.4   265.4 28.6 236.3 58.2 50.2 
 
 
 
Table 4.10: Protocol Day 7 Meal Duration and GI 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 10 10 6 15 
GI 65.4 50 83 43.9 
 
 
4.5 Sensitivity Analysis 
 
 
Sensitivity analysis was performed similar to Section 3.6 with sensitivity 
coefficients calculated according to the following equation, varying each parameter 
by +/- 10% (Lehman et al, 1982): 
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(𝐵+−𝐵−)
𝐵𝑜
⁄
(𝑃+−𝑃−)
𝑃𝑜
⁄
. 
Inputs are outlined in Table 4.11 below for the subject in the Phase 2 Case Study.  
 
 
Table 4.11: Sensitivity Analysis Inputs (Subject: BW = 65 kg, rattype1i = 0.2)  
Anaerobic Exercise 
Simulation 
Aerobic Exercise 
Simulation 
Snack + Exercise Simulation 
 2-Hour Lifting Workout 
(Case Study 2 Protocol Day 
8) 
o 7:00-9:00 AM 
 Bouts of 800 kcal/hr 
exertions informed by HR 
input 
 
 2.5 Hour Long Run (Case 
Study 2 Protocol Day 4) 
o 7:00-9:30 AM 
 500-600 kcal/hr 
informed by HR input 
 
 1 Hour Tempo Run (Case 
Study 2 Protocol Day 1) 
o 7:00-8:00 AM 
 15g CHO snack at 6:30 
(kfast = 0.8, fraccarbs = 
0.8) 
o No insulin 
 
 
 
It was determined from Appendix 7.6.2 that glucagon controllers were 
sensitive. Figure 4.13 below shows over plotted trajectories of varying Cga, the non-
muscle glucagon controller for exercise protocol 2: circuit training. Other sensitive 
parameters included non-muscle and muscle GLUT2/GLUT4 gradient parameters, 
Kg2Max and Kmintol (Xg), tissue mass and basal tissue metabolism (Xnm), demand-
based Hill saturation parameter Kmxex (all states) and insulin d-action (Xi).  The 
subject Type 1 ratio was also varied in Figure 4.13 for the long aerobic exercise 
simulation (Protocol Day 4), demonstrating the effect if a subject’s exact insulin 
production is not known. This estimate is often a function of the amount of insulin a 
T1D must take to maintain daily BG within the healthy range. Table 4.12 quantifies 
this sensitivity.  
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Figure 4.13: Model Sensitivity to Glucagon Control. Model sensitivity to Cga, the glucagon 
controller using the personalized model and parameters defined in Table 4.5. 
 
 
Figure 4.14: Model Sensitivity to Type 1 Diabetic Variations. Model sensitivity to ratType1i, the 
T1D ratio of remaining insulin production. Simulation is of 24-hour day 7, circuit training, similar to 
Figure 4.11 above. 
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Table 4.12: Sensitivity Coefficients for Parameter RatType1i* 
 Xg Xnm Xm Xi Xgn Xmito 
Xmax -2.20 0.00 -3.45 2.46 -5.03 -0.32 
Xmin 0.00 -0.14 0.08 0.82 0.29 0.02 
Before Exercise 
(6:30 AM) -0.20 0.17 0.57 0.59 -0.13 0.02 
During Exercise 
(8:00) -2.11 0.34 2.08 2.97 -7.99 -0.16 
Recovery (9:30) -2.18 0.43 -4.71 2.48 -8.68 -0.30 
*Long aerobic exercise simulation 
 
 
4.6 Personalized Parameters for Muscle Compartment and Trained Individuals 
 
 
Based on Section 4.4.2, particularly Figure 4.10, there are vast differences in 
BG response to aerobic and anaerobic exercise due to reasons discussed in Section 
4.2 including training effects. Training zones from Table 4.6 also are used to inform 
u3 perceived exertion based on HR and % of VO2max. The 10th state, Xmito, was 
added after some exercise effects, i.e. hyperglycemia at the onset and with high-
stress situations, could not be replicated in the Schunk-Winters model. The addition 
also allows for GLUT4 action to bring glucose into muscle tissue when a u3 input is 
not occurring—this is a more realistic demand-based approach.  
 Section 4.3.2 outlined personalized parameters used for simulations to 
replicate case study data. These values were decided after analyzing case study 
results; however, were presented in 4.3.2 to outline parameters used for model 
simulations throughout Section 4.4. Figure 4.15 shows a model comparison by 
overplot of the new, personalized model for the case study subject compared to the 
prediction using only default values. Values used were outlined in Section 4.3.2. The 
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only exception is a heart rate input, u5, is used in both cases, as opposed to only a 
predicted u3 for the default case.  
 
 
Figure 4.15: Comparison of Default and Personalized Model. Case study day 5 (Sprint Training) 
using default vs. personalized parameters described in Table 4.6. 
 
 
 
4.7 Discussion 
 
 
The aim of Chapter 4 is to form a basis for adaptive personalized modeling, to 
further develop algorithms for those with T1D that live an active lifestyle. This could 
potentially enable a CGM to have higher accuracy in predicting ‘trends’ or where BG 
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is headed based on external exercise inputs, body composition parameters, and 
overall lifestyle habits.  
Meal effects were one area of focus for Phase 2 results, particularly in regard 
to digestive and insulin state model validation. Chapter 3 (Section 3.5) highlights 
some key results, comparing to literature.  Here the focus was on controlled meal 
and snack inputs, often tied closely with studies from this literature, and often 
designed in tandem with exercise protocols (e.g., a snack a certain time prior, or a 
sustained lunch a few hours subsequent to exercise).  Key insights can be seen in 
glycogen replenishment with post-exercise meals, which varied on the basis of 
exercise type and lingering sensitivity effects. Other insights further continued 
model validation for low vs. high GI food effects particularly in regard to Yamamoto 
(2014) snack simulation days.  For example, the post-exercise meal after high-
intensity circuit training did not elevate BG as significantly as the same post-
exercise meal for the bike and run moderate aerobic protocol—BG levels remained 
below 140 mg/dL, whereas they became elevated close to 160 mg/dL post-aerobic. 
Insights here relate to total glucose consumption and glycogen depletion during 
exercise—it seems that on a time-dependent basis, anaerobic components of 
exercise present a lingering glycogen-depleting effect. Additionally, throughout all 
protocol days, low GI mixed meals again proved (as in Phase 1) to be the best option 
for BG management if a reduced amount of insulin intake is desired. For example, in 
comparing barley consumption on Day 3 of Phase 2 (GI = 25) vs. an instant white 
potato on Day 7 (GI = 83), BG remained significantly below the ‘high’ range for 
barley as opposed to the white potato. Additionally, hypoglycemia occurred about 2 
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hours post-potato—insulin was still in effect, but little to no slow absorbing 
carbohydrates from the potato were present.  
Pre-test data involving the DXA body composition test and VO2max stress test 
point out differences of trained vs. untrained individuals recognized throughout the 
exercise physiology field. Particularly, muscle mass is close to and perhaps exceeds 
greatly non-muscle mass (or, only fat mass based on DXA results), resting HR is 
significantly lower, and VO2max and respective training zones are significantly 
higher (Tables 4.5 and 4.6 and Appendix 7.5). Trained individuals are more efficient 
in terms of energy utilization and typically demonstrate higher mitochondrial 
volume, which implies an ability to rely more heavily on sustained fat oxidation, 
especially in trained endurance athletes with adequate fat available as fuel (see 
Section 4.2.2). These phenomena are indicative of a need to characterize these 
adaptations and to design a model that has the capability for personalization—
current models lack ability to model the flow of glucose as a source of energy for an 
athletic individual, particularly in regard to sports with varying intensities and 
durations.  
 Case study phase 2 was designed to better quantify differences in exercise 
type in terms of BG fluctuations, as well as characterize predictors for these changes 
(i.e. heart rate, level of training, fed state, etc.). After initial observation from Phase 
1, Figure 4.10 made it clear that there is some anticipatory ‘stress’ effect that often 
results in hyperglycemia during intense exercise. Phase 2 confirmed the presence of 
this effect, particularly with fluctuations during circuit training, sprint intervals, and 
anaerobic lifting (see Figure 4.11). The original model was limited to only predict 
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generic end results—mainly, BG decrease due to glucose flux into the muscle 
compartment. Although the rate of which this decrease occurred as well as the 
magnitude could be quantified, there was no ability to show BG variation during 
exercise or post-exercise during recovery. The addition of the 10th mitochondrial 
state made this possible, especially for exercise involving aerobic components, as 
there is now a demand-supply mechanism between BG and tissue that can occur 
without activity or exercise present. The mitochondrial state is plotted in Figures 
4.10 and 4.11 for varying types of inputs. Long endurance aerobic exercise showed a 
significant magnitude increase in mitochondrial action, as expected—primary 
energy is resultant from a fuel-mix and higher fat utilization in the personalized 
model. Long anaerobic efforts demonstrated a faster rate of mitochondrial 
consumption, but at a reduced magnitude than aerobic.  Sprint training 
demonstrated the highest rate and magnitude of mitochondrial consumption and 
most significant decrease in muscle glucose. This idea is validated by CGM clinical 
data, as fluctuations ensue, but resulted in lowest ending BG level of the four 
protocol sessions. Sprint training has a high intensity aerobic component, despite 
rest periods. Additionally, tempo run training and combined bike/run protocols had 
varying mitochondrial consumption, particularly if effort variation occurred (i.e. at 
the end of tempo training). Circuit training showed high mitochondrial action for the 
personalized model, as expected due to higher mitochondrial volume.  
It is important to note that sprint training HR data, Protocol Day 7, was not 
fully representative as HR was not recorded for the first four rest periods. The 
overall u3 input that was used was shortened to match the HR duration, as well as 
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fluctuation characterization of just the recorded sprint events (i.e. u3 informed). 
This experimental limitation makes it difficult to capture BG effects shown in the 
corresponding CGM data.  
Figure 4.10 is important in comparing long endurance sessions, characteristic 
of trained endurance athletes. Despite beginning snack and BG relatively constant, 
different responses were elicited—a long aerobic workout was characterized by a 
significant decrease in BG before settling at a steady value of around 65-70 mg/dl 
with a steady (straight arrow) trend seen on the Dexcom G4 CGM. This is indicative 
of the low to moderate intensity of running as a fuel-mix of fat and glucose energy 
oxidation, thus conserving glucose. The average HR of 147 verifies this, as it falls in 
Zone 3, or moderate aerobic, according to the subject’s metabolic testing found in 
Section 4.4. This trend continued for the entire 2.5 hour course (~19 mile run) with 
a slight rise due to some fueling and other mechanisms such as hepatic production, 
particular towards the end when stores become depleted. On the other hand, the 
long anaerobic workout had a slightly different response, despite an initial trend of 
decreasing BG similar to that of the long aerobic. In the anaerobic case, BG actually 
elevated again after an initial decrease and continued to have fluxes throughout. The 
overall trend and ending value was similar to that of long aerobic—around 75 
mg/dl. The fluctuations are most likely due to varying intensities and fuel source 
throughout, as HR was inconsistent (hence, zones do not apply here). Often, during 
quick bursts of activity, there is an inefficient burning of glucose and hence a 
separate form of glycolysis (i.e. without oxidation) is used for ATP production. Our 
model has the ability to predict this with utilizing a low level u3 input 
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simultaneously with the u4 anaerobic activity input, as well as mitochondrial 
consumption.  
In comparison of exercise type and intensity variation with constant duration 
(1 hour), Figure 4.11 provides CGM data of an athletic subject to quantify these 
variations. HR is also indicative of the varying intensity and exercise type in each 
case. It is clear that sprint intervals and circuit training have fluxes and even ‘severe’ 
cases of hyperglycemia briefly (>140 mg/dl), unlike forms of aerobic exercise, such 
as the tempo and run/bike combination. Sprint training is modeled as a form of u3 
exercise, and hence is tuned with HR which is clear in Figure 4.11, model prediction 
(right), as the model is able to predict initial rises due to onset of increased intensity 
and reaching threshold HR. The model is reasonably valid for tempo aerobic activity, 
and including the bike/run protocol. As expected, a higher u3 aerobic input is 
indicative of higher mitochondrial action and consumption. 
However, in regards to circuit training, some fluctuations were ‘missed’ most 
likely due to the HR difference not being a significant enough deviation from the u3 
reference value, although differences can be seen in the mitochondrial state. Most 
importantly, BG was much higher than could be expected from an energetic model 
that emphasized glucose consumption during exercise.  An additional hormonal 
input, uHM, scaled by a stressor ratio is proposed in Chapter 4, particularly on the 
basis of circuit training and anaerobic results. Upon first iteration of Figure 4.11, 
circuit training appeared to have a similar Schunk-Winters simulation response as 
to sprint training. The two exercise types are similar in concept (high intensity with 
bouts of rest), but not in terms of anaerobic vs. aerobic basis. Hence, stressorrat, a 
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parameter formed to scale added stress other than only HR fluctuation, was 
implemented for the circuit training simulation of Figure 4.11b by increasing the 
rate at which glucose leaves xg from xnm via the GLUT2 flux pathway in a 
multiplicative manner with uHM. Greft and Kg2Max also have an effect due to 
increased sensitivity (Table 3.13) and as parameters involved in the GLUT2 Hill 
functional. Stressorrat works to inform exercise of additional catecholamine action 
(and general sympathetic neural system drive) that may be present and to generate 
an added flux of glucose. Figure 4.11 now shows improved results, similar to that 
predicted by CGM clinical data. This input and parameter will be used for future 
exercise interactions involving HR fluctuation characterized by both aerobic and 
anaerobic componentry that cannot be predicted by HR-informed u3 alone.  
In the 24-hour Phase 2 case study CGM output and model 
simulation/replication (Figure 4.12), the effects of insulin due to assumption that 
the subject produces ~20% (and takes the rest via injection) are dominant. The 
model is a strong predictor in regard to magnitude and steady-state, as well as for 
exercise (circuit training is shown in the example). The model predicts meal 
magnitude and the ‘drop’ overnight in BG (both start at the same time). As in 
Chapter 3, it is recognized that insulin control is a bit faster than seen in CGM data 
and some literature sources, however trends remain consistent. Other confounding 
factors, such as exact GI, etc. could be source of error/limitation to the model.  
Due to a bit of uncertainty in regard to ratType1i (i.e. how much insulin 
production remaining for a T1D is often guesswork based on daily insulin amount 
required), sensitivity analysis was performed. It is clear this parameter is sensitive, 
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making it an important model input. Other sensitive parameters include glucagon 
control, exercise-based muscle gradient, and basal metabolism parameters.  
Sections 4.3.2 and 4.6 and Table 4.8 solidify the model’s ability to predict BG in 
a personalized and adaptive manner. These parameters refer to those that can be 
changed with emphasis on an athlete, while the inputs are also key in regard to 
exercise type, intensity, duration, and HR which furthers model capabilities 
compared to current BG predictive modeling techniques. Figure 4.9 demonstrates 
the ability to adjust the amount of maximum fat consumption and its effect on 
glucose consumption input to the model—an important adjustment for trained 
individuals with higher fat oxidation capacity. This idea explains why long distance 
endurance athletes tend to avoid severe cases of hypoglycemia as there is less 
reliance on BG for energy when fat can be used as a primary substrate during 
moderate intensity (i.e. 500 kcal/hr) for an extended period of time as seen in 
Protocol Day 8 CGM data (Figure 4.10). BG declines at the onset of a 2.5 hour 
running session, but tends to steady at around 75 mg/dl without any risk of 
hypoglycemia, assuming the subject is well-fed and maintains moderate intensity 
(i.e. does not start sprinting and elevating HR).  
Figure 4.15 of Section 4.6 provides a key insight and summary of the purpose 
behind model personalization. Although the exercise session is small and meals are 
quite larger than normal for the simulated subject, it can be seen that even on an 
‘unhealthy’ day, our model predicts that a trained individual demonstrates higher 
basal metabolism, higher aerobic capacity and potential for mitochondrial state 
consumption, and an overall more lifestyle-based and robust model.  
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As a result of personal experience, interactions with diabetes support and 
educational groups, endocrinologist’s experience, and speaking with other elite 
athletes living with T1D, it is clear that adaptations and BG trends/management 
differ from many other T1D. Elite T1D athletes must use trial and error to predict 
BG and know what intensities/sports have the most drastic effect. In the future, a 
personalized model such as described here, augmented with adaptive learning 
algorithms to continually improve the personalized parameters, could work as a 
sort of “personal assistant” that provides ever-improving predictions that can help 
inform the athlete.  
The Schunk-Winters model is not limited to athlete personalization—other 
parameters, such as GLUT2 gradient, tissue intolerance, and mass ratios can be 
adjusted for T2D implications and predictive of a more sedentary lifestyle. 
Additional applications involving conversion of excess glucose will be discussed in 
Chapter 5. 
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5. CONCLUSION AND FUTURE DIRECTIONS 
 
Chapter 3, the general Schunk-Winters model, is intended for both research 
and clinical use, particularly diabetes educators, and to develop medical device 
technologies in order to eliminate guesswork of bolus corrections, often in error due 
to unknown food GI or exercise effects. This may help people with diabetes manage 
BG with exercise, diet, and dual-hormonal control based on algorithm feedback. 
Chapter 3 provides a model that can take a wider variety of lifestyle inputs than 
most CGM and artificial pancreas designs, enhancing where BG is headed before it 
occurs. For example, a device working under the Schunk-Winters default model 
would inform a person eating a 50g low GI meal vs. a 50g high GI meal differently, 
and furthermore make different predictions based on different consumption times 
for the same meal content. It can then be used to inform a person or an artificial 
pancreas algorithm to adjust any insulin bolus given—other models do not do this 
and hypoglycemia may occur in the low GI and slow consumption case, if the same 
insulin amount is taken for both high and low GI of the same CHO amount.  
 As discussed in Section 3.4.7, additional hormonal controllers may provide 
increased control in addition to strictly glucagon and insulin. Oftentimes, gradients 
of glucose to blood plasma exist, without means of foodstuff ingestion, etc. 
Additional hormone control could be categorized into 3 cases: 1) real-time rate 
controlling for both digestive rates (i.e. slow path) and glucagon tissue effects 
during periods of high BG, in particular slowing down glucose delivery fluxes 
(operating somewhat in tandem with insulin, e.g. similar to the role of amylin 
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hormone), 2) real-time ‘anticipatory’ for sympathetic nervous system “stress” 
effects, and 3) longer-term adaptive adjustments for energy storage.  
The real-time anticipatory hormonal state would aid in quantizing stress 
hormones (catecholamine’s such as epinephrine) and would most likely be a 
function of the GLUT2 non-muscle demand gradient, HR or other stress predictor. 
This concept was initiated in Sections 3.4.7 and a base implementation for this 
hormone, with additional input uHM and parameter stressorrat, acts as a multiplier 
of the GLUT2 bi-directional gradient for BG and non-muscle-tissue. With further 
tuning and other multiplying factors, the model now has capability of modeling 
inputted events that have an effect on BG other than foodstuff intake, activity, and 
exercise. 
The third class is illuminated by 24-hour plus simulations and would be 
‘slow’ due to excessive tissue glycogen buildup over time (e.g., over days, weeks, 
months) – an effect that can be highlighted in the present model because of 
framework glucose conservation. A steady state value at the end of a 24-hour day 
that is consistently higher than the initial value (which already may be high based on 
a previously simulated day) would indicate need for adaptive processes for dealing 
with excess glucose. This would involve characteristics similar to the hormone 
leptin, and would play a key role in the transport of excess glucose build up and 
tissue intolerance overtime, converting to fat (i.e. transport to the proposed fat 
compartment from BG). Such longer-term effects are especially relevant to study of 
the etiology of T2D. 
145 
 
 
 
Chapter 3 demonstrated that with proper modeling, there are in fact 
limitations with current device design, as with the initial GI example. This same idea 
can be applied to exercise, as indicated by the need of implementing uHM. For 
example, if a diabetic wearing a dual-hormonal controlled artificial pancreas begins 
high intensity exercise, a BG spike, or hyperglycemia, may occur. A device that does 
not account for exercise would provide insulin on the basis of elevated BG, which 
should not occur—a phenomenon known as a ‘false high’ to most diabetes 
educators. They recognize BG will most likely drop after exercise and that a 
corrective bolus should not be taken. However, if the educator is not present, a 
device should have this capability, as modeled in Chapter 3.  
This was the motivation behind Chapter 4, which takes an important step 
towards extending the default BG regulation model of Chapter 3. By expanding 
personal input parameters and mechanisms such as ability to take external HR data 
and distinctions between exercise types, a ‘library’ of adaptive models can be 
formed. One example was shown in comparing the personalized model to the 
default in Section 4.6. By expanding a subject base, a majority of these curves could 
be built for different lifestyles. Once developed, as a form of adaptive learning, a 
particular user profile would drive overall trends and baselines with instantaneous 
inputs (i.e. meal GI, stress, and/or exercise) affecting immediate BG. Long-term, 
basal metabolism adjustment parameters play a role.   
As discussed throughout Chapter 4, glucose and its conservation throughout 
the human body can, in most cases, single-handedly provide energy for human 
organ function and all processes. However, fat and protein are also key, with fat 
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breakdown as another energy source, along with fatty acid and protein 
supplementation. This can also affect the digestive state absorption parameters and 
fuel mix in regard to exercise. Although not a state in the model, fat consumption is 
subtracted off of total glucose exercise consumption and is increased in a trained 
individual. However, the addition of a ‘fat’ associated compartment and state could 
improve model capabilities and actually be modeled in conjunction with glucose 
consumption during exercise—i.e. completely quantifying ‘fuel-mix’ which occurs 
throughout daily activity, and especially with moderate intensity exercise. On the 
other hand, a fat compartment could provide a means of storage for excess glucose, 
thereby overcoming two model limitations: 1) fat buildup overtime and increase in 
BW and steady-state levels, as well as 2) a more personalized ‘T2D’ or ‘unhealthy’ 
lifestyle model.  
 An aim of the Schunk-Winters model is to take real-time glucose monitoring 
and experience from a T1D and aide in algorithm development for predictive 
modeling and artificial pancreas design in the future. Many opportunities exist to 
better improve current models, as most lack adaptation to athletes. As it stands, 
many elite T1D athletes are forced to learn by trial and error or through community 
advice, instead of relying on expensive medical devices which should provide this 
capability. Additionally, trends can be sport dependent. For example, T1D triathletes 
must take a separate approach for each sport in a multi-hour race. It is often noted 
in blog posts, etc. that one endurance sport can have vastly different BG response; 
for example, a runner who is swimming (i.e. their ‘weaker’ sport) would have a 
different uHM response during this portion than a practiced swimmer might. Other 
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factors also must be taken into account, such as body composition, fuel intake, and 
intensity. For this reason, programs such as the Diabetes Sports Project exist so as to 
better inform the diabetic population on BG effects and the difficulty in management 
during endurance sports of varying intensities, especially for those that are 
beginners (DSP, 2015). An algorithm such as the Schunk-Winters personalized 
model would be of interest so as to quantify effects and trends before they occur, 
thereby preventing trial and error.  
         Future versions could also involve the use of a Simulink (Matlab software 
extension) ‘artificial pancreas’ framework, as has been used throughout classroom 
design competitions. Future iterations and simulations could gain interactive insight 
from this Simulink framework, as it takes a multitude of inputs ranging from 
digestive foodstuff (and future GI additions), exercise, and body parameters. The 
ability for an interactive environment provides more efficient model 
personalization, as well as potential to be incorporated into a medical device. 
 Theoretically, algorithms such as those in Chapter 4 could also have market 
value for general, non-diabetic athletic performance. Algorithms would better 
inform performance, characterizing and predicting when one’s blood glucose may 
be elevated, or, more importantly, when tissue is becoming depleted—therefore, 
proper timing for sports performance aides such as gels, drinks, etc. would be better 
informed. Chapter 3 demonstrates the importance of knowledge behind glycemic 
index control, as well as insulin type. Integrated into Chapter 4, modeling can 
inspire and inform sports performance for T1D athletes, as well as T2D beginning an 
exercise program, and potentially for non-diabetic population enhancement. 
148 
 
 
 
6. BIBLIOGRAPHY 
 
 
Ahlborg G, Felig P, Hagenfeldt L, Hendler R, Wahren J. Substrate Turnover during 
Prolonged Exercise in Man. 1974;53:1080-1090.  
 
American Diabetes Association.  diabetes.org. 
 
Aronoff SL. Glucose Metabolism and Regulation: Beyond Insulin and Glucagon.   
Diabetes Spec. 2004; 17(3): 183-189. 
 
Befroy DE, Petersen KF, Dufour S, Mason GF, Rothman DL, Shulman GI. Increased 
substrate oxidation and mitochondrial uncoupling in skeletal muscle of 
endurance-trained individuals. PNAS. 2008; 105(43):16701-16706.  
 
Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th Edition. New York: W H Freeman. 
2002; 30.2. 
 
Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling 
glucose tolerance in man: measurement of insulin sensitivity and beta-cell 
glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981 
Dec; 68(6):1456-67. 
 
Boyadjiev N. Adaptation to submaximal physical training. Kinesiology. 2004; 2:154-
164.  
 
Brooks GA, Mercier J. Balance of carbohydrate and lipid utilization during exercise: 
the “crossover” concept. J of Appl Physiol. 1994; 76(6): 2253-2261. 
 
Cobelli C, Mari A. Control of Diabetes with Artificial Systems for Insulin Delivery – 
Algorithm Independent Limitations Reveal by a Modeling Study. IEEE Trans 
Biomed Eng. 1985; 32 (10): 840-845. 
 
Cobelli C, Dalla Man C, Breton MD. Physical Activity into the Meal Glucose—Insulin 
Model of Type 1 Diabetes: In Silico Studies. J of Diabetes Sci Technol. 2009; 
3(1):56-67. 
 
Costill DL, Fink WJ, Pollock ML. Muscle fiber compostioion and enzyme activities of 
elite distance runners. Med Sci Sports. 1976. 8: 96-100. 
 
Dalla Man C, Cobelli C, Rizza RA. GIM, Simulation Software of Meal Glucose- Insulin 
Model. J of Diabetes Sci Technol. 2007; 1(3):323-328. 
 
149 
 
 
 
Dalla Man C, Cobelli C, Rizza RA . Meal Simulation Model of the Glucose-Insulin 
System. IEEE Trans Biomed Eng. 2007. 
 
Dalla Man C, Micheletto F, Li D, Breton M, Kovatchev B, Cobelli C. The UVA/PADOVA 
Type 1 Diabetes Simulator: New Features. J of Diabetes Sci Technol. 2014; 8(1): 
26-34. 
 
Derouich, M., Boutayeb, A., 2002. The effect of physical exercise on the dynamics of 
glucose and insulin. J Biomech, 35, 911–917. 
 
Diabetes Sports Project. DSP. 2015. http://www.diabetessportsproject.com/. 
 
Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, 
Cholesterol, Protein, and Amino Acids (Macronutrients). The National 
Academy of Sciences, Institute of Medicine, Food and Nutrition Board. 2005. 
 
Duun-Henriksen AK, Juhl R, Schmidt S, Norgaard K, Madsen H. Modeling the Effect of 
Exercise on Insulin Pharmacokinetics in “Continuous Subcutaneous Insulin 
Infusion” Treated Type 1 Diabetes Patients. DTU Compute Technical Report. 
2013; 1-20. 
 
Garcia A, Rack-Gomer AL, Bhavaraju NC, Hampapuram H, Kamath A, Peyser T, 
Facchinetti A, Zecchin C, Sparacino G, Cobelli C. Dexcom G4AP: An Advanced 
Continuous Glucose Monitor for the Artificial Pancreas. J Diabetes Sci Technol. 
2013 Nov; 7(6): 1436-1445. 
 
Gastin PB. Energy system interaction and relative contribution during maximal 
exercise. Sports Medicine. 2001; 37: 337-340. 
 
Gesztelyi R, Zsuga J, Kemeny-Beke A, Varga B, Juhasz B, Rosaki A. The Hill equation 
and the origin of quantitative pharmacology. 2012; 66:427-438. 
 
Guidelines for Exercise Testing and Prescription. 9th Edition. American College of 
Sports Medicine (ACSM). 2014. 
 
Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette 
M, Boulet B, Rabasa-Lhoret R. Glucose-responsive insulin and glucagon 
delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a 
randomized crossover controlled trial. CMAJ. 2013 Mar; 185(4): 297-305. 
 
Harmer AR, Ruell PA, Hunter SK, McKenna MJ, Thom JM, Chisholm DJ, Flack JR. 
Effects of type 1 diabetes, sprint training and sex on skeletal muscle 
sarcoplasmic reticulum Ca2+ uptake and Ca2+-Atpase activity. J of Physiol. 
2013; 592(3):523-535.  
 
150 
 
 
 
Harmer AR, Chisholm DJ, McKenna MJ, Hunter SK, Ruell PA, Naylor JM, Maxwell LJ, 
Flack JR. Sprint training increases muscle oxidative metabolism during high-
intensity exercise in patient with Type 1 Diabetes. Diabetes Care. 2008; 
31(11):2097-2102.  
 
Hernandez-Ordonez M, Campos-Delgado DU. An extension to the compartmental 
model of type 1 diabetic patients to reproduce exercise periods with glycogen 
depletion and replenishment, J Biomech, 41:744-752, 2008. 
 
Holloszy JO. Muscle Metabolism during Exercise. Arch Phys Med Rehabil. 1982; 63: 
231-234. 
 
Holloszy JO. Regulation of Mitochondrial Biogenesis and GLUT4 Expression by 
Exercise. Compr Physiol. 2011; 1:921-940. 
 
Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and 
their metabolic consequences. J Appl Physiol. 1984; 56, 831-838. 
 
Hovorka R, Shojaee-Moradie F, Carroll PV, Chassin LJ, Gowrie IJ, Jackson NC, Tudor 
RS, et al. Partitioning glucose distribution/transport, disposal, and endogenous 
production during IVGTT. Am J Physiol Endocrinol Metab. 2002 May; 
282(5):E992-1007. 
 
Hurley BF, Nemeth PM, Martin III WH, Hagberg JM, Dalsky GP, Holloszy JO. Muscle 
triglyceride utilization during exercise: effect of training. J of Appl Physiol. 
1986; 60(2):562-567.  
 
Jacobs PG, Youssef JE, Castle JR, Engle JM, Branigan DL, Johnson P, Massoud R, 
Kamath A, Ward WK. Development of a fully automated closed loop artificial 
pancreas control system with dual pump delivery of insulin and glucagon. IEE 
Conf Boston, Massachusetts. 2011; 397-400. 
 
Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 
468 men and women aged 18-88 yr. J Appl Phys. 2000; 89: 81-88. 
 
Jenkins DJA, Wolever TMS, Taylor RH. Glycemic index of foods: a physiological basis 
for carbohydrate exchange. Am. J. Clin. Nutr. 1981; 34, 362 – 366. 
 
Rockl K, Witczak CA, Goodyear LJ. Signaling Mechanisms in Skeletal Muscle: Acute 
Responses and Chronic Adaptations to Exercise. IUBMB Life. 2015. 60(3): 145-
153. 
 
Kiens B, Essen-Gustavsson B, Christensen NJ, Saltin B. Skeletal Muscle Substrate 
Utilization during Submaximal Exercise in Man: Effect of Endurance Training. 
J of Physiol. 1993; 469: 459-478. 
 
151 
 
 
 
Kim J, Wei Y, Sowers JR. Role of Mitochondrial Dysfunction in Insulin Resistance.  
Ciruclation Research. 2008. 401-413. 
 
Kjaer M. Epinephrine and some other hormonal responses to exercise in man: with 
special reference to physical training. Int J Sports Med. 1989; 10: 2-15. 
 
Knoebel KL. Energy Metabolism. Physiology. Boston, MA: Little Brown & Co. 1984. 
635-650. 
 
Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, et al. Multinational 
Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 
Diabetes Mellitus: Summary of the Results. J of Diabetes Sci Technol. 2010; 4(6): 
1374-1381. 
 
Lehman SL, Stark LW. Three algorithms for interpreting models consisting of 
ordinary differential equations: Sensitivity coefficients, sensitivity functions, 
global optimization. Mathematical Biosciences. 1982; 62(1): 107-122. 
 
Li J, Kuang Y, Li B. Analysis of IVGTT glucose-insulin interaction models with time 
delay. Discrete Contin Dyn Syst Ser. 2001; 1: 103-124. 
 
Li J, Kuang Y, Mason CC. Modeling the glucose-insulin regulatory system and 
ultradian insulin secretory oscillations with two explicit time delays. J of 
Theoretical Biol. 2006. 
 
Maarbjerg SJ, Sylow L, Richter EA. Current understanding of increased insulin 
sensitivity after exercise –emerging candidates. Acta Physiol. 2011; 2002:323-
335.  
 
MacDonald MJ. Postexercise Late-Onset Hypoglycemia in Insulin-Dependent 
Diabetic Patients. Diabetes Care. 2006; 10:584-88. 
 
Makroglou A, Li J, Kuang Y. Mathematical models and software tools for the glucose-
insulin regulatory system and diabetes: an overview. Appl Numerical 
Mathematics, 2006; 56:559-573. 
 
Melzer K. Carbohydrate and fat utilization during rest and physical activity. J Clin 
Nutr and Metab. 2011; 6: e45-e52. 
 
Millan, I. Zone 2 Training for Endurance Athletes. Training Peaks, 2014. 
 
Mohammed NH, Wolever TMS. Effect of carbohydrate source on post-prandial blood 
glucose in subjects with type 1 diabetes treated with insulin lispro. J Diabetes 
Research and Clinical Practice, 2004; 65:29-35. 8 
 
152 
 
 
 
Monro JA, Shaw M. Glycemic Impact, Glycemic Glucose Equivalents, Glycemic Index, 
and Glycemic Load: definition, distinctions, and implications. Amer J of Clinical 
Nutrition. 87(1):2375-2435. 
 
Mukhopadhyay A, De Gaetano A, Arino O. Modeling the intra-venous glucose 
tolerance test: A global study for a single-distributed-delay-model. Discrete 
Contin Dyn Syst Ser, 2004; 2: 407-417. 
 
National Diabetes Information Clearinghouse. Types of Insulin, Insert C. National 
Institute of Diabetes and Digestive and Kidney Diseases, National Institute of 
Health. 2012, 
http://diabetes.niddk.nih.gov/dm/pubs/medicines_ez/insert_C.aspx.  
 
Neelakanta PS, Meta L, Roth Z. A Complex System Model of Glucose Regulatory 
Metabolism. Complex Systems. 2006. 
 
Nielsen J, Holmberg HC, Shroder HD. Human skeletal muscle glycogen utilization in 
exhaustive exercise: role of subcellular localization and fiber type. J of 
Physiology. 2011: 2871-2885. 
 
Northrop RB. Exogenous and Endogenous Regulation and Control of Physiological 
Systems. Chapman & Hall/CRC Press, Boca Raton FL., 2000. 
 
Northrop RB. Introduction to Complexity and Complex Systems. CRC Press. 2011; 8, 
(4.2):258-277. 
 
Ohlendieck K. Proteomics of skeletal muscle glycolysis. Biochimica et Biophysica 
Acta. 2010; 2089-2101.  
 
Parillo J, Annuzzi G, Rivellese AA. Effects of meals with different glycaemic index on 
postprandial blood glucose response in patients with Type 1 Diabetes treated 
with continuous subcutaneous insulin infusion. Diabetic Med. 2011. 
 
Powers S, Howley E. Exercise Physiology: Theory and Application to Fitness and 
Performance. 9th Edition. McGraw-Hill. 2014.  
 
Richter EA, Hargreaves M. Exercise, GLUT 4 and skeletal muscle glucose uptake. 
Physiol Rev. 2013; 93:993-1017. 
 
Roy A, Parker RS. Dynamic Modeling of Exercise Effects on Plasma Glucose and 
Insulin Levels. J of Diabetes Sci Technol. 2007;1(3):338-347. 
 
Rynders CA, Angadi SS, Weltman NY, Gaesser GA, Weltman A. Oxygen uptake and 
ratings of perceived exertion at the lactate threshold and maximal fat oxidation 
rate in untrained adults. European Journal of Applied Physiology. 2011. 111: 
2063-2068. 
153 
 
 
 
 
Sankaranarayanan S, Fainekos G. Simulating Insulin Infusion Pump Risks by In-Silico 
Modeling of the Insulin-Glucose Regulatory System. NSF Funded. 2012. 
 
Sekigami T, Shimoda S, Nishida K, Matsuo Y, Ichimori S, Ichinose K, Shichiri M, 
Sakakida M, Araki E. Comparison between closed-loop portal and peripheral 
venous insulin delivery systems for an artificial endocrine pancreas. J Artif 
Organs. 2004 Feb; 7:91-100.  
 
Shiavon M, Dalla Man C, Kudva YC, Basu A, Cobelli C. In Silico Optimization of Basal 
Insulin Infusion Rate during Exercise: Implication for Artificial Pancreas. J of 
Diabetes Sci Technol. 2013; 7(6):1461-1469. 
 
Sorensen JT. A physiologic model of glucose metabolism in man and its use to design 
and assess improved insulin therapies for diabetes. Ph.D. Dissertation, Chemical 
Engineering Department, MIT, Cambridge. 1985. 
 
Sturis J, Polonsky KS, Mosekilde E, Van Cauter E. Computer-model for mechanisms 
underlying ultradian oscillations of insulin and glucose. Amer J Physiol 
Endocrinol Metab, 1991; E801-E809. 
 
Tonoli C. Effects of Different Types of Acute and Chronic (Training) Exercise on 
Glycaemic Control in Type 1 Diabetes Mellitus. Systematic Review: Sports Med. 
2012; 42. 
 
Walsh J, Roberts R, Heinemann L. Confusion Regarding Duration of Insulin Action: A 
Potential Source for Major Insulin Dose Errors by Bolus Calculators. J of 
Diabetes Sci Technol. 2014; 8(1) 170-178. 
 
Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R. Insulin 
Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting 
Insulin. IEEE Trans on Bio Eng. 2005; 52(1): 1-12.  
 
Wolfe RR. Metabolic Interactions between glucose and fatty acids in humans. Amer 
Soc for Clinical Nutrition. 1998; 67. 
 
Yamamoto Noguchi C, Furutani E, Sumi S. Mathematical model of glucose-insulin 
metabolism in Type 1 Diabetes including digestion and absorption of 
carbohydrates. SICE J of Control, Measurement, and System Int. 2014; 4(1) 
001-007. 
 
Yardley JE. Effects of Performing Resistance Exercise Before Versus After Aerobic 
Exercise on Glycemia in Type 1 Diabetes. Diabetes Care. 2012; 35. 
 
Yavari A, Naiafipoor F, Aliasgarzadeh A. Effect of Aerobic Exercise, Resistance 
Training or Combined Training on Glycaemic Control and Cardiovascular Risk 
154 
 
 
 
Factors in Training or Patients with Type 2 Diabetes. Biology of Sport. 2012; 
29. 
 
 
 
 
 
 
 
 
1
5
5
 
 
7. APPENDICES 
 
7.1 Model Parameters 
 
 
 
Parameter Value (default) Literature Explanation Units 
Glucose Compartmental Flow 
bm Varies (70) Body Mass; for 70 Kg, muscle ~30, fat~15, brain ~1.3, liver ~1.4, blood plasma~3, RBC’s 
~2.2  
Kg 
wmu Varies (30) Body mass of muscle for normalizing f2 Kg 
wnm Varies (25) Body mass of non-muscle for normalizing f3 (brain, liver, etc.) Kg 
ratBM bm/70 Ratio of body mass to the default 70 Kg for scaling purposes None 
ratMUSC wmu/30 Ratio for muscle relative to default value of 30 Kg None 
ratNONM wnm/35 Ratio for non-muscle relative to default value of 35 Kg None 
ratmito Varies (0.1) Proportion of muscle mass that is mitochondria None 
wmito ratmito*wmu Mass of mitochondria Kg 
Stressrat Varies (1.0) Added stressor value for hormonal action, uHM; default of 1.0 None 
kprop 0.2 Proportion of  glucose consumption (activity) that reaches mitochondria None 
ratType1i Varies If Type 1, ratio of insulin still produced by beta cells; 1.0 = normal Decimal % 
ratType1g Varies If Type 1, ratio of glucagon still produced; 1.0 = normal Decimal % 
ratType2i Varies If type 2, ratio of insulin resistance Decimal % 
Ki 3.0 Insulin Elimination Rate /hour 
Kgt 1.0*0.287 Basal tissue elimination rate, scaled to grams  /hour 
Knm_up 1.0 Non-Muscle Uptake (e.g. liver) without insulin signal /hour 
Grefi 70 Reference threshold of blood glucose in mg/dl for insulin control action; normal blood 
glucose is 80-120 and is cited in many sources  
mg/dl 
Grefg 110 Reference threshold of blood glucose for glucagon control action mg/dl 
Greft 90 Reference threshold of blood glucose for non-muscle flux direction (due to GLUT2) mg/dl 
Kg2Max 6.0 Maximum rate associated with non-muscle GLUT2 flux /hr 
Ktintol 12.0*ratNONM Reference threshold for non-muscle tissue in mg/dl—estimated from J. Nielson’s study 
before and after aerobic exercise  
mg/dl 
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Kmintol 14.0*ratMUSC Reference threshold for muscle tissue  mg/dl 
Kbr** ((20/4(*ratNONM)) Blood glucose to steady consumption sink, no storage (mostly brain, also erythrocytes) Kcal/hr/4 
= g/hr 
Metab Varies (1.0) Metabolism scaling; fit individuals range from 1.0-1.5 with default of 1.0 None 
Gbt** Metab*(10/4)*ratNONM Basal elimination rate to non-muscle tissue scaled by amount of non-muscle tissue due to 
metabolism (but not brain) 
g/hr 
Gbm** Metab*(6/4)*ratMUSC Basal metabolic elimination rate to muscle tissue scaled by amount of muscle tissue g/hr 
Kbd 8*ratBM Ratio of volume of blood plasma to volume of non-muscle tissue (mg/dl)/g 
wratm (1/drat)/wmu Scaling from glucose blood concentration (mg/dl) to glucose muscle tissue amount in grams, 
normal to mass of segment (g/Kg of muscle) 
(g/kg)/(m
g/dl) 
Wratt (1/drat)/wnm Scaling from glucose blood concentration (mg/dl) to glucose non-muscle tissue amount in 
grams, normal to mass of segment (g/Kg of non-muscle) 
(g/kg)/(m
g/dl) 
Gratm 0.01*wmu Blood-Muscle Glucose Gradient (e.g. exercise demand) mg/dl 
Glucose Controllers 
Cinm 0.3 Insulin Control Parameter, Non-Muscle Tissue; gain None 
Cim 0.4 Insulin Control Parameter, Muscle Tissue; gain None 
Cgnm 0.4*0.287*100 Glucagon Control Parameter, Non-Muscle Tissue scaled to pg/dl Pg/dl 
Cgm 0.001*0.287*100 Glucagon Control Parameter, Muscle Tissue scaled to pg/dl Pg/dl 
Kid 0.04 Derivative, d-action parameter None 
Insulindel 0.15 Delay of insulin action Hours 
Kg 0.4 P-Action for glucagon, from Cobelli  /hour 
Kugf 5.0/ratBM Forward rate (1/tau) of bolus (glucose-fast)  1/tau 
Kugs 0.3/ratBM Forward rate of bolus (glucose-slow)  1/tau 
Kui 1.0/ratBM Forward rate of bolus (insulin)  1/tau 
Kgc 8 Glucagon Addition Rate /hour 
rat_ia 0.5 (varies) Ratio of non-monomeric: to monomeric (slow:fast) insulin absorption paths None 
kai 0.02*60 Scaling for base rate constant (estimated from Cobelli, 2007)  
Ka2 rat_ia*kai Rate constant of monomeric insulin absorption /hour 
Ka1 (1-rat_ia)*kai Rate constant of non-monomeric insulin absorption /hour 
Kd 10*0.0164*60 Rate constant of insulin dissociation /hour 
Glucose Forward Mass Flow 
drat 30 Conversion of digestive mass flow in grams into the blood mg/dl 
Kuga 2.0 Forward rate of bolus for slow glucose path; estimated with Cobelli model  1/tau 
Kcarb 0.2 Carbohydrate scaling for dietary thermogenesis (normalized thermic effect of food)  
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**Add up to basal metabolism, e.g. Kbr+Gbt+G
Gugf 0.98 Digestive effectiveness ratio, fast carbs Decimal % 
Gugs 0.88 Digestive effectiveness ratio, slow carbs Decimal % 
Exercise and Activity 
WorkEff 0.22 (varies) Efficiency in performing physical work (typically 20-25%, higher for skilled tasks) Decimal % 
AerCap 1000 (varies) Maximum capacity mapped to aerobic/mitochondrial metrics Kcal/hr 
Intens Varies Intensity of exercise out of maximum aerobic capacity Kcal/hr 
Kmusc 20.0 Rate of delivery to muscle /hour 
HRrest Varies (60) Resting heart rate bpm 
HRmax Varies (180) Maximum heart rate bpm  
Additional Hill Parameters 
Kg2-Max 10.0 Maximum Saturation for Glut 2 Pathway (muscle) 1/tau 
ks-ex 40.0 Half-way value for muscle gradient  1/tau 
kmx-nm 1.0 Maximum Saturation for Non-Muscle Intolerance 1/tau 
Kmx-m 1.0 Maximum Saturation for Muscle Intolerance 1/tau 
ks-ds 5.0 Half-way value for slow digestive pathway (rising) 1/tau 
ks-ds2 10.0 Half-way value for slow digestive pathway (falling) 1/tau 
ks-d 5.0 Half-way value for fast digestive pathway (rising) 1/tau 
ks-d2 30.0 Half-way value for fast digestive pathway (falling) 1/tau 
ks-ins 12.0 Half-way value for endogenous insulin controller 1/tau 
ks-gn 2.0 Half-way value for endogenous glucagon controller 1/tau 
hs_max 45 Maximum saturation for exogenous insulin infusion controller (magnitude) 1/tau 
hs_ks 23 Half-way value for exogenous insulin infusion controller (magnitude) 1/tau 
Hs_rate 20 Maximum saturation for exogenous insulin infusion controller (rate) 1/tau 
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7.2 Case Study Phase 1 Protocol 
 
 
Case Study Control Protocola 
Time Wednesday Protocol (4 consecutive weeks) 
7:00 AM Wakeup 
 4 Units of Fast-Acting Insulinf (breakfast) 
7:30 AM Breakfast 
 GI =52.6 
 400 Calories 
 55 g carbohydrates 
10:30 AM Snack (No Insulin) 
 GI = 70 
 120 Calories 
 50 g carbohydrates 
9:00 AM- 11:00 AM Activity (soccer camp, walking, etc.) 
12:30 PM Lunch (5 units fast-acting insulinf) 
 30 min. maximum 
 GI = 58 
 560 Calories 
 66 g carbohydrates 
2:30 PM Exercise 
 Long, moderate aerobic running workout for 1 hour at 800 kcal/hr 
 Consistent distance (~8 miles) 
4:15 PM Snack (No Insulin) 
 GI = 20 
 100 Calories 
 15 g carbohydrates 
6:00-8:00 PM Activity (beach volleyball…etc.) 
 Higher than morning activity 
8:30 PM Dinner (6 units fast-acting insulinf) 
 GI = 35 
 610 Calories 
 65 g carbohydrates 
Totals  15 Units Fast-Acting Insulinf 
 14 Units Long-Acting Insulinf 
 1800 Calories 
 220 g carbohydrates 
a BG was tested every 30 minutes upon waking, measured using a FDA approved glucose meter (OneTouch 
Ultra Mini, LifeScan Inc., Wayne, PA). 
bProtocol 1 is control as outlined above.  
cProtocol 2: high GI dinner with 690 calories (constant), 103 g carbohydrates (constant), and GI = 70. 
d Protocol 3: track interval anaerobic running workout at 1100 kcal/hr with timing and duration constant.  
eProtocol 4: lunch and exercise timing, with exercise occurring prior to lunch (snacks occur in same suit). 
f Insulin dosage calculated based on clinical prescription of 1 unit per 12 g of carbohydrates. 
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7.3 Case Study Phase 2 Protocol 
 
 Dates: June 24-June 28, 2015, and July 5-July 9, 2015 
 
IRB Approval: June 18, 2015 
 
Simulation Day 1: ‘Non-Exercise’ Protocol 1 (Kotachev Morning Meal, Parillo 
Low Glycemic) 
 Date: Monday, June 24, 2015 
 7:30 AM Breakfast: KOTACHEV, CGM Simulation (starting night before) 
o 50 g CHO bolus with optimal insulin bolus 
 Ensure Plus 
o GI = 44  
o Total Calories = 350  
o Total Carbs = 50  
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted 
based on exercise) 
 Fasting until ~ 1 PM to see full effects of meal  
 1 PM Lunch 
o 400 Calorie Meal A 
 4 PM Snack (50 g CHO) 
o Yamamoto, White Bread 
o 50g CHO, 105 g portion size, GI = 76 
 Dinner Meal Simulation Parillo Simulation-Starting BG: ~120 mg/dl 
 See Excel Meal Substitute, Record time to replicate Day 5 
o Replicating Low GI: Pasta (90 g), beans (70g), Tomato (300 g), tuna 
fish (80g), olive oil(25g), apple(150g) 
o Meal Sub: Brown Rice, Chicken, Black Beans, Tomato/Veggies, Red 
Wine, Dark Chocolate 
 Total Cals: 796 
 Carbs: 102.4 
 GI = 36 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 RECORD GI, TOTAL CHO INTAKE, TOTAL CALORIES, INSULIN IN EXCEL 
SPREADSHEET 
 
Simulation Day 2: Exercise Protocol 1 (Aerobic Endurance Exercise) 
 DATE: Thursday, June 25, 2015 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar, (15 g CHO typical) 
 7 AM Run, <60 min. at moderate intensity continuously (~60% VO2max) 
o Thursday AM running group 
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o Characterize intensity based on HR and VO2max test results 
 9 AM Breakfast B (or equal amount) 
o Banana and/or similar fruit (calories, GI, etc.) 
 100 calories, 25 g CHO, GI = 60 
 0 g fat, 0 g protein 
o 2 eggs 
 GI eggs = 0 
 0 g CHO (eggs) 
 8 g fat (eggs) 
 8 g protein(eggs) 
o Whole Wheat Toast (2 slices if eggs)1  TBS PB 
 70 calories/slice 
 Toast, 1 wheat slices, 1 g fat, 14 g CHO, ~ 2 g protein, GI = 60 
 Peanut Butter = 105 calories, 8.5 g Fat, 3.5 g CHO, ~3.5 g 
protein, GI = 14 
o GI = 57.1  
o Total Calories = 485 (eggs and toast) 
o Total Carbs = 56.5 (eggs and toast) 
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted 
based on exercise) 
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal)  
o 400 Cal Option A 
 3 PM: Keep blood glucose consistent around 110 mg/dl (could change 
based on first day  
 4 PM Snack (50 g CHO) 
o Yamamoto protocol  
  Spaghetti, 50 g CHO portion (72.3g) 
 Dinner (timing flexibility) 
o About 800 Calories to fulfill daily calorie, protein, fat, CHO quota. 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 
Simulation Day 3: Exercise Protocol 2 (Circuit Training) 
 DATE: Friday, June 26 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar 
 Circuit Training 7AM 
o Work Capacity Circuit x 8 
 100 Jump Rope, 20 Air Squats, 15 Push-Ups, 16 Step-Ups, 12 
Burpees, 30 Full Sit-ups (1 round takes approx.. 3.5-4 minutes) 
o This is routine to the subject and will be performed with a certified 
strength and conditioning coach at Marquette University.  
 9 AM Breakfast B  
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal)  
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o 400 Calorie Dalla Man Protocol (1 x BW in CHO = ~63 g CHO) 
 3 PM: Keep blood glucose consistent around 110 mg/dl (could change 
based on first day  
 4 PM Snack (50 g CHO) 
o Yamamoto protocol  
 Barley, 50g CHO, 79.6 g portion size 
 Dinner 
o ~800 Calories or fulfill remaining nutritional goals 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 
Simulation Day 4: Exercise Protocol 3 (Long Aerobic Run) 
 DATE: Saturday, June 27 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar, (15 g CHO typical) 
 7 AM Run, ~1.5-2hr (or combined with ‘brick’ biking workout) at moderate 
intensity continuously (~60% VO2max) 
o Lake Park with Badgerland Striders (14 miles)—subject to change 
o Characterize intensity based on HR and VO2max test results 
o Snack if subject starts to experience hypoglycemia (<60 mg/dl), 15 g 
CHO 
 Breakfast B (or equal amount) post-exercise 
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal)  
o 400 Cal Option A 
 Afternoon/Nighttime  (Flexible) Alcoholic Protocol Test 
o 2-3 Alcoholic drinks recording CHO, timing, etc. This will be compared 
to the effect of only one drink resulting as part of a separate protocol 
day. 
 Remaining 2 meals will be based on individual’s needs due to intense 
morning exercise. It will be important to record differences in 
choices/hunger effect of Days 4 and 8.  
 Bedtime and ending blood glucose flexible, but important for recording.  
 
Simulation Day 5: ‘Non-Exercise’ Protocol 3 (Dalla Man, 2007, Parillo High GI) 
 DATE: Sunday, July 5 
 7:30 AM Breakfast: KOTACHEV, CGM Simulation (starting night before) 
o 50 g CHO bolus with optimal insulin bolus 
 Ensure Plus 
o GI = 44  
o Total Calories = 350  
o Total Carbs = 50  
o Insulin = 4 U (following about a 1:15g CHO ratio; may be adjusted 
based on exercise) 
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch- Kotachev, 75 g CHO meal (will repeat Day 7) 
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o Kotachev 75 g, 5 U insulin Simulation (~365 cal) 
 4 PM Snack (50 g CHO) 
o Yamamoto, Pineapple Juice 
 72.3 g portion size, 0.5 pg, GI = 46 
 Meal Simulation #6: Parillo High Glycemic Index – Starting Glucose ~120  
 Same time as Day 1 Dinner Meal 
 See Excel Substitutes  
o High GI: Rice, Artichoke, Tomato, Tuna Fish, White Bread, Banana 
o Substitutions: White Rice, Chicken, Vegetables, Corn, ICEE from 711 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 
Simulation Day 6: Exercise Protocol 4 (Continuous Bike/Swim/Run <60 min.) 
 DATE: Monday, July 6, 2015 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar, (15 g CHO typical) 
 7 AM Workout, <60 min. at moderate intensity continuously (~60% 
VO2max) 
o Characterize intensity based on HR and VO2max test results 
 9 AM Breakfast B  
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal)  
o 400 Cal Option A or similar 
 3 PM: Keep blood glucose consistent around 110 mg/dl (could change 
based on first day  
 4 PM Snack (50 g CHO) 
 Dalla Man, UVA/PADOVA Model Simulation  
 Protein bar, fulfilling 50 g CHO requirement 
 Dinner (timing flexibility) 
o About 800 Calories to fulfill daily calorie, protein, fat, CHO quota. 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 
Simulation Day 7: Exercise Protocol 5(Sprint Intervals) 
 Date: Tuesday, July 7 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar 
 7AM Sprint Intervals, < 60 minutes 
o Track workout consisting of high intensity (~80-90% VO2max) 
intervals with full recovery in between 
o 5x400’s (1:15-1:20) 
o 8x200’s(35 seconds or faster) 
 9 AM Breakfast B  
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal) –Repeated from Day 5 
o Kotachev 75 g, 5 U insulin Simulation (~365 cal) 
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 3 PM: Keep blood glucose consistent around 110 mg/dl (could change 
based on first day  
 4 PM Snack (50 g CHO) 
 Yamamoto: Instant Potato, 50 g CHO, 67.3g 
 Dinner- typical to subject, record first day and keep somewhat consistent or 
note variation 
 Bedtime at around 11 PM, Blood glucose around 120 mg/dl 
 
Simulation Day 8: Exercise Protocol 6 (Fatigue Inducing Anaerobic ‘Brick’) 
 Performed last, in case of any lingering soreness. DATE July 8, 2015 
 Wakeup 6 AM, adjust glucose levels accordingly 
o Banana and/or granola bar 
 7 AM Anaerobic (Lifting) Exercise Session (Duration 105 Minutes) 
o 4 sets of 8-10 seconds of heavy lifting exercise (last few repetitions 
should be stopped due to muscle fatigue and glycolytic limitations) 
 Set #1 
 Squats (50 kg), Pull-Ups (with 20 lb weight vest) 
 Set #2 
 Deadlifts (80 kg), Seated Rows (120 lbs) 
 Set #3 
 Push Press (35 kg), Back Extensions (10 kg) 
 Set #4 
 Cable Twists (10 kg), Split Lunges (100 lb) 
 Set #5  
 Hip Thrusters (90 kg), Kettle Bell Russian Twists (35 lb) 
o Significant rest between each set 
 2-4 minutes  
o Bike sprint (gear 20 for 20 seconds) and row machine (8 pulls, ~10 
seconds) in between each set 
 Breakfast B (same time as Day 4) 
 Fasting until ~ 1 PM to see full effects of exercise + meal  
 1 PM Lunch (~400 kcal)  
o 400 Cal Option A 
 Afternoon/Nighttime  (Flexible) Alcoholic Protocol Test 
o 2-3 Alcoholic drinks recording CHO, timing, etc. This will be compared 
to the effect of only one drink resulting as part of a separate protocol 
day. 
 Remaining 2 meals will be based on individual’s needs due to intense 
morning exercise. It will be important to record differences in 
choices/hunger effect of Days 4 and 8.  
 Bedtime and ending blood glucose flexible, but important for recording.  
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7.4 Logbook and Results 
 
Recorded by CGM (replaced every 7 days; takes 2 hours to replace): 
o Blood glucose (1 sample every five minutes) 
o TRENDS 
o Calibration by finger prick every 12 hours 
o Insulin amount and time stamp 
o CHO amount and time stamp 
o Exercise time and duration 
o Also record HR with Garmin 
 
Recorded in EXCEL spreadsheet 
o Meals/Food 
o GI, serving size, CHO, fat, protein 
 
 
Summary Of Dates and Protocols Performed   
Date Main Protocol Other Important Notes 
(Stress levels, etc.) 
Day 1: June 24 (Wed) Non-Exercise Minimal 
Day 2: June 25 (Thurs) Aerobic < 60 min.  Some midday 
Day3: June 26 (Fri) Circuit Training <60 min.  Yes- AM 
Day4: June 27 (Sat) Intense Long Run/Brick  Relaxing day 
Day5: July 5 (Sun) Non-Exercise Some, driving to 
Chicago 
Day6: July 6 (Mon) Swim (Flexible) < 60 min Stressful  Working Day 
Day7: July 7 (Tues) Sprint Training < 60 min Hard Workout 
Day8: July 8 (Wed) Anaerobic Brick Workout  Fluxes of Stress 
 
 
 
Approximate Caloric Intake Days 2, 3, 6, 7 
Meal Calories CHO 
(grams) 
Starting BG 
1  ~500 (Exercise)/ 
350 (Non-Exercise) 
50-56 g 100 + 5 (before exercise), 85 + 5 
non-exercise 
2 400 (+/-) Varies Dependent on protocol 
3 200 (+/-) 50 120 mg/dl 
4 800 Varies Dependent on protocol 
Total 1900   
*On days 4 and 8, caloric intake will be expected to be higher and will be 
documented accordingly. 
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Meal Timing 
Meal Exercise Day Non-Exercise 
1 9 AM 7:30 AM 
2 1 PM 1 PM 
3 4 PM 4 PM 
4 Flexible Flexible  
 
 
Day Before Simulation Day 1 
 
 
 Day Before Protocol Set (Date: June 23) 
Total Calorie and 
Carbohydrate Intake 
1915 Calories, 256 g CHO 
Exercise (Time/Intensity), 
Activity Level  
Warmup strides, VO2max test 
Blood Lactate Levels: 1.5 and 18.8 mmol/L (before 
and after VO2max test) 
Schlitz Mile: 5:07, ~ 3 miles total with warm-
up/cool-down 
Food Logbook (and 
Insulin intake), Dinner 
should be similar to what 
is typical for subject and 
kept consistent 
throughout.  
NOTE: For KOTACHEV 
Simulation, starting at 
21:30, readings will need 
to be recorded 
Greek yogurt, 120 cal, 19 g CHO 
GoLean 1 cup, 220 cal, 41 g 
Peanut Butter, 1 TBS, 95 cal, 3 g 
Coffee 
Turkey Sandwich, 220 cal, 25 g CHO 
Pretzels, 220 Cal, 46 g CHO 
Coconut Water, 90 cal 
Nature Valley Bar, 140 cal, 10 g 
Chocolate Blueberries, 100 cal, 14 g 
Riesen, 40 cal, 7 g 
Banana, 100 cal, 23 g 
Beer, 300 cal, 20 g 
PB, 90 cal, 3 g 
½ cup brown rice, 110 cal, 23 g 
2 emergenc, 70 cal, 16 g 
bell peppers/tomatoes, 50 cal, 5g 
almond milk, 40 cal 
Blood Glucose Level 
Before Bed (mg/dL) 
76 
 
 
 
 
 
 
Simulation Day 1- Non- Exercise Protocol 1 
166 
 
 
 
Description: Non-Exercise 1, Kotachev morning meal and Parillo Low GI 
 
 
Protocol Day 1, Date: June 24 (Dexcom Studio, half of this day saved as 6/24/14) 
Blood Glucose and Time of 
Wake-up, Breakfast 
Option 
7:30 AM Ensure Plus Nutritional- wakeup 7 AM (4 
U insulin at 7:20); 6 grapes 5 AM (low BG) 
Lunch Notes Insulin 10 min before with a few almonds; 4 U for 
62 g; however only 70 mg/dl 
3 PM Blood Glucose, 
adjusting for 4 PM 
Snack—Note this value 
and replicate 
Yamamoto, White Bread ; 102—had a peach ~14 g 
total to get to 120 (NOTE: Insulin 4U) 5 min before; 
Before starting: BG 98 mg/dl (had to have a 
caramel at 4:45 since low!) 
Food/Insulin/BG levels 
before dinner protocol  
and correction needed to 
reach 120 mg/dl + 5 
mg/dl   
Grapes/cheese as snack to increase BG 
Start at 116 mg/dl 
Unfortunately a LATE dinner due to JDRF event 
(8:50 PM insulin, 6 U), ate at 9:06 PM 
NEW dinner window: 6:30 – 9 PM 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Morning 7 AM, within 2 mg/dl; 8:30 PM, within 6 
mg/dl 
Blood Glucose Level 
Before Bed (mg/dL) 
103 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
1965 Cal, 281 g CHO, 25 g Fat, 90 g Protein 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber (g) 
Available 
CHO FAT (g) 
PROTE
IN(g) LOAD 
Grapes 60 34 10 grapes 9 0.5 8.5 0.1 0.4 5.4 
Ensure Plus 44 350 1 bottle 50 0 50 11 13 22 
Turkey 0 60 4 slices 4 0 4 1.5 7.625 0 
Bread ,2 
slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Spinach 0 25 1/2 cup 3.5 0.7 2.8 0.5 1.625 0 
Pretzels  83 100 1 oz 22 0.9 21.1 0 3 18.26 
Almonds 7 80 0.5 OZ 4.5 2 2.5 6.5 2.5 0.315 
Peach 28 59 1 peach 14 2.2 11.8 0.4 1.4 3.92 
White 
Bread 71 250 
105g (~4 
slices) 50 0 50 3 8 35.5 
Brown Rice 65 220 
1 cup 
cooked 46 3.5 42.5 2 4.5 29.9 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
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Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 1 10 5 15 
GI 44 64 71 59 
CHO 50 62 50 102 
FracCarbs 0.57 0.61 0.8 .51 
 
 
 
Wednesday, June 24, 
2015 
 
7:20 AM Insulin 4 units 
7:30 AM Carbs 50 grams 
12:50 PM Insulin 4 units 
1:00 PM Carbs 62 grams 
 
Tuesday, June 24, 2014 
 
3:00 PM Carbs 15 grams 
8:52 PM Insulin 4 units 
11:36 PM Insulin 12 units 
 
 
 
Black Beans 40 105 1/2 cup 21 15 6 0 5.25 8.4 
Tomato/ 
Carrots 45 51 300 g 8.4 0.5 7.9 0.6 3.6 3.78 
Red Wine 15 130 1 glass 5 0 5 0 0 0.75 
Dark 
Chocolate 40 90 2 pieces 12 1.5 10.5 6 1 4.8 
Celery/PB 14 105 1 tbs 3.5 1 2.5 8.5 3.625 0.49 
Totals  1965  281.9 30.8 260.1 45 90.9  
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Simulation Day 2- Exercise Protocol 1 
Description: Aerobic Endurance Exercise <60 minutes Running 
 
 
 
Date: June 25 (6/25/14 In Dexcom Studio) 
Blood Glucose at 6 AM, 
Correction Needed to 
reach  100 + 5 mg/dl 
97—Cascade Farms granola bar (and a few banana 
chips) 
BG seemed slightly uncalibrated 
Soreness and Fatigue 
Present?  
No—a bit fatigued during 
HR Before Exercise After Warmup: 130 
Peak HR 180 
Average HR 162 
Training Zone 3 
Post-Exercise Meal  Hot Shower 8:35; 4 U insulin at 8:50, breakfast at 
9:00 AM; Low glucose alarm at 11:00 AM (was 
actually 75) 
BG at 1 PM lunch, 
corrections needed?  
4 U, 119 mg/dl, took a bit late @ 12:54; ate at 1:00 
(1:04 so 10 min post-insulin) 
3 PM Adjustment to get 
BG to around 100 mg/dl 
(consistent each week) 
Was ~120, took 2 U and ate a peach 
3:15—111 mg/dl, 3:55—92, 4 U 5 min before 
4 PM 50 g CHO snack Yamamoto, Spaghetti 
Dinner Notes and Timing 
(Note the flexibility here) 
109 mg/dl (116 night prior); Insulin at 7:55, BG 
was a bit higher since had some chocolate 
(originally for dinner). however; started at similar 
value to 6/24, took 5 U and ate at 8:00 PM 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Was off around 3 PM (registered too low) so 
calibrated 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
1990 cal, 293 g CHO, 37 g Fat, 90 g Protein 
Blood Glucose Level 
Before Bed (mg/dL) 
~116, steady, bed at 10:00 
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Meal 1 
Mea
l 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber(g) 
Available 
CHO FAT (g) PROTEIN(g) LOAD 
Cascade 
Farms 
Granola 30 90 1 bar 15 1 14 2.5 2   
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread ,2 
slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut 
Butter 14 105 1 tbs 3.5 1 2.5 8.5 3.625 0.49 
Grapes 60 105 1 cup 28 0.5 27.5 0 0 16.8 
Greek 
Yogurt 33 140 1 15 0 15 0 12 4.95 
Kash 
GoLean 55 142.5 3/4 cup 27 8 19 2.25 3.5625 14.85 
Peach 28 59 1 peach 14 2.2 11.8 0.4 1.4 3.92 
Spaghetti 41 270 72.3g 50 6 44 2 9 20.5 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
Black 
Beans 40 155 3/4 cup 30 20 10 0 7.875 12 
Bell 
Peppers 45 50 300 g 8.4 0.5 7.9 0 0 3.78 
Dark 
Chocolate 40 90 2 pieces 12 1.5 10.5 10 0 4.8 
Red Wine 15 130 1 glass 5 0 5 0 0 0.75 
Barley 25 160 
1/3 cup 
uncooke
d 37 5 32 0.5 5 9.25 
TOTALS   1986.5   292.9     36.65 90.2125   
 
 
 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 6 8 6 15 
GI 65 60 47 42 
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Thursday, June 25, 2014 
 
6:15 AM Carbs 15 grams 
9:00 AM Carbs 56 grams 
8:50 AM Insulin 4 units 
12:54 PM Insulin 4 units 
1:04 PM Carbs 67 grams 
3:00 PM Carbs 14 grams 
2:58 PM Insulin 2 units 
8:02 PM Carbs 100 grams 
7:55 PM Insulin 5 units 
7:00 AM Tempo Run (50 
minutes) 
9:47 PM Insulin 11 units 
 
Simulation Day 3- Exercise Protocol 2 
Description: Circuit Training at Al  
 
 
Date: June 26 (Dexcom 6/26/14…Thursday) 
Blood Glucose at 6 AM, 
Correction Needed to 
reach  100 + 5 mg/dl 
72, had granola bar (15g) and some berries; higher, 
~135 
Soreness and Fatigue 
Present?  
No 
HR Before Exercise 96 bpm 
Peak HR 183 (spikes with circuits) 
Average HR 164 
Training Zone 3 
Post-Exercise Meal  4 U at 8:50, had some low calorie Gatorade 
172 
 
 
 
BG at 1 PM lunch, 
corrections needed?  
No—steady at 80; 4 U at 12:50, same lunch as 6/24 
3 PM Adjustment to get 
BG to around 120 mg/dl 
(consistent each week) 
~94 mg/dl, steady, no adjustments 
4 PM 50 g CHO snack Yamamoto, Barley 
Dinner Notes and Timing 
(Note the flexibility here) 
Dinner earlier, during USA game—hungrier today 
as well. 4 U at 7:10, dinner ~7:20, BG around 84 
mg/dl 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Had a low alarm at 5:30, maybe due to hot shower? 
It was actually 67 (not <55); otherwise, daily 
readings were accurate 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
1950 cals, 270 g CHO, 45 g Fat, 28 g Protein 
Blood Glucose Level 
Before Bed (mg/dL) 
116 mg/dl @ 10:45 
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories SERVING SIZE CHO (g) Fiber(g) 
Available 
CHO FAT (g) 
PROTEIN
(g) LOAD 
Cascade Farms 
Granola 30 90 1 bar 15 1 14 1 14 2.5 
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread ,2 slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut Butter 14 105 1 tbs 3.5 1 2.5 8.5 3.625 0.49 
Turkey 0 60 4 slices 4 0 4 1.5 7.625 0 
Bread ,2 slices  60 140 2 slice 28 3 25 2 2.5 16.8 
Spinach 0 25 1/2 cup 3.5 0.7 2.8 0.5 1.625 0 
Pretzels  83 100 1 oz 22 0.9 21.1 0 3 18.26 
Almonds 7 80 0.5 OZ 4.5 2 2.5 6.5 2.5 0.315 
Barley 25 215 79.6g 50 5 45 1 7 12.5 
Dove Dark 
Blueberries 50 200 42g 28 2 26 10 2 14 
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Black Beans 40 105 1/2 cup 21 15 6 0 5.25 8.4 
Red Wine 15 130 1 glass 5 0 5 0 0 0.75 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
Corn Tortillas 52 120 2 tortillas 23 2 21 1.5 2 11.96 
TOTALS   1950   270.5     45.5 98.875   
 
  
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 8 6 4 15 
GI 65.36437247 63.85379061 27.77777778 53.10294118 
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Thursday, June 26, 2014 
 
9:00 AM Carbs 56 grams 
6:15 AM Carbs 15 grams 
8:50 AM Insulin 4 units 
7:02 AM Exercise Medium (40 minutes) 
12:50 PM Insulin 4 units 
1:00 PM Carbs 63 grams 
4:00 PM Carbs 50 grams 
3:55 PM Insulin 4 units 
7:23 PM Carbs 85 grams 
7:15 PM Insulin 4 units 
 
 
 
Simulation Day 4- Exercise Protocol 2 
Description: Fatigue-Inducing Long Aerobic Brick Workout 
 
 
Date: June 27 (Long Run, 19 miles, 2 hr 30 minutes) 
Blood Glucose at 6 AM, 
Correction Needed to 
reach 100 + 5 mg/dl 
72, had granola bar (same one) and handful banana 
chips at 6:15; spiked to 144 
Soreness and Fatigue 
Present?  
Yes, back and arms, but did not affect running 
HR Before Exercise 120 
Peak HR 165 
Average HR 150 
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Training Zone 3 
Post-Exercise Meal  10:20, with insulin (4 U) at 10:10 
BG at 1 PM lunch, 
corrections needed?  
2:20 lunch, steady @ 92, no corrections but only 3 
U since walking/exercising 
3 PM Adjustment to get 
BG to around 120 mg/dl 
(consistent each week) 
N/A (Cappucino, no insulin before, at 2:00 before 
lunch) 
Dinner Notes and Timing 
(Note the flexibility 
here)/ Alcohol Protocol  
Low BG around 5 PM, grapes and corona, no 
insulin; Dinner at Belair—tortilla chips appetizer 
(6:30), Insulin 4 U, 2 tacos—mahi mahi and Korean 
beef each with 2 corn tortillas 
Beers at Downer, Strawberry Margarita 
2 Beers at bar after 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Well Calibrated; left CGM in car from 11:50-12:20 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
2700 Calories, 321 g CHO, 52 g Fat, 97 g Protein 
Blood Glucose Level 
Before Bed (mg/dL) 
150 mg/dl @ midnight 
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber(g) 
Available 
CHO FAT (g) PROTEIN(g) LOAD 
Cascade Farms 
Granola 30 90 1 bar 15 1 14 1 14 2.5 
Almond Milk 0 80 1 Cup 4 1 3 2.5 2   
Watermelon 72 50   10 1 9 0 1 7.2 
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread ,2 slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut Butter 14 160 1.5 tbs 5 1 4 12.5 7 0.7 
Cappuccino 25 100 12 oz 12 0 12 4 8 3 
Grapes 60 105 1 cup 28 0.5 27.5 0 0 16.8 
Greek Yogurt 33 140 1 15 0 15 0 12 4.95 
Kash GoLean 55 142.5 3/4 cup 27 8 19 2.25 3.5625 14.85 
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VegaOne 
Protein   90 23.3 g 4 0 0 0 15 0 
Grapes 60 105 1 cup 28 0.5 27.5 0 0 16.8 
Corona light 15 105 12 0z 5 0 5 0 0 0.75 
Margarita 45 160 1 glass 15 0 15 0 0 6.75 
Belair Tacos 52 450 2 tacos 40 2 38 15 20 20.8 
Tortilla Chips 55 200 20 chips 40 1 39 5 0 22 
Fat Tire 20 320 24 0z 20 0 20 0 0 4 
TOTALS   2677.5   321 22.1 294.9 52.25 97.0625   
 
 
 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 6 10   20 
GI 65 60   51.8556701 
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Friday, June 27, 2014 
 
6:15 AM Carbs 15 grams 
9:53 AM Carbs 10 grams 
7:00 AM Exercise Light (150 minutes) 
10:08 AM Insulin 4 units 
10:25 AM Carbs 56 grams 
2:07 PM Insulin 3 units 
2:20 PM Carbs 60 grams 
6:30 PM Carbs 77 grams 
6:20 PM Insulin 4 units 
5:17 PM Carbs 15 grams 
7:36 PM Carbs 10 grams 
8:43 PM Carbs 10 grams 
9:16 PM Carbs 10 grams 
11:30 PM Insulin 11 units 
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Day Before Simulation Day 5 
Date: July 4 
Total Calorie and 
Carbohydrate Intake 
2630 cals, 299 g CHO 
Exercise (Time/Intensity), 
Activity Level  
6 miles easy run with Lauren and Megan, low 
intensity 
Food Logbook (and 
Insulin intake), Dinner 
should be similar to what 
is typical for subject and 
kept consistent 
throughout.  
NOTE: For KOTACHEV 
Simulation, starting at 
21:30, readings will need 
to be recorded 
PB (2 Tbs), 190 cals, 4 CHO 
Pretzels, 200 cals, 25 g CHO 
GoLean 190 cals, 40 g CHO 
Shrimp/Smoked Salmon, 200 cals, 
Chicken Noodle Soup, 140 cals, 20g 
Sourdough Bread, 210 cals, 43 g 
4 Chocolates, 210, 21 g 
Banana, 100, 15 
Bloody Mary, 120, 4 g 
Wine, 120, 2 g 
Chips/guac, 280 cals, 40 g 
Cake (small), 200 cals, 30 g 
Coors Light, 200 cals, 8 g 
Chicken Tenders, 170, 14 g 
Quinoa, 100, 15 g 
 
Blood Glucose Level 
Before Bed (mg/dL) 
126 
 
 
 
Simulation Day 5- Non- Exercise Protocol 2 
Description: Non-Exercise 1, Kotachev morning meal and Parillo High GI 
 
 
Date: July 5 
Blood Glucose and Time of 
Wake-up, Breakfast 
Option 
7:30 AM Ensure Plus Nutritional  (late night before, 
had some snacks); 187—high! slight exercise to 
~80 
Lunch Notes In car driving, 4 Units, 12:50, 75 g Kotachev (added 
turkey) 
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3 PM Blood Glucose, 
adjusting for 4 PM 
Snack—Replicate Day 1 
Value 
Yamamoto, Pineapple Juice 
Somewhat up in the air BG 
At 3 PM—115 to 125 
Fresh (premium brand) 100% juice 
Food/Insulin/BG levels 
before dinner protocol  
and correction needed to 
reach 120 mg/dl + 5 
mg/dl   
Went low at 5:45, had a bit of juice, rose to 81 
Insulin, 6 U (consistent with Day 1) at 7:50 PM 
Dinner at 8:00 PM (Parillo High Glycemic) 
Low at 9:30—pretzels and PB 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Within Range 
Blood Glucose Level 
Before Bed (mg/dL) 
~120, rose with grapes, pretzels 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
2016 cals, 296 CHO, 49.6 g fat, 50 g protein 
 
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber (g) 
Available 
CHO (g) FAT (g) 
PROTEIN
(g) LOAD 
Ensure Plus 44 350 1 bottle 50 0 50 11 13 22 
Banana 60 100   25 3.1 21.9 0 0 15 
Yoplait 
Strawberry 35 170 6oz 33 0 33 1.5 -28.125 11.55 
Cheese 0 110 1/3 cup 0.5 0 0 9 7 0 
Turkey 0 60 4 slices 4 0 4 1.5 7.625 0 
Kashi 
GoLean 
Crunch 55 95 1/2 cup 18 6 12 1.5 -10.875 9.9 
Tortilla Chips 55 100 8 chips 25 1 24 5 0 13.75 
Pineapple 
Juice 46 160 72.3 g 50   50     23 
White Rice, 
Instant 89 200 1 cup 40 2 38 3 4 35.6 
Chicken 10 300 6 oz 0 0 0 14 43.5 0 
Tomato/Veg
gies 27 51 300g 8.4 3 5.4 0.6 3.6 2.268 
Corn 60 120 5.5v oz 28 12 16 0.5 0.875 16.8 
Chobani 
Tube 85 100 2 tubes 15 0 15 2 10 12.75 
Pretzels  83 100 1 oz 22 0.9 21.1 0 3 18.26 
TOTALS   2016   318.9 28 290.4 49.6 53.6   
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Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 1 5 3 15 
GI 44 51.41043724 46 90.6155914 
CHO (g)    91.4 
FracCarbs    47.4 
 
 
 
 
Simulation Day 6- Exercise Protocol 4 
Description: Continuous Bike/Swim/Run <60 min 
 
 
 
Date: July 6 (Bike 10 mi, Run 2 mi..45 minutes total) 
Blood Glucose at 6 AM, 
Correction Needed to 
reach  100 + 5 mg/dl 
84, half of a granola bar; 115 at 6:40 
Soreness and Fatigue 
Present? Exercise Chosen 
No 
HR Before Exercise** 119 
Peak HR ~150? (HR monitor died, used app on phone) 
Average HR 143 
Training Zone 2 
Post-Exercise Meal  BG slightly rising, 4 U insulin at 8:50 
BG at 1 PM lunch, 
corrections needed?  
~125, consistent from breakfast, 4 units 
 
Sunday, July 5, 2015 
 
7:20 AM Insulin 4 units 
6:30 AM Exercise Light 
(30 minutes) 
7:30 AM Carbs 50 grams 
12:50 PM Insulin 4 units 
1:00 PM Carbs 75 grams 
7:50 PM Insulin 6 units 
8:00 PM Carbs 100 grams 
10:18 PM Insulin 11 units 
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3 PM Adjustment to get 
BG to around 120 mg/dl 
(consistent each week) 
~75, checked late (3:55—4 U insulin) 
4 PM 50 g CHO snack Dalla Man, UVA/PADOVA (Protein/ Granola Bar) 
Low at 5:45, 10 g CHO (pretzels) 
Dinner Notes and Timing 
(Note the flexibility here) 
Insulin, 5 U at 7:05 
Dinner @7:15 PM 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
12 mg/dl, low during morning calibration 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
~2000 (1940), 261 g CHO, 51 g fat, 108 g Protein 
Blood Glucose Level 
Before Bed (mg/dL) 
125 mg/dl 
**NOTE: Exercise was redone in order to get HR data  
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber (g) 
Available 
CHO (g) FAT (g) 
PROTEIN
(g) LOAD 
Fiber One 
Protein 30 120 1 bar 17 5 12 6 6 5.1 
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread ,2 
slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut 
Butter 14 105 1 tbs 3.5 1 2.5 8.5 3.625 0.49 
Grapes 60 105 1 cup 28 0.5 27.5 0 0 16.8 
Greek 
Yogurt 33 140 1 15 0 15 0 12 4.95 
Kashi 
GoLean 55 142.5 3/4 cup 27 8 19 2.25 3.5625 14.85 
Luna 
Protein 
Bar 33 350 2 Bars 48 7 41 11 21 15.84 
Quinoa 53 174.75 3/4 cup 35 4 31 4 8 18.55 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
Bell 
Peppers 27 50 300g 8.4 3 5.4 0.6 3.6 2.268 
Almonds 7 80 0.5 OZ 4.5 2 2.5 6.5 2.5 0.315 
Dark 
Chocolate 40 90 2 pieces 12 1.5 10.5 10 0 4.8 
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TOTALS   1937.25   261.4 38.1 223.3 51.85 108.0375   
 
 
 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 1 6 12 20 
GI 65.36437247 59.51219512 33 45.34175084 
 
 
184 
 
 
 
 
 
185 
 
 
 
 
 
 
 
Monday, July 6, 2015 
 
6:11 AM Carbs 15 grams 
8:50 AM Insulin 4 units 
9:00 AM Carbs 57 grams 
12:50 PM Insulin 4 units 
5:54 PM Carbs 10 grams 
4:00 PM Carbs 50 grams 
3:55 PM Insulin 4 units 
7:00 AM Exercise Medium 
(45 minutes) 
 
 
Simulation Day 7- Non- Exercise Protocol 5 
Description: Sprint Intervals at Track 
 
 
 
Date: July 7 (4x400’s, 4x200’s, 1x400, 1x200, 4x100’s) 
Blood Glucose at 6 AM, 
Correction Needed to 
reach  100 + 5 mg/dl 
Low, ~60, had 18 g granola bar at 6:00 (earlier than 
other days) 
Soreness and Fatigue 
Present?  
Some but didn’t affect exercise 
HR Before Exercise 130 after warmup 
Peak HR 163 
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Average HR 182 
Training Zone 3-4 
Post-Exercise Meal  High, took an extra unit, 5 U 
BG at 1 PM lunch, 
corrections needed?  
Adjusted a bit with some berries to get ~96 (4 U) 
3 PM Adjustment to get 
BG to around 120 mg/dl 
(consistent each week) 
Took 2 units since at 140 mg/dl; dropped to ~118 
4 PM 50 g CHO snack Yamamoto, Instant Potato (4 U, 5 min before) 
Dinner Notes and Timing 
(Note the flexibility here) 
Something came up; no dinner until 9:30 PM, 3 U 
insulin, 58 g CHO 
Calibration Times and 
Levels/ Status of CGM and 
Sensor 
All seemed well calibrated 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
2003 calories, 263 g CHO, 53 g fat, 58 g Protein 
Blood Glucose Level 
Before Bed (mg/dL) 
120 
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber (g) 
Available 
CHO (g) FAT (g) 
PROTEIN(
g) LOAD 
Fiber One 
Protein 30 120 1 bar 17 5 12 6 6 5.1 
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread ,2 
slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut 
Butter 14 105 1 tbs 3.5 1 2.5 8.5 3.625 0.49 
Grapes/ 
Berries 60 105 1 cup 28 0.5 27.5 0 0 16.8 
Yoplait 
Strawberr
y 35 170 6oz 33 0 33 1.5 -28.125 11.55 
Cheese 0 110 1/3 cup 0.5 0 0 9 7 0 
Turkey 0 60 4 slices 4 0 4 1.5 7.625 0 
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Kashi 
GoLean 
Crunch 55 95 1/2 cup 18 6 12 1.5 -10.875 9.9 
Instant 
Potato 83 333.6 67.3 g 50 3 47 12.6 5.56 41.5 
Quinoa 53 174.75 3/4 cup 35 4 31 4 8 18.55 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
Bell 
Peppers 27 50 300g 8.4 3 5.4 0.6 3.6 2.268 
Red Wine 15 130 1 glass 5 0 5 0 0 0.75 
TOTALS   2033.35   265.4 28.6 236.3 58.2 50.16   
 
 
 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 1 10 6 15 
GI 65.36437247 50 83 43.90661479 
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Tuesday, July 7, 2015 
 
9:00 AM Carbs 57 grams 
8:50 AM Insulin 5 units 
1:00 PM Carbs 75 grams 
12:25 PM Carbs 10 grams 
12:50 PM Insulin 5 units 
3:55 PM Insulin 4 units 
4:00 PM Carbs 50 grams 
9:38 PM Carbs 50 grams 
9:30 PM Insulin 4 units 
7:00 AM Exercise Heavy (45 minutes) 
11:41 PM Insulin 11 units 
 
 
 
Simulation Day 8- Exercise Protocol 6 
Description: Long Anaerobic Fatigue-Inducing Brick Workout 
 
 
 
 
Date: July 8 
Blood Glucose at 6 AM, 
Correction Needed to 
reach  100 + 5 mg/dl 
72, ate Fiber One Bar (15 g CHO) 
Soreness and Fatigue 
Present?  
Yes, some 
HR Before Exercise 120 after jogging 
Peak HR 169 
Average HR 126 
Training Zone 1-2 
Post-Exercise Meal  A Couple of snacks (nuts, pretzels) right after; had 
meal, 4 U, similar breakfast 
BG at 1 PM lunch, 
corrections needed?  
Snacked on half a bagel then had meal (~1:00 
snack, 1:45 meal) 
3 PM Adjustment to get 
BG to around 120 mg/dl 
(consistent each week) 
N/A 
Dinner Notes and Timing 
(Note the flexibility 
here)/ Alcohol 
Protocol/Hot 
Environment 
Chicken and Broccoli, 3 Units 
Chips at 5:00 PM 
3 glasses wine between 7:00-9:00 
Chocolate 
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Calibration Times and 
Levels/ Status of CGM and 
Sensor 
Off by >10 after exercise in the morning 
Total Daily Calorie, CHO, 
Fat, Protein Intake, GI 
2209 cals, 274 g CHO, 47 g Fat, 94 g protein—more 
hungry today! 
Blood Glucose Level 
Before Bed (mg/dL) 
Had late snack, so ~105 but rising 
 
 
 
Meal 1 Meal 2 Meal 3 Meal 4             
FOOD GI Calories 
SERVING 
SIZE CHO (g) Fiber (g) 
Available 
CHO (g) FAT (g) PROTEIN(g) LOAD 
Fiber One 
Protein 30 120 1 bar 17 5 12 6 6 5.1 
Almonds 7 80 0.5 OZ 4.5 2 2.5 6.5 2.5 0.315 
Pretzels  83 100 1 oz 22 0.9 21.1 0 3 18.26 
Banana 60 100 1 banana 25 3.1 21.9 0 0 15 
Eggs 0 140 2 eggs 0 0 0 8 12 0 
Bread,2 
slices  60 140 2 slices 28 3 25 2 2.5 16.8 
Peanut 
Butter 14 160 1.5 tbs 5 1 4 12.5 7 0.7 
Coconut 
Water   90 16 oz 22 0 22 0 0 0 
Semi-Sweet 
Chocolate 40 70 1 tbs 10 0 10 4 1 4 
Grapes 60 200 2 cups 52 3 49 0 0 31.2 
Greek 
Yogurt 33 140 1 15 0 15 0 12 4.95 
Turkey 0 60 4 slices 4 0 4 1.5 7.625 0 
Broccoli 30 60 2 cups 12 3 9 0 0 3.6 
Quinoa 53 174.75 3/4 cup 35 4 31 4 8 18.55 
Chicken 10 200 4 oz 10 0 10 3 33.25 1 
Red Wine 15 375 
2.5 
glasses 12.5 0 12.5 0 0 1.875 
TOTALS   2209.75   274 25 249 47.5 94.875   
 
 
 
Meal 
Duration Meal 1 Meal 2 Meal 3 Meal 4 
Time (min) 15 10 N/A 30 
GI 44.6 53.2   40.0 
191 
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Wednesday, July 8, 2015 
 
6:15 AM Carbs 14 grams 
7:03 AM Exercise Heavy (105 minutes) 
10:00 AM Carbs 50 grams 
9:50 AM Insulin 4 units 
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7.5 DXA and VO2Max Data 
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Blood lactate level (mmol/l) at end of VO2max stress test. Lactic threshold was reached. Initial level 
was 1.7 mmol/l. 
 
 
 
Vo2 Max Stress Test: June 23, 2015 
 
Schunk Sofie 
Date: 6/23/15 
Program Exercise Science 
Marquette University 
Milwaukee WI 
Speed Ramp Test (0.5 miles/min) @ 1% 
Grade   
Test Duration 11 min 08 sec 
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VO2max (mL/kg/min) 62.65 
    
Anaerobic Threshold Parameters 
VO2 (ml/kg/min) 50.4 
% VO2max 80.4 
Speed @ 1% Grade (mph) 9-9.5 
HR (BPM) 170 
*Note: Entire RER Table and HR Values are Available  
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
0 100 200 300 400 500 600 700
V
E
 (
L
/m
in
)
Time (s)
0
10
20
30
40
50
60
70
0 100 200 300 400 500 600 700
V
O
2
 (
m
L
/k
g/
m
in
)
Time (s)
199 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
V
C
O
2
 (
L
/m
in
)
VO2 (L/min)
 
 
 
2
0
0
 
 
 
7.6 Sensitivity Analysis 
 
 
7.6.1 Chapter 3 Sensitivity Analysis  
 
Inputs 
Meal Snack Exercise 
 700 kcal at 13 hours 
 30 minute duration 
 175 g CHO  
o GI = 50, 50% CHO 
 Insulin bolus  (Fast) = 50 
 
 60 kcal at 10 hours 
 6 minute duration 
 15 g CHO  
o GI = 80, 80% CHO 
 No Insulin 
 600 kcal/hr for 1 hour 
 Aerobic Capacity = 1000 
 Simulation times 
o 30 min before 
o 30 min after start 
o 18 min after end 
(Recovery) 
 
Full Sensitivity Analysis Table Non-Diabetic—Most Sensitive Parameters (>0.4, bold >1.0) 
 Xg Xnm Xm Xd Xds Xi Xinj-m Xgn Xinj-nm Xmito 
Meal Simulation 
Xmina   ___ ___ ___ Ki 2.756 
Cia 3.007 
Cga -3.025 
Kgt -3.025 
Grefi 2.630 
Grefg -2.821 
Greft -2.999 
___  ___  
Xmaxa Ki 1.149 
Cia -0.733 
Kugs 0.578 
Grefg -0.463 
Kg2Max -0.476 
Kmintol -0.784 
Wratt 1.068 
Kmintol -0.523 
Cib 0.589 
Kmintol 1.306 
 Kugs 0.662 Ki -0.796 
Grefi 0.612 
Grefg -1.272 
  ___ ___ 
 
 
 
2
0
1
 
 
XBMb Ki -1.879 
-1.225 
Cib 3.090 
Cga 1.461 
Kgt 1.446 
Grefi -4.317 
Grefg 5.518 
Greft 1.872 
Kg2Max -0.751 
Kmxex -1.233 
Kse -0.921 
Kmintol -4.281 
Ratmito 1.079 
Ki -0.550 
Cib 0.732 
Grefi -1.106 
Grefg 1.267 
Gbt 0.504 
Wratt 0.496 
Kmintol 0.971 
Ki -0.973 
Cib 1.296 
Cga 0.620 
Kgt 0.611 
Grefi -1.952 
Grefg 2.249 
Greft 0.605 
Kmxex -0.665 
Kse -0.500 
Kmintol 
1.690 
Ratmito 0.645 
___ ___ Ki -3.031 
Cia -1.147 
Cib 3.129 
Cga 1.311 
Kgt 1.296 
Grefi -4.489 
Grefg 4.857 
Greft 1.726 
Kg2Max -0.707 
Kmxex -1.252 
Kse -0.936 
Kmintol -
4.060 
Ratmito 1.083 
 Ki -2.472 
Cia -0.857 
Cib 3.297 
Cga 0.768 
Kgt 0.752 
Grefi -5.576 
Grefg 6.373 
Greft 1.191 
Kg2Max -0.540 
Kmxex -1.338 
Kse -1.001 
Kmintol -4.043 
Ratmito 1.060 
___  
XDMRc  Ki -1.311 
Cia -1.131 
Cib 2.198 
Cga 0.796 
Kgt 0.780 
Grefi -2.666 
Grefg 2.966 
Greft 0.894 
Gbt 1.486 
Kugf -1.035 
Wratt -0.486 
KgwMax -1.315 
Kmxex -1.125 
Kse -0.848 
Kmintol 2.995 
Ki -0.845 
Cib 1.201 
Cga 0.533 
Kgt 0.526 
Grefi -1.686 
Grefg 1.939 
Greft 0.522 
Kmxex -0.544 
Kse -0.421 
Kmintol 
1.622 
Ratmito 0.506 
 Kugs 0.717 Kid 0.890  Ki -0.511 
Cga 0.635 
Kgt 0.636 
Grefi -1.025 
Grefg 1.301 
Greft -0.615 
  
XDMFd Ki 0.546 
Cia -0.431 
Kid -0.402 
Wratt 1.077 
Kmintol -0.456 
Cib 0.649 
Kmintol 
1.137 
 Kugs 0.600 
 
Ki -1.165 
Grefi 0.455 
Grefg -0.621 
 Ki -0.451 
Cga -0.608 
Kgt -0.609 
Grefi -1.002 
Grefg 1.444 
Greft -0.582 
  
Snack Simulation 
Xmina   ___ ___ ___ Ki 2.479 
Ciaa 2.697 
Cga -2.629 
Kgt -2.629 
Grefi 2.390 
Grefg -2.423 
Greft -2.658 
Kmintol 2.702 
___ Grefg 0.621 
 
___  
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Xmaxa Ki 1.380 
Cia -0.618 
Cga 1.197 
Kgt 1.200 
Grefi 1.424 
Grefg 4.366 
Greft 0.991 
Kmintol -0.471 
___ Ki -0.940 
Cib 1.327 
Cga 0.633 
Kgt 0.625 
Grefi -1.760 
Grefg 2.242 
Greft 0.603 
Kmxex -0.611 
Kse -0.459 
Kmintol 
1.150 
 
Kugf 
0.549 
 
Kugs 0.972 Ki -6.047 
Cia -0.487 
Cga 1.927 
Kgt 1.932 
Grefi -8.041 
Grefg 6.924 
Greft 1.307 
Kid 1.261 
 
   ___ 
XBSb Ki 0.776 
Cia -0.479 
Cga 0.920 
Kgt 0.922 
Grefi 1.562 
Grefg 3.415 
Greft 0.890 
Ki -0.534 
Cib 0.778 
Cga 0.449 
Kgt 0.444 
Grefi -1.049 
Greft 1.593 
Greft 0.418 
Gbt 0.451 
Wratt 0.549 
Kmintol 0.621 
Ki -1.014 
Cib 1.406 
Cga 0.719 
Kgt 0.710 
Grefi -1.994 
Grefg 2.534 
Greft 0.666 
Kmxex -0.684 
Kse -0.513 
Kmintol 
1.126 
Ratmito 0.605 
 
___ ___ Ki 54.629 
Cia 12.176 
Cib 7.400 
Cga -23.404 
Kgt -23.455 
Grefi 109.876 
Grefg -86.464 
Greft -22.650 
Kg2Max 6.985 
Kmxex -3.746 
Kse -2.814 
Kmintol 8.313 
 Ki 0.866 
Cia -0.531 
Cga 1.026 
Kgt 1.028 
Grefi 1.744 
Grefg -2.752 
Greft 0.991 
  
XDSRc Ki 0.774 
Cia -0.479 
Cga 0.921 
Kgt 0.923 
Grefi 1.559 
Grefg 3.416 
Greft 0.891 
Ki -0.536 
Cib 0.778 
Cga 0.448 
Kgt 0.442 
Grefi -1.053 
Grefg 1.587 
Greft 0.417 
Gbt 0.452 
Wratt 0.548 
Kmintol 0.626 
Ki 1.014 
Cib 1.405 
Cga 0.718 
Kgt 0.708 
Grefi -1.995 
Grefg 2.530 
Greft 0.666 
Kmxex -0.684 
Kse -0.513 
Kmintol 
1.135 
___ ___ Ki 55.564 
Cia 12.392 
Cib 7.468 
Cga -23.805 
Kgt 23.587 
Grefi 111.732 
Grefg -87.947 
Greft -23.045 
Kg2Max 7.110 
Kmxex -3.786 
Kse -2.844 
Kmintol 8.532 
 Ki 0.864 
Cia -0.531 
Cga 1.026 
Kgt 1.028 
Grefi 1.739 
Grefg -2.746 
Greft 0.991 
  
XDSFd Grefi 0.608 
Grefg 1.054 
Ki -0.547 
Cib 0.797 
Cga 0.451 
Kgt 0.446 
Grefi -1.076 
Grefg 1.604 
Greft 0.426 
Gbt 0.465 
Ki -1.009 
Cib 1.399 
Cga 0.711 
Kgt 0.702 
Grefi -1.987 
Grefg 2.510 
Greft 0.661 
Kmxex -0.680 
 Kugs 0.887 Ki -0.852 
Grefi -0.985 
Grefg 0.619 
Kugf 0.450 
Kid 0.836 
 Grefi 0.510 
Grefg -1.046 
  
 
 
 
2
0
3
 
 
Wratt 0.535 
Kmintol 0.653 
Kse -0.510 
Kmintol 
1.152 
Exercise Simulation 
Xminc ___ ___  ___  Ki -0.510 
Grefi -0.501 
Grefg 0.674 
 Grefg 0.696 ___ ___ 
Xmaxa Ki 1.819 
Cia -2.214 
Cib -1.456 
Cga 1.168 
Kgt 1.170 
Grefi 2.091 
Grefg 4.594 
Greft 1.611 
Kg2Max -0.522 
Kmintol -1.315 
Kid -2.706 
 
___ Ki -0.550 
Cib 0.994 
Cga 1.449 
Kgt 1.440 
Grefi -0.993 
Grefg 4.197 
Greft 0.675 
Kmxex 0.591 
Kse -0.557 
Kmintol 0.692 
Ratmito -
1.166 
___ ___ Ki -2.196 
Cia -0.418 
Cga 0.836 
Kgt 0.839 
Grefi -2.160 
Grefg 2.902 
Greft 0.541 
Kmxex 0.915 
Kid 0.745 
___ Ki 1.043 
Cia -1.337 
Cib -0.901 
Cga 1.429 
Kgt 1.432 
Grefi 1.412 
Grefg -4.218 
Greft 1.160 
Kg2Max -0.458 
Kmintol -0.789 
Kid -1.682 
___ ___ 
XBEe Ki 0.810 
Cia -0.469 
Cga 0.913 
Kgt 0.915 
Grefi 1.629 
Grefg 3.388 
Greft 0.877 
Ki -0.403 
Cib 0.708 
Cga 0.525 
Kgt 0.520 
Grefi -0.738 
Grefg 1.797 
Greft 0.464 
Wratt 0.602 
Ki -0.941 
Cib 1.404 
Cga 0.772 
Kgt 0.763 
Grefi -1.756 
Grefg 2.582 
Greft 0.666 
Kmxex -0.654 
Kse -0.489 
Kmintol 0.903 
___ ___ Ki 42.380 
Cia 9.306 
Cib 6.628 
Cga -18.140 
Kgt -18.185 
Grefi 85.304 
Grefg -66.975 
Greft -17.457 
Kmxex -3.283 
Kse -2.465 
Kmintol 4.891 
___ Ki 0.916 
Cia -0.527 
Cga 1.030 
Kgt 1.032 
Grefi 1.839 
Grefg -2.889 
Greft 0.987 
___ ___ 
XDEf Cga -0.951 
Kgt -0.953 
Grefg -2.478 
Kmxex 0.838 
Cib 0.421 
Cga 0.538 
Kgt 0.535 
Grefi -0.460 
Grefg 1.570 
Wratt 0.743 
Ki -0.533 
Cib 0.893 
Cga 0.976 
Kgt 0.969 
Grefi -0.996 
Grefg 2.902 
Greft 0.572 
Kse -0.432 
Kmintol 0.585 
___ ___ Ki 2.378 
Cga -1.293 
Kgt -1.297 
Grefi 3.298 
Grefg -3.808 
Greft -0.541 
Kmxex 0.475 
Kid -0.911 
___ Kgt -1.197 
Kgt -1.199 
Grefg 1.085 
Kmxex 0.874 
___ ___ 
XRg Cga 0.838 
Kgt 0.840 
Grefi 0.539 
Grefg 2.788 
Greft 0.470 
Kmxex 0.548 
Cga 0.464 
Kgt 0.461 
Grefg 1.355 
Wratt 0.825 
Ki -0.567 
Cib 0.996 
Cga 1.539 
Kgt 1.529 
Grefi -1.059 
Grefg 4.433 
___ ___ Ki -0.958 
Cga 0.614 
Kgt 0.616 
Grefi -0.910 
Grefg 2.101 
Kmxex 0.827 
 Ki 0.509 
Cga 3.173 
Kgt 3.181 
Grefi 0.890 
Grefg -2.388 
Greft 0.983 
___  
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Kid -0.442 Greft 0.711 
Kmxex 0.619 
Kse -0.589 
Kmintol 0.673 
Ratmito -
1.310 
Kid 1.033 
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.  
a All maximum behaviors occur at a peak during meal and  snack simulation subtasks. 
b Sensitivity behavior values were taken 0.5 hrs prior to this subtask (meal XBM, snack XBS), to document initial fluctuations. 
c Rising sensitivity behavior measured at 0.3 hrs after start of this subtask (meal XDMR, snack XDSR).  
d Falling sensitivity behavior measured at 1.0 hrs after the start of this subtask (meal XDMF, snack XDSF).  
e Sensitivity behavior values were taken 0.3 hrs prior to exercise subtask event, to document initial fluctuations.  
f Behaviors values taken during exercise subtask,  0.5 hrs after its start. 
g Behavior values taken during exercise ‘recovery’ phase, at 0.25 hrs after the end of exercise (i.e., 1.25 hrs after its start).  
*  Exception to the >0.1 threshold. 
 
 
 
Full Sensitivity Analysis Table T1D—Most Sensitive Parameters (>0.4, bold >1.0) 
 Xg Xnm Xm Xd Xds Xi Xinj-m Xgn Xinj-nm Xmito 
Meal Simulation  
Xminb Ki -5.444 
Cga -5.529 
Kgt -5.529 
Grefg -4.969 
Kd 5.133 
Ki 0.799 
Cib -1.153 
Grefg -1.120 
Gbt -0.547 
Wratt -0.655 
Kmintol -
6.498 
Ka1 -0.439 
Kd -5.966 
___ ___ ___  ___ Ki -1.042 
Cia 0.959 
Cga -0.792 
Kgt -0.792 
Grefg 0.800 
Greft -0.542 
Kmintol 0.797 
Ka1 0.546 
Kd 2.294 
___ Kmintol 0.483 
Xmaxb Ki 1.605 
Cga -0.655 
Kgt -0.659 
Kugs 1.136 
Grefg -1.924 
Kmintol -1.237 
Ka2 -1.936 
Ka1 -0.773 
Kd -2.294 
 Kmintol 
2.073 
 Kugs 0.662 Ki -0.866 
Ka2 0.933 
Ka1 0.429 
Kd 1.216 
Ka1 0.439 
Kd 1.555 
Cia -0.877 
Cga -1.464 
Kgt -1.468 
Kugs 0.782 
Grefg -1.608 
Ka2 -1.446 
Kd 0.458 
Ka1 1.418 
Kd 3.283 
___ 
XBMc Grefg 0.550 
Greft 0.418 
Ka2 0.596 
Wratt 0.743 
Kmintol 
1.402 
Kmintol 
2.039 
Kd 1.007 
___ ___ Ki -0.996 
Ka1 0.571 
Kd 2.423 
Ka2 -0.733 
Ka1 0.512 
Kd 2.543 
Ki -0.936 
Cia 0.779 
Cga -1.026 
___  
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Kd 0.664 
 
Kgt -1.027 
Kmintol 0.806 
Ka1 0.563 
Kd 2.304 
XDMRd  Grefg -1.579 
Gbt 0.433 
Wratt -4.717 
Kmintol -
4.846 
Kd -6.107 
Ki -0.420 
Kmintol 
2.065 
Ka2 -0.455 
Kd 1.081 
 Kugs 0.717 Ki -1.057 
Kd 0.574 
Kd 2.563 
Ka2 -0.877 
Ka1 0.543 
Kd 2.683 
 
Ki -0.817 
Cia 0.619 
Cga -0.983 
Kgt -0.984 
Greft -0.459 
Kmintol 0.600 
Ka1 0.436 
Kd 2.021 
  
Ka1 0.930 
Kd 3.419 
 
XDMFe Kd -0.710 Grefg 0.455 
Wratt 1.914 
Kg2Max 0.480 
Kmintol 0.491 
Kd 1.656 
 
Kmintol 
2.154 
Ka2 -0.473 
Kd 0.821 
 
 Kugs 0.600 
 
Ki 0.617 
Ka2 1.260 
Kd -1.780 
 
___ Ki -0.772 
Cia 0.579 
Cga -0.935 
Kgt -0.936 
Greft -0.474 
Kmintol 0.557 
Ka1 0.408 
Kd 1.913 
Kd 0.431 Kmintol 0.406 
Snack Simulation 
Xminb Grefg 0.446 Wratt -0.434 
KMintol -0.625 
Kd -0.587 
___ ___ ___  ___ Ki -0.531 
Cia 0.411 
Cga -0.578 
Kgt -0.578 
Grefi 2.390 
Kmintol 0.413 
Kd -2.493 
___  
Xmaxb Ki -2.927 
Cia 2.278 
Cib 0.419 
Cga -3.595 
Kgt -3.600 
Grefg 11.472 
Greft -1.303 
Kmintol 2.281 
Ka2 -0.425 
Ka1 .1655 
Kd 7.322 
 
___ Ki -0.506 
Cib 0.675 
Grefg 0.649 
Kmintol 
1.197 
Kd 1.181 
 
Kugf 0.549 
 
Kugs 0.972 Ki -1.026 
Ka1 0.588 
Kd 2.478 
 
Ka2 -0.971 
Ka1 0.530 
Kd 2.563 
Ki -2.160 
Cia 1.670 
Cga -2.350 
Kgt -2.353 
Grefg 0.694 
Greft -0.932 
Kmintol 1.680 
Ka1 1.226 
Kd 5.343 
Ka1 0.577 
Kd 1.734 
___ 
XBSc Ki -1.462 
Cia 1.094 
Cga -1.668 
Kgt -1.671 
Ki -0.410 
Cib 0.585 
Grefg 0.682 
Wratt 0.764 
Ki -0.538 
Cib 0.726 
Grefg 0.714 
___ ___ Ki -1.026 
Ka1 0.588 
Kd 2.478 
 
Ka2 -0.971 
Ka1 0.530 
Kd 2.563 
Ki -1.541 
Cia 1.140 
Cga -1.755 
Kgt -1.758 
Ka1 0.577 
Kd 1.734 
___ 
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Grefg -5.019 
Greft -0.515 
Kmintol 1.122 
Ka1 0.849 
Kd 3.562 
 
Kmintol 0.843 
Kd 0.941 
 
Kmintol 
1.056 
Kd 1.240 
 
Greft -0.534 
Kmintol 1.160 
Ka1 0.891 
Kd 3.725 
XDSRd Ki -1.522 
Cia 1.148 
Cga -1.745 
Kgt -1.747 
Grefg -5.285 
Greft -0.550 
Kmintol 1.179 
Ka1 0.894 
Kd 3.721 
 
Ki -0.408 
Cib 0.580 
Grefg 0.674 
Wratt 0.766 
Kmintol 0.865 
Kd 0.938 
 
Ki -0.533 
Cib 0.718 
Grefg 0.707 
Kmintol 
1.080 
Kd 1.232 
___ ___ Ki -1.034 
Ka1 0.592 
Kd 2.503 
Ka2 -1.000 
Ka1 0.536 
Kd 2.586 
Ki -1.565 
Cia 1.167 
Cga -1.791 
Kgt -1.793 
Greft -0.556 
Kmintol 1.192 
Ka1 0.905 
Kd 3.797 
Ka1 0.580 
Kd 1.766 
 
XDSFe Ki 1.668 
Cia -1.277 
Cga 1.277 
Kgt 1.278 
Grefg 4.2267 
Greft 0.605 
Kugf 0.799 
Kmintol -1.307 
Ka1 -0.964 
Kd -4.094 
Ki -0.402 
Cib 0.578 
Grefg 0.664 
Wratt 0.766 
Kmintol 0.923 
Kd 0.929 
Ki -0.525 
Cib 0.701 
Grefg 0.685 
Kmintol 
1.132 
Kd 1.218 
 
 Kugs 0.887 Ki -1.049 
Ka1 0.598 
Kd 2.555 
Ka2 -1.065 
Ka1 0.546 
Kd 2.633 
Ki -9.343 
Cia 7.058 
Cib 1.797 
Cga -9.803 
Kgt -9.815 
Grefg 6.947 
Greft -3.447 
Kugf -3.078 
Ksds 0.633 
Kmintol 7.205 
Ka1 5.389 
Kd 22.855 
Ka1 0.586 
Kd 1.839 
 
Exercise Simulation 
Xminb   ___ ___ ___  ___  ___  
Xmaxb Cga 0.562 
Kgt 0.563 
Grefg 2.168 
Greft 0.988 
Kg2Max -0.563 
 
___ Ratmito 
0.812 
___ ___  ___  ___  
XBEf Cga 0.562 
Kgt 0.563 
Grefg 2.168 
Greft 0.989 
Kg2Max -0.563 
 
Grefg 0.891 
Greft 0.415 
Gbt 0.584 
Wratt 0.416 
 
Ratmito 
.5421 
___ ___  ___ Grefg -0.529 
Greft 0.529 
___ ___ 
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XDEg Cga 0.562 
Kgt 0.563 
Grefg 2.168 
Greft 0.988 
Kg2Max -0.563 
Grefg 0.784 
Gbt 0.633 
Ratmito 
0.530 
___ ___  ___ Grefg -0.529 
Greft 0.529 
___  
XRh Cga 0.562 
Kgt 0.563 
Grefg 2.168 
Greft 0.988 
Kg2Max -0.563 
Grefg 0.694 
Gbt 0.674 
Ratmito 
0.819 
___ ___  ___ Grefg -0.529 
Greft 0.529 
___  
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.  
b All maximum behaviors occur at a peak during meal and  snack simulation subtasks. 
c Sensitivity behavior values were taken 0.3 hrs prior to this subtask (meal XBM, snack XSM), to document initial fluctuations. 
d Rising sensitivity behavior measured at 0.3 hrs after start of this subtask (meal XDMR, snack XDSR).  
e Falling sensitivity behavior measured at 1.0 hrs after the start of this subtask (meal XDMF, snack XDSF).  
f Sensitivity behavior values were taken 0.3 hrs prior to exercise subtask event, to document initial fluctuations.  
g Behaviors values taken during exercise subtask,  0.5 hrs after its start. 
h Behavior values taken during exercise ‘recovery’ phase, at 0.25 hrs after the end of exercise (i.e., 1.25 hrs after its start).   
 
 
7.6.2 Chapter 4 Sensitivity Analysis 
 
 
Inputs (Subject: BW = 65 kg, rattype1i = 0.2, wmu = 30, wnm = 25) 
Anaerobic Exercise Simulation Aerobic Exercise Simulation Snack + Exercise Simulation 
 2 Hour Lifting Workout (Case Study 
2 Protocol Day 8) 
o 7:00-9:00 AM 
 Bouts of 800 kcal/hr exertions 
informed by HR input 
 
 2.5 Hour Long Run (Case Study 2 
Protocol Day 4) 
o 7:00-9:30 AM 
 500-600 kcal/hr informed by HR 
input 
 
 1 Hour Tempo Run (Case Study 2 
Protocol Day 1) 
o 7:00-8:00 AM 
 15g CHO snack at 6:30 (kfast = 0.8, 
fraccarbs = 0.8) 
o No insulin 
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Full Sensitivity Analysis Table—Most Sensitive Parameters (>0.4) 
 Xg Xnm Xm Xd Xds Xi Xinj-m Xgn Xinj-nm Xmito 
Exercise Simulation 1 Long  Anaerobic 
Xminb  Cib  
Grefi  
Grefg  
Kmintol  
 ___ ___ Ki  
Cia 
Cga  
Kgt  
Grefi  
Grefg  
Greft  
Kmintol 
___ Ki  
Cia  
Cga  
Kgt  
Grefi  
Grefg  
Greft  
Kmintol  
___  
Xmaxb Ki  
Cia  
Grefg  
Kg2Max  
Kmintol  
Wratt  
Kmintol 
Cib 
Kmintol  
___  Ki 
Gref 
Grefg  
___  ___ Wmu 
Before 
Exercise 
(6:45) 
 
Ki 
Cia 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft  
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ratmito 
Ki 
Cib 
Grefi 
Grefg 
Gbt 
Wratt 
Kmintol 
 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft 
Kmxex 
Kse 
Kmintol 
Ratmito 
___ ___ Ki 
Cia 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kg2Max 
Kmxex 
Kse 
Kmintol 
ratmito 
 
 
___ Ki 
Cia 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft 
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ratmito 
___ Ki 
Cia 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft 
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ratmito  
Wmu  
Halfway 
During 
Exercise 
(8:00) 
 Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft  
Gbt 
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Greft  
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ratmito 
 ___ Kid ___ Ki 
Cga 
Kgt 
Grefi 
Grefg 
Greft 
___  
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Recovery 
(9:45) 
Ki 
Cia 
Kid 
Wratt 
Kmintol 
Cib 
Kmintol 
___ ___ Ki 
Grefi 
Grefg 
___ Ki 
Cga 
Kgt 
Grefi 
Grefg 
Greft 
 
  
Long Aerobic Exercise Simulation 
Xminb Grefg   ___ ___ Ki 
Grefg 
___ Grefg ___  
Xmaxb Cga 
Kgt 
Grefg 
Kmxex 
Kse 
___ Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kmxex 
Kse 
Kmintol 
Ka1 
 
___ ___ Ki 
Cga 
Kgt 
Grefg 
Kmxex 
 
___ Cga 
Kgt 
Grefg 
Kmxex 
___ Grefg 
Before 
Exercise 
(6:45) 
Cga 
Kgt 
Grefg 
Kg2Max 
 
Grefg 
Gbt 
Wratt 
 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kmintol 
Ka1 
Ratmito 
___ ___ Ki 
Cga 
Kgt 
Grefg 
Kg2Max 
___ Cga 
Kgt 
Grefg 
___  
Halfway 
During 
Exercise 
(8:00) 
Cga 
Kgt 
Grefg 
Kmxex 
Kse 
Grefg 
Gbt 
Wratt 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kmxex 
Kmintol 
Ka1 
 
___ ___ Ki 
Cga 
Kgt 
Grefg 
Kg2Max 
Kmxex 
Kse 
Ksds 
___ Ki 
Cia 
Cga 
Kgt 
Grefg 
Kg2Max 
Kmxex 
Kse 
Ka2 
___  
Recovery 
(9:15) 
Cga 
Kgt 
Grefg 
Kmxex 
Grefg 
Wratt 
 
Ki 
Cib 
Cga 
Kgt 
___ ___ Ki 
Cga 
Kgt 
Grefg 
___ Ki 
Cia 
Cga 
Kgt 
___ Grefg 
 
 
 
2
1
0
 
 
Kse Grefi 
Grefg 
Kmxex 
Kse 
Kmintol 
Ka1 
Kmxex Grefg 
Kg2Max 
Kmxex 
Kse 
Ka2 
Exercise Simulation 3: Snack + Tempo 
Xminb ___   ___ ___  Ki 
Grefg 
 ___  
Xmaxb Cga 
Kgt 
Grefg 
 
___ Ki 
Cia 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ka2 
Ka1 
Ratmito 
___ ___ Ki 
Cga 
Kgt 
Grefg 
Kg2Max 
Kid 
___ ___ ___ Wmu 1.120 
Before 
Exercise, 
after snack 
(6:36) 
Cga 
Kgt 
Grefg 
Kg2Max 
 
Grefg 
Gbt 
Wratt 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kmintol 
Ka1 
Ratmito 
 
___ ___ Ki 
Cga 
Kgt 
Grefg 
Kg2Max 
___ Cga 
Kgt 
Grefg 
___ Wmu -0.972 
Halfway 
During 
Exercise 
(7:30) 
Ki 
Cia 
Cga 
Kgt 
Kugs 
Grefg 
Kg2Max 
Kmxex 
Kse 
Ksds 
Ka2 
 
Cib 
Grefg 
Gbt 
Ka1 
Ki 
Cib 
Cga 
Kgt 
Grefi 
Grefg 
Kg2Max 
Kse 
Kmintol 
Ka1 
___ ___ Ki 
Cia 
Cga 
Kgt 
Kugs 
Grefg 
Kg2Max 
Kmxex 
Ka2 
___ Ki 
Cia 
Cga 
Kgt 
Kugs 
Grefg 
Kg2Max 
Kmxex 
Kse 
Ka2 
___ Kugs 
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Recovery 
(8:15) 
Cga 0.204 
Kgt 0.204 
Grefg 0.746 
Cga 
Kgt 
Grefg 
Grefg 
Gbt 
Wratt 
Ki 
Cia 
Cib 
Cga 
Kgt 
Kugs 
Grefi 
Grefg 
Kg2Max 
Kmxex 
Kse 
Kmintol 
Ka2 
Ka1 
Ratmito 
___ Ki 
Cga  
Kgt 
Grefg 
Kmxex 
Kid 
___ Cga 
Kgt 
Grefg 
___ Kugs 
edge For these cases, extremer behaviors occur at the beginning or end of respective time windows for the subtask event.  
b All maximum behaviors occur at a peak during exercise subtasks.  
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8. CODE 
 
 
% STARTER CODE, GLUCOSE 8- or 10-STATE 
% States: x1: Glucose, Blood/plasma; also key regulated output  
%         x2: Glucose, Tissue (non-muscle, lumped);  
%         x3: Glucose, Muscle Tissue 
%         x4: Glucose, Stomach (final path, fast & slow converge); 
%         x5: Glucose, Stomach (slow food path, converges to x4) 
%         x6: Insulin, Blood (controller; glucagon is ~mirror)  
%         x7: Insulin, Local Tissue (for external input only), monomeric 
%           insulin absorbtion 
%         x9: Insulin, Local Tissue (for external input only), nonmonomeric 
%           insulin absorbtion 
%         x8: Glucagon, Blood (controller; insulin is ~mirror) 
%         x10: Mitochondrial Consumption State               
% Inputs: u1: Food ingestion (meals): Lines 36-38, via x4 (1st-ord filter) 
%         u2: Insulin injection or pump: Lines 39-40, via x7 (1st-ord filt) 
%         u3, exer: exercise of certian intensity in kcal/hr 
%         u4,activity: activity as a randomized input of certian intensity 
%               with max of 200 kcal/hr 
%         u5: External Heart Rate (bpm)    
%         uHM: Hormonal Stress 
  
% Key Output: y:  Blood glucose (x1) 
% Notes:  This is set up as 1 model, but has an embedded NL controller for 
%         insulin & glucagon 
%         Type I:  change ratType1i/g; add u(2,i) exogenous insulin  
%         Type II: change (at minimum) starting levels, BM, wmu/wnm, 
%         insulin rate, GLUT2 rate 
clear all; 
  
%PARAMETERS:              
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bm = 70;             % Body Mass, in Kg;  for 70, muscle ~30, fat ~15, brain ~ 1.3, liver 1.4 each, b-
plasma ~ 2.8, interstit ~ 10, RBCs ~2.2? 
wmu = 30;            % BM of skeletal muscle, in Kg, ~40-45% healthy (less if obese), for normalizing in 
f3, etc 
wnm = 25;            % BM, "Non-Musc" in Kg, of: "BM - BMskeletal - BM_ECF - BM_brain+RBCs", for 
normalizing in f2, etc 
ratBM = bm/70.; 
ratmito = 0.1; %proportion of muscle mass that is mitochondria; mitochondrial volume increases with 
training 
ratMUSC = wmu/30.;  ratNONM = wnm/25.;  % ratios for musc and non-musc relative to "normal" 
wmito = ratmito*wmu; %Mass of mitochondria in kg 
kprop = 0.2; %Proportion of glucose consumption (activity) that reaches mitochondria 
stressrat = 1.0; %scaling for stressors for GLUT2; i.e. >1.0 will dump more glucose from non-muscle  
                    %i.e. competitiveness of athletes >1.0; circuit/sprint 
                    %training; 2.0 = MAXIMUM 
metab = 1.0; %Basal Metabolism adjustment >1.0 = fit; <1.0 = unfit (default = 1.0); 2.0 = MAXIMUM 
  
ratType1i = 1.0;     % If Type 1, ratio of insulin still produced by beta cells; 1.0 = normal, lower for 
Type 1 
ratType1g = 1.0;     % If Type 1, ratio of glucagon still produced by beta cells; 1.0 = normal, lower for 
Type 1 
ratType2i = 1.0;     % If Type 2, level of insulin resistance as ratio 
  
Cia = .3; %1.0 %0.035;    % Insulin Control Param, Non-Muscle Tissue; Gain  
Cib = 0.4; %1.0 %0.03;    % Insulin Control Param, Muscle;  now Cia + Cib = original C1; JW: .019 to .024 
Cga = 0.4*.287*100;   % Glucagon Control Param, Non-Musc scaled to pg/mL 
Cgb = 0.001*.287*100; % Glucagon Control Param, Muscle scaled to pg/mL 
insulindel = 0.15;    % Delay in hours (Man-Cobelli use 10 min, 0.15=9 min) 
Kid = 0.04;           % derivative 
  
%NEW PARAMS FROM COBELLI INSULIN MODEL--INSULIN ABSORPTION 
rat_ia = 0.5; %ratio of nonmonomeric:monomeric (slow:fast) insulin absorb. paths 
kai = 0.02*60; 
ka2 = rat_ia*kai; %rate constant of monomeric insulin absorption; originally 0.018*60 
ka1 = (1-rat_ia)*kai; %rate constant of nonmonomeric insulin absorption converted to /hr from /min; 
originally 0.0018*60 
kd = 8*0.0164*60; %rate constant of insulin dissociation 
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Kg = 0.4;             % /hr, Cg, ~P-action for glucagon, .4 or 1  NOT USED? 
Ki = 3.0;             % /hr, a4, Insulin elinimation rate 
Kgt = 1.0*.287;       % /hr, a5, Basal tissue elimination rate JW: WHY???  NOT WELL-USED (Mult by Cia, 
Cgb)? 
Kugf = (5./ratBM);    % forward rate (~1/tau) of glucose bolus (JW: now min rate, mid-range max nearly 
double) 
Kugs = (0.4/ratBM);   % min slow path rate (~1/tau) of glucose bolus (can be as high as double this double) 
Kugd = (5./ratBM);    % max digestive absorbtion rate (can be half of this at very low or high)  
Gugf = 0.98;          % digestive effectiveness ratio, fast carbs 
Gugs = 0.88;          % digestive effectiveness ratio, slow carbs 
Kui = 1./ratBM;       % forward rate (1/tau) of insulin bolus 
Kuga = 2.0;           % forward rate of bolus for slow glucose path 
Kgc = 8.;            % /hr, glucagon addition rate 
Knm_up = 1.0;         % /hr, non-muscle uptake (e.g., liver) without insulin signal 
Kmusc = 20.0;      % rate of delivery to muscle - for example, "10" would be a time constant of 6 min 
Grefi = 70;           % Ref thresh (BG) for insulin control 
Grefg = 110;           % Ref thresh (BG) for glucagon 
Greft = 90;           % Ref thresh (BG) for Non-muscle flux direction (due to GLUT2) 
Kg2Max = 2.0;         % Max for Non-muscle GLUT2 flux (gradient, without control action 
Ktintol = 12.*ratNONM;  % Ref thresh for non-musc tissue, g/Kg (  (typical body can store 2000 Kcal = 500 g 
of glycogen 
Kmintol = 14.*ratMUSC;  % Ref thresh for muscle (means 75% = 0.25 + 0.5 passed),  
                      % insref = 30; %pmol/L; %glucref = 120; %glucagon max pg/mL 
  
% Next three should add to basal metabolism, e.g., Kbr+Gbt+Gbm is "low side" of (glucose) basal metab (if 
fully sedentary, no complex foods)  
Kbr = ((20./4)*ratNONM);         % BG to steady consumption sink, no storage (mostly to brain, also 
erythrocytes), in Kcal/hr/4 = g/hr   
Gbt = metab*((10./4)*ratNONM);%/wnm;   % Non-musc tissue basal metabolic elimination (not brain, but liver, 
cardiac, adipose...), Kcal/hr/4;  
Gbm = metab*((6./4)*ratMUSC);%/wmu;    % muscle basal metabolic elimination rate, Kcal/hr/4;  
Kcarb = 0.2;                     % NEW: Carb scaling for dietary thermogenesis (normalized digestive 
thermic effect of food, using x5)  
  
%ADDED HILL PARAMETERS 
%note: for glut2 hill function, half is Greft and max is kg2max 
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kmxex = 10.0; %maximum gmgrad 
kse = 40.0; %half gmgrad 
kmxnm = 1.0; %max gtintol (half is ktintol) 
kmxm = 1.0; %max gmintol (half is kmintol) 
ksds = 5.0; %half slow digestive (max is kugs) - JW: not use? 
ksds2 = 20.0; %half slow digestive falling (min is kugs) 
ksd = 10.0; %half fast digestive (max is kugf) 
ksd2 = 100.0; %half fast digestive falling (max is kugf) 
  hs_max = 45; 
  hs_ks = 23; 
  hs_rate = 20; 
% Mapping/scaling Params: 
vratm = 0.1;         % ratio of volume_blood-plasma to volume_muscle tissue ... not used 
vratt = 0.1;         % ratio of volume_blood-plasma to volume_non-muscle tissue ... not used 
drat =  8.0*ratBM;   % NEW: Conversion of digestive mass flow in grams into ECF (blood plasma + 
interstitial) in mg/dL, scaled by BW 
wratm = (1/drat)/wmu;  % CHANGE: scaling from gluc blood conc (mg/dL) to gluc musc tissue amount in g, norm 
to mass of segment (g/Kg_musc) 
wratt = (1/drat)/wnm;  % CHANGE: scaling from gluc blood conc (mg/dL) to gluc non-musc tiss amount in g, 
norm to mass of segment (g/Kg_n-m) 
  
gratm = 0.01*wmu;   % for blood-muscle glucose gradient (e.g., exercise demand) 
gratt = 0.01*wnm;   % not used 
% NOTES:  % "normal" (70Kg BW) amount in blood plasma: (100 mg/dL)*(0.55*5L of blood) = (1 g/L)*(2.75L) = 
2.75g ~ 3 g total (lit ~ 4g) 
          % Adding in most of interstitial that is assumed to rapidly equilibriate for glucose: ~3.5*BP, 
thus let ECF = 12.5 L, so norm ~ 12.5 g total   
          % Consistent with Man-Cobelli: V = 1.88 dL/Kg * 70 = 132 dL = 13L 
          % "normal" amount in muscle: 0.012*30Kg ~= 350 g (or 1400 Kcal) - ~25x more in musc than BP_ECF 
          % "normal" amount in mon-musc (mostly liver): ~5 (3-8)?%*2.8Kg liver + ~1% adipose + other = 150 
g other (lit)   
          % side note: humans consume ~300 g/day, but OK with about 100 or so ... so multi-day store if no 
exercise? 
          % Ex, let density=1: if change of 10 mg/dL = 100 mg/L = 100 mg/Kg_ECF then 1300 mg transfer, or 
1.4 Kg to 30 Kg = .047 g/Kg   
          % Ex, conc grad: 100 mg/dL = 10 mg/L = 10 mg/Kg_ECF = .01 g/Kg_ECF) = .01*wmu g/Kg_tissue 
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          % Ex, for drat: if 12.5 g/hr added to, say, 12.5 L of BP, then added 1 g/L or 100 mg/dL added in 
1 hour, so mult by ~8    
  
% PREP FOR SIMULATION: 
delt = 0.01; tmin = 0;  tmax = 24;      % delt, tmax = 12 means 12 hours   JW CHANGE TO CHECK LONG_ACTING  
t = tmin : delt : tmax;        % t=0 is wakeup (e.g., 8 AM); t=16=midnight 
idel = insulindel/delt;       % number of samples for delay 
  
%CHOOSE Sofie Protocol HR Input 
%u = HRin_prot1(); %Tempo 
 %u = HRin_prot2(); %Circuit Training 
 %u = HRin_prot3(); %Long Run 
%u = HRin_prot4(); %40 min bike + 20 min run 
 %u = HRin_prot5(); %Sprint Intervals 
 %u = HRin_prot6(); %Long Anaerobic 
 u = HRin_noinput; %IF HR DATA IS NOT PROVIDED  
 deltu3 = zeros(1,2401); 
  
ug = 0.0; ui = 0.0;  ua = 0.0;  % init input matrix; residual produc levels  
% %u = [ug*ones(1,length(t)); ui*ones(1,length(t)); zeros(1,length(t));  ua*ones(1,length(t))]; 
u1fast = ug*ones(1,length(t)); u1slow = ug*ones(1,length(t));  u1carb = ones(1,length(t));  
% u = [ug*ones(1,length(t)); ui*ones(1,length(t)); zeros(1,length(t));  ua*ones(1,length(t)); 
zeros(1,length(t))];  % JW: added u5 
u1fast = ug*ones(1,length(t)); u1slow = ug*ones(1,length(t));  u1carb = ones(1,length(t));  
x = [zeros(5,length(t))];     % init state matrix size 
  
  
% SETTING INPUTS (time and magnitude): 
% Input 1: FOODSTUFF (MEALS) 
nmeals = 6;  %define beginning:end of meals (every 10 is 6 min), total Kcal/hr rate, prop fast carbs (on 
<0,1>): 
mbeg(1) = 50;    mend(1) = 75;    mtot(1) = 800.;  kfast(1) = 0.8; FracCarbs(1) = 0.8;   % breakfast (in 
Kcal/hr, area under curve is Kcal) 
mbeg(2) = 500;   mend(2) = 550;   mtot(2) = 800.;  kfast(2) = 0.8;   FracCarbs(2) = 0.7; % lunch (in 
Kcal/hr, area is ph*pw Kcals) 
mbeg(3) = 1300;  mend(3) = 1350;  mtot(3) = 1400.;  kfast(3) = 0.5;  FracCarbs(3) = 0.5;  % dinner 
mbeg(4) = 1800;  mend(4) = 1810;  mtot(4) = 600.;  kfast(4) = 1.0;   FracCarbs(4) = 1.0; % snack#1 
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mbeg(5) = 1000;  mend(5) = 1010;  mtot(5) = 600.;  kfast(5) = 0.2;   FracCarbs(5) = 0.5; % snack#2 
mbeg(6) = 800;    mend(6) = 810;  mtot(6) = 2000.;  kfast(6) = 0.5;   FracCarbs(6) = 0.8; % snack#3 
xtot(1:nmeals,1:5) = 0.0;  scale4(1:nmeals) = 0; scale5(1:nmeals) = 0; lost4(1:nmeals) = 0.0;    
for i = 1 : nmeals        % Pre-run to scale glucose conservation 
    u1fast(i,length(t)-1) = 0.0; u1slow(i,length(t)-1) = 0.0; 
    u1fast(i,mbeg(i):mend(i)) = mtot(i)*kfast(i);          % Area under fast meal curve in Carb-Energy   
    u1slow(i,mbeg(i):mend(i)) = mtot(i)*(1-kfast(i));   
    utotf(i) = (mend(i) - mbeg(i) + 1)*mtot(i)*kfast(i);  
    utots(i) = (mend(i) - mbeg(i) + 1)*mtot(i)*(1-kfast(i)); 
    xx(4,1) = 0.0; xx(4,1:length(t)-1) = 0.0;                 % Glucose, Stomach, fast meal path 
    xx(5,1) = 0.0; xx(5,1:length(t)-1) = 0.0; 
    % Glucose, Stomach, slow meal path 
    for ii = 1 : length(t) - 1 
       Gfast = fhill((xx(4,ii)),(Kugf/2),5,4) + fhillr((xx(4,ii)),(Kugf/2),30,4); % Kugf is mid-range max 
       Gslow = Kugs + fhillr(xx(5,ii),Kugs,10,4);        % Kugs is min, mid-range max nearly double August 
Fit 
       f(4) = Gfast*(Gugf*(u1fast(i,ii)/4) - xx(4,ii)); % + x(5,ii); % 1st-order on glucose bolus, coud be 
f8old  %JW changed!   
       f(5) = Gslow*(Gugs*(u1slow(i,ii)/4) - xx(5,ii)); 
       %%  
       for j =  4 : 5     
          xx(j,ii+1) = xx(j,ii) + f(j)*delt;       % Euler integration 
          xtot(i,j) = xtot(i,j) + xx(j,ii+1); 
       end 
    end 
    scale4(i) = (xtot(i,4)/utotf(i));   
    scale5(i) = (xtot(i,5)/utots(i));  
end 
  
for i = 1 : nmeals     % setting up input #1 (foodstuff) 
    u1fast(1,mbeg(i):mend(i)) = mtot(i)*kfast(i);    
    u1slow(1,mbeg(i):mend(i)) = mtot(i)*(1-kfast(i));  
    if i < nmeals  
    u1carb(1,mbeg(i):mbeg(i+1)-1) =FracCarbs(i); 
    elseif i == nmeals 
        u1carb(1,mbeg(i):length(t)) = FracCarbs(i); 
    end 
 
 
 
2
1
8
 
 
end 
  
% Input 2: Insulin Injections, as half-sine: 1: Regular (max in 2 hrs); 2: Fast (max in 1 hr); 3: Long-
acting (max in 6 hrs) 
%ninjec = 3;  %define beginning:end of meals (every 10 is 6 min), total Kcal/hr rate, prop fast carbs (on 
<0,1>): 
% Prep: 
t2r = [0 : 1 : 400];   u2r(1:length(t2r)) = sin(pi*(t2r/400));  % Regular half-sine 
t2f = [0 : 1 : 20];   u2f(1:length(t2f)) = sin(pi*(t2f/20));  % Fast half-sine 
t2s = [0 : 1 : 1200];  u2s(1:length(t2s)) = sin(pi*(t2s/1200));  % Slow half-sine 
itype = [zeros(3,4)]; idose = [zeros(3,4)]; ibeg = [zeros(3,4)]; iend = [zeros(3,4)]; 
itbeg = tmin/delt;  itend = (tmax/delt)+1; 
% Regular (max delivery in 2 hrs, through 4 hrs): give idose, ibeg 
itype(1,1) = 1; idose(1,1) = 0; ibeg(1,1) = 10;   iend(1,1) = ibeg(1,1) + 400;  
itype(1,2) = 1; idose(1,2) = 0; ibeg(1,2) = 475;  iend(1,2) = ibeg(1,2) + 400; 
itype(1,3) = 1; idose(1,2) = 0; ibeg(1,2) = 2100;  iend(1,2) = ibeg(1,2) + 400; 
% Fast-Acting (max delivery in 1 hr, ends 2 hrs): give idose, ibeg 
itype(2,1) = 1; idose(2,1) = 0; ibeg(2,1) = 1;   iend(2,1) = ibeg(2,1) + 10;  
itype(2,2) = 1; idose(2,2) = 0; ibeg(2,2) = 1325;  iend(2,2) = ibeg(2,2) + 20;    
itype(2,3) = 1; idose(2,3) = 0; ibeg(2,3) = 475;  iend(2,3) = ibeg(2,3) + 20;    
% Long-Acting (max delivery 6 hrs, ends 12 hrs): given idose, ibegitype(2,1) = 1; idose(2,1) = 5; ibeg(2,1) 
= 100;   iend(2,1) = ibeg(2,1) + 400;  
itype(3,1) = 1; idose(3,1) = 0; ibeg(3,1) = 10;  iend(3,1) = ibeg(3,1) + 1200;    
itype(3,2) = 1; idose(3,2) = 0; ibeg(3,2) = 1800;  iend(3,2) = ibeg(3,2) + 1200; 
for i = 1 : 3 
    for ii = 1 : 4 
        if iend(i,ii) > itend   % e.g., if end of day, then shorten array 
           iend(i,ii) = itend;    
        end 
        if ibeg(i,ii) < itbeg 
           ibeg(i,ii) = 0; 
        end 
        if idose(i,ii) > 0 
           if i == 1   % regular 
             u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2r(1:(iend(i,ii)-
ibeg(i,ii)+1)); 
           end 
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           if i == 2   % fast 
             u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2f(1:(iend(i,ii)-
ibeg(i,ii)+1)); 
           end 
           if i == 3   % slow 
             u(2,ibeg(i,ii):iend(i,ii)) = u(2,ibeg(i,ii):iend(i,ii)) + 1.414*idose(i,ii)*u2s(1:(iend(i,ii)-
ibeg(i,ii)+1)); 
           end     
        end  
    end 
end 
  
%IF/THEN CODE FOR DECIDING ON KA_RATE FOR SLOW VS FAST INSULIN PATHWAY 
%k as a function of insulin type, tissue at area of injection/infusion, and 
%increased blood flow of localized area 
%Fast if fast-acting insulin, increased blood flow (i.e. heat, exercise) 
%and lean tissue 
%k_rate = k_type*k_tiss*k_flow 
%by default k_tissue = k_flow = 1.0  % JW: not k_type 
%RANGES: k_type: 3 subgroups 
%        k_tissue: greater for people with excess body fat 
%        k_flow: greater for decreased flow 
  
% if itype(1,:) > 0 
%     k_type = 0.2; 
% elseif itype(2,:) > 0 
%     k_type = 0.5; 
% elseif itype(3,:) > 0  
%     k_type = 0.8; 
% end 
  
% if ratMUSC >= 1.0 
%     k_tissue = 0.2; 
% elseif ratMUSC < 1.0 
%     k_tissue = 0.8; 
% end 
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%WILL HAVE TO PUT AFTER EXERCISE INPUT 
% if u3 > 0 
%     k_flow = 0.2; 
% elseif u4 > 0 
%     k_flow = 0.5; 
% else 
%     k_flow = 1.5; 
% end 
     
  
% Input 3: Energy over time (power) consumed during Exercise (in Kcal/Hr) 
    % Notes: - Steady: WorkWatts/WorkEff, e.g., if max is 256 W = 220 Kcal/Hr, 220/.22 = 1000 Kcal/hr 
    %        - HRdiff in beats/min, e.g., if HRdiff = (HRmax-HRrest) = 170-70 = 100, then 10 Kcal/hr-HRdiff 
    %        - RRdiff in beaths/min, e.g., RRdiff = (RRdiff-RRrest) = ... 
    %        - PVO2Max: percent VO2max (can with resting being ~8% of this) 
    %        - If at <25% of VO2max: kcal/hr*0.6 (but at some stage higher), 25-50%: *0.7; 50-60%: *0.8 (or 
lower); >60%: *0.95 
WorkEff = 0.22;               % Efficiency in performing physical work (typically 20-25%, higher for 
skilled tasks) 
AerCap = 1100;                % Max capacity, in Kcal/hr, can map to "aerobic/mitochondrial" metrics (each 
with scaling capability): 
uptime = 1;  downtime = 1;  % exercise up-time & down-time, without using metric such as HR - hour is 100 
units 
intens =0; slopeu = intens/uptime; sloped = intens/downtime; % steady aerobic intensity, in Kcal/Hr 
u(3,350:(350+uptime-1)) = [slopeu*([1:uptime].*ones(1,uptime))];   % aerobic ramp up, for now  
u(3,(350+uptime):450) = intens;           % USER: Add exercise with intensity = kcal/hr (glucose) burned 
u(3,451:(451+downtime-1)) = [sloped*((downtime-[1:downtime]).*ones(1,downtime))];  
%CHAPTER 4 EXERCISE INPUTS 
HRrest = 60; 
HRmax = 200; 
  
%NEW HOROMONAL INPUT--Grow array to multiple levels--time dependent. 
uHM = ones(1,2401); 
uHM(700:800) = stressrat*uHM(700:800); 
  
% Input 4: DAILY ACTIVITY (using randomization) for u(4,:), in Kcal/Hr 
nactive = 3;   % "moving/fidgeting activity" time periods of the day where muscles consume glucose 
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abeg(1) = 200;   aend(1) = 250;    actave(1) = 100.0;   alow(1) = 0.7;  ahi(1) = 1.3; 
abeg(2) = 1100;  aend(2) = 1200;   actave(2) = 80.0;   alow(2) = 0.6;  ahi(2) = 1.4; 
abeg(3) = 1600;  aend(3) = 1700;   actave(3) = 60.0;   alow(3) = 0.7;  ahi(3) = 1.3; 
u4max = 50;     % assumed max Anaerobic in Kcal/hr before switch to mitochondrial/aerobic 
for i = 1 : nactive 
    u(4,abeg(i):aend(i)) = actave(i)*(alow(i) + ((ahi(i)-alow(i)).*rand(1,(aend(i)-abeg(i)+1)))); 
end 
  
% nsens = 19;  salo = 0.9;  saloM1 = 1/salo; sahi = 1.1;  sahiM1 = 1/sahi; sadiff = sahi - salo;  
% bt1 = 1250;  bt2 = 1325; bt3 = 1375;  % times for state magnitude behaviors 
% btlo = 1250; bthi = 1500;  % time window for examining behaviors (bt1, bt2 should be within this range) 
% bx_min = zeros(2*nsens+1,9);  bx_tmin = zeros(2*nsens+1,9);   % initializing behaviors for min 
% bx_max = zeros(2*nsens+1,9);  bx_tmax = zeros(2*nsens+1,9);   % init behaviors for max 
% bx_t1 =  zeros(2*nsens+1,9);  bx_t2 = zeros(2*nsens+1,9); bx_t3 = zeros(2*nsens+1,9);    % init behaviors 
for magn at strategic times 
% for isens = 1 : (2*nsens)+1 
% % bm, Cia, Cib, Cga, Kgt, Kugs, Grefi, Grefg, Greft, Gbt, wratm, wratt,Gratm 
%   switch (isens-1) 
%      case 1;   Ki     = salo*Ki;        case 2;   Ki     = sahi*Ki; 
%      case 3;   Cia    = salo*Cia;       case 4;   Cia    = sahi*Cia; 
%      case 5;   Cib    = salo*Cib;       case 6;   Cib    = sahi*Cib; 
%      case 7;   Cga    = salo*Cga;       case 8;   Cga    = sahi*Cga; 
%      case 9;   Kgt    = salo*Kgt;       case 10;  Kgt    = sahi*Kgt; 
%      case 11;  Kugs   = salo*Kugs;      case 12;  Kugs   = sahi*Kugs; 
%      case 13;  Grefi  = salo*Grefi;     case 14;  Grefi  = sahi*Grefi; 
%      case 15;  Grefg  = salo*Grefg;     case 16;  Grefg  = sahi*Grefg; 
%      case 17;  Greft  = salo*Greft;     case 18;  Greft  = sahi*Greft; 
%      case 19;  Gbt    = salo*Gbt;       case 20;  Gbt    = sahi*Gbt; 
%      case 21;  wratm  = salo*wratm;     case 22;  wratm  = sahi*wratm; 
%      case 23;  wratt  = salo*wratt;     case 24;  wratt  = sahi*wratt; 
%      case 25;  Kg2Max = salo*Kg2Max;    case 26;  Kg2Max = sahi*Kg2Max; 
%      case 27;  kmxex  = salo*kmxex;     case 28;  kmxex  = sahi*kmxex;  %new pars 
%      case 29;  kse    = salo*kse;       case 30;  kse    = sahi*kse;  %new pars 
%      case 31;  ksds   = salo*ksds;      case 32;  ksds   = sahi*ksds;  %new pars  
%      case 33;  Kmintol= salo*Kmintol;   case 34;  Kmintol= sahi*Kmintol;  %new pars 
%      case 35;  insulindel= salo*insulindel; case 36;  insulindel  = sahi*insulindel;  %new pars 
%      case 37;  Kid= salo*Kid;               case 38;  Kid  = sahi*Kid; 
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%      otherwise ; % no change, e.g., last run 
%   end  
%  
% SETTING INITIAL CONDITIONS: 
x(1,1) = 100.;                % Glucose, Blood, x1=xG0  
x(2,1) = (150*ratNONM)/wnm;  % Glucose, Non-Musc, AMOUNT, in g/Kg_non-m, e.g., 140 g/ 35 Kg = 4, & max ~20 
(~3-8% liver, ~1% adipose) 
x(3,1) = (300*ratMUSC)/wmu;  % Glucose, Musc, AMOUNT, in g/Kg_musc, e.g., 300 g/ 30 Kg = 10, & max ~600/30 
= 20 (2%) 
x(4,1)= 0.0;                 % Glucose Mass Flow, Stomach, fast meal path, in grams/hr glucose 
x(5,1) = 0.;                 % Glucose Mass Flow, Stomach, slow meal path, in grams/hr glucose 
x(6,1) = 1.0*ratType1i;      % Insulin, Blood, x6=xS0; default 1.0 mU/dL (7 mMol/L); for Type I, set to 0  
JW CHANGE 
x6(1:idel) = x(6,1);         % priming for delay 
x(7,1) = 0.0;                % Insulin, Tissue, forward path state, monomeric 
x(8,1) = 0.45*ratType1g ;    % Glucagon, blood; ~70 in pg/mL or 0.7 in micro-g/dL or ; for Type I, lower 
than 0.35  JW CHANGE 
x1d = 0.0; 
x(9,1) = 0.0;                % Insulin, Tissue, forward path state, monomeric 
x(10,1) = 0.0;               % Mitochondrial consumption  
%  
%PART OF SENSITIVITY ANALYSIS 
% bxmin(1:9) = x(1:9,1);  tbxmin(1:9) = btlo;  % seting up auto-behaviors 
% bxmax(1:9) = x(1:9,1);  tbxmax(1:9) = btlo; 
  
% LOOP FOR SIMULATION:    
GG = [zeros(14,length(t))]; 
u1sum = 0; u1slowsum = 0; 
x4sum = 0;  x5sum = 0; 
for i = 1 : length(t)-1    
  % NONLINEAR HILL Functionals: 
   
  % For Controllers: 
  % NEW NOTES:  Basal (non-meal) insulin level is about 1 mU/dL (70 pMol/L), and max is about 10 mU/dL 
  GCi = ratType1i*fhillp1(x(1,i),6,Grefi,4);     % New control action: ratio, with k_1/2 higher 
  GCi2 = u(2,i)*(ka1+kd); 
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  GCi_hs_mag = fhill(u(2,i),hs_max,hs_ks,1);  GG(10,i) = GCi_hs_mag; %Rate of exogenous infusion rate 
(pmol/kg/min) 
  GCi_hs_rate = fhill(x(9,i),hs_rate, kd, 1); GG(11,i) = GCi_hs_rate; 
  if (x1d > 0)  
      GCiD = Kid*x1d*ratType1i;  % rising, represents residual storage in pancreas, and "lead"    
  else 
      GCiD = 0.0;                % dropping, currently assumed 0 
  end 
  GCg = ratType1g*fhillrp1((x(1,i)),4,Grefg,4);     GG(2,i) = GCg;          % glucagon drive, sensing x1, 
strong if low 
   
  % For Digestive: 
  %Gfast = 0.5 + fhill(x(4,i),0.5,10,2); % rate at which fast stomach glucose enters blood, either x4 or u1 
(max overall is ~70 g/hr) 
  %Gslow = fhill(x(5,i),75,20,2); 
  %Gslow = 0.5 + fhill(x(5,i),0.3,4,2);  % rate for slow path 
  Gabs = (fhill(x(4,i),(Kugd/2),ksds,4) + fhillr((x(4,i)),(Kugf/2),ksd2,4))*u1carb(1,i);  GG(8,i) = Gabs; % 
Kugd is max, in mid-range 
  Gslow = (Kugs + fhillr(x(5,i),Kugs,ksds2,4))*u1carb(1,i); GG(9,i) = Gslow;  % Kugs is min, mid-range max 
nearly double August Fit 
  
  % For Non-Muscle   NEW 
  Gnm_glut2 = fhill((x(1,i)),Kg2Max,Greft,2) - (Kg2Max/2);   % bi-dir rate for non-musc, GLUT2 (mostly to 
liver, also pancreas, intestines, ...)  
   
  % For Intolerance (or could be used for glucose-to-fat conversion): 
  Gtintol = fhillr(x(2,i),kmxnm,Ktintol,8)+0.0;   GG(4,i) = Gtintol; % NL Hill - tissue intolerance, mult, 
1.0=none, <0.1,1> 
  Gmintol = fhillr(x(3,i),kmxm,Kmintol,8)+0.0;   GG(7,i) = Gmintol; % NL Hill - muscle intolerance, mult, 
1.0=none, <0.5,1>  
   
  % For Muscle (and exercise): 
  %NEW HR U5 
  %Take u3 and put through LPF with time constant of 6 min 
  %Perfect u3 and anticipated u3 informed by u5; as a function of u3 
  %Derivative of u5; sum the two 
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%   %U5 INPUT 
  
  
        %Case Study Anaerobic Threshold (AT) = 170 bpm = 80% of HRmax, or (170-48)/(191-48) = 0.85 
normalized 
        %Case Study AEROBIC ZONES:   Active Recovery = 0.7*AT = 111-126 bpm 
%                               Easy Aerobic = 0.8*AT = 128-145 bpm 
%                               Moderate Aerobic = 0.9*AT = 146-169 bpm 
%                               Threshold = 1.02*AT = 170-180 bpm 
% Maximal = 1.06*AT = 180-191 (max HR) 
  
%normalize HR 
  
%for j = 1:1:length(t) 
     
%     if u(5,j) >= 128 && u(5,j) <= 145 
%          u(3,j) = 0.8*AerCap; 
%         elseif u(5,j) > 145 && u(5,j) <= 169 
%             u(3,j) = 0.9*AerCap; 
%         elseif u(5,j) > 169 && u(5,j) <= 180 
%             u(3,j) = 1.02*AerCap; 
%         elseif u(5,j) > 180 
%             u(3,j) = 1.06*AerCap; 
%         elseif u(5,j) == 0 
%             u(3,j) = u(3,j); 
      
        %NEW STEPS 
      %1. Take steps zones and create a hill functional to map u3 ref to HR 
      %ref; use delta hr to get delta u3 that adds or subtracts 
      %normalize HR 
     urelHR(i) = (u(5,i)-HRrest)/(HRmax-HRrest); 
     upredex(i) =(u(3,i)/AerCap); 
     urelHR = upredex; %IF NO HR DATA AVAILABLE delt will be 0 
     kscale = 500; %scaling 
     if urelHR(i) == 0 
         u3new(i) = u(3,i); 
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     else  
      deltu3(i) = kscale*(upredex(i) - urelHR(i)); 
      u3new(i) = u(3,i) + deltu3(i); 
     end 
 %  end 
     
    if u(5,i) >= 1.25*HRrest && u(5,i) < 130 
    u(4,i) = 100; %200 would be 50 W 
    end 
%end 
  
  
  
  %BAND PASS Filter for fluctuation?  
%if (u3 is very high) & (u5 is very high) then (Gu35 is high) 
Gsh2_u35 = u(3,i)*(fhill(u(3,i),1,500,2)) * fhill(u(5,i),1,0.85,4);  GG(12,i) = Gsh2_u35;    % "aerobic 
effort"-related high stress hormone to f2 
%if (u4 is very high) & (u4 is fluctuating) & (u5 is high) then (Gu45 is high) 
Gsh2_u45 = (u(3,i)+ u(4,i))*(fhill(u(3,i) + u(4,i),1,100,2)) * fhill(u(5,i),1,0.5,2);   GG(13,i) = 
Gsh2_u45;     % "anaerobic effort"-related high stress hormone to f2  
%if (u5 is not low) & [(u3 is low) & (u4 is low) & (x4 is low)] then (Gu5 is higher)  
Gsh_ant = fhill(u(5,i),1, 0.8, 4)*[fhillr(u(3,i),1,100,2) * fhillr(u(4,i),1,10,2) * fhillr(u(4,i),1,10,2) * 
fhill(x(4,i),1,0.5,2)];  GG(14,i) = Gsh_ant; %HR is high and not exercising 
  
  
if Gsh2_u35 > 0  
    GfatAer = fhill(((u3new(i)/AerCap)), 0.4*AerCap, 0.2, 2); 
else 
    GfatAer = fhill(((u3new(i)/AerCap)), 0.3*AerCap, 0.3, 2); 
end 
  
  %GexerAer = 0.1*u(3,i) + fhill(u(3,i),10.0,500,1);  GG(5,i) = GexerAer;   % NL Hill - exercise 
consumption rate (muscle),  
 % GfatAer = fhill((u(3,i)/(AerCap)),0.3*AerCap,0.3,2); % proportion of fuel mix that is fats, normalized 
  GexerAer = (u3new(i)) - GfatAer; GG(5,i) = GexerAer;   % assumed energy of glucose within fuel mix 
  %if (u(3,i)) > 0  # JW COMMENTED OUT 7/24 
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  %    GexerAna = u4max;        % max out non-aerobic "activity" energy, to transition to need for aerobic 
  %else 
      GexerAna = 0;             
  %end 
  % Anaerobic max before aerobic, direct, assumed all glucose fuel, continues? Drops with slopeu? 
  GexerTot = (GexerAer + GexerAna);        % total glucose energy (not yet in grams-equivalent)               
  
  %Gmgrad = fhill(u(3,i),0.6,100,1) + fhill((x(1,i)-x(6,i)),0.04,100,1);     GG(6,i) = Gmgrad; % NL Hill - 
blood glucose loss, with muscle demand gradient 
  Kgrad = .0; 
  Gmgrad = fhill(u(3,i)/4.0,kmxex*ratType1i,kse,1) - 0.1*fhillr(x(1,i), kmxex*ratType1i,kse,1); % + 
Kgrad*(x(1,i)-(x(3,i)/gratm));     GG(6,i) = Gmgrad; % NL Hill - blood glucose loss, with muscle demand 
gradient 
  
  % State Equation Functionals (dx/dt=): 
  f(1) = drat*x(4,i)- Kbr/wnm - ((Cia*Gtintol)+(Cib*Gmintol))*x(1,i)*x6(idel) - uHM(1,i)*Gnm_glut2*x(1,i) - 
Gmgrad*(x(1,i)-(x(3,i)/gratm)) + (Cga+Cgb)*Kgt*x(8,i)*x(1,i); %- Gsh2_u45; % +uHRAer +uHRAna;  %*G4; 
%x(2,i)-;  %+Gb %Gluc Bl 
  f(2) = wratt*(uHM(1,i)*Gnm_glut2 + Cia*x6(idel)*Gtintol)*x(1,i) - wratt*Cga*Kgt*x(8,i)*x(1,i) - (Gbt + 
(Kcarb*x(5)))/wnm ; % - uHRAer - uHRAna; %.2*x(4,i)*x(5,i); %+.6*x(4,i); %*G4; % non-muscle tissue 
  f(3) = wratm*Cib*x(1,i)*x6(idel)*Gmintol - Gbm/wmu - wratm*Cgb*Kgt*x(8,i)*x(1,i) + wratm*(Gmgrad*(x(1,i)-
(x(3,i)/gratm)))  + ratmito*x(10,i); %g/kgmusc %+uHRAna +uHRAer %+kFAT*x(10,i); %+.4*x(4,i)*0.2*x(8,i)*G5; 
% musc tissue 
  f(4) = Gabs * ((u1fast(1,i)/4) + x(5,i) - Gugf*x(4,i)); % + x(5,ii); % Final common digestive rate 
  f(5) = Gslow* ((u1slow(1,i)/4) - Gugs*x(5,i));   % Slow low-GI path 
  f(6) = (ka2)*x(7,i) + (ka1)*x(9,i) - (Ki)*x(6,i) + GCi + GCiD ;  %+ Kid*x6(idel)+ (ka1)*x(9,i);  % 
insulin in blood plasma, up via controller; fast monomeric path 
  f(9) = (ka1*x(9,i)) - GCi_hs_rate + GCi_hs_mag;     % new insulin tissue state 
  f(7) = (kd*(x(9,i)) - (ka2)*(x(7,i)));%GCi_hs; %*GCi_hs; 
  f(8) = Kgc*(GCg - x(8,i));                 % glucagon in blood plasma (compare to f6) 
  f(10) = (Kmusc*((GexerTot + kprop*u(4,i))/4 - x(3,i) - x(10,i)))/wmito; % kcpt*(GexerAna+u(4,i)) - 
kFAT*(x(10,i)); %MITOCHONDRIAL CONSUMPTION STATE, GIVEN DEMAND 
  
  %Generate Simulation Iteration of States  
  
  for j =  1 : 10                       
    if x(j,i) < 0 
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      x(j,i) = 0.0; 
    end 
    x(j,i+1) = x(j,i) + f(j)*delt;       % Euler integration 
    if j == 4 
        x4sum = x4sum + x(4,i)*delt;  % integrating x4 to get total grams 
        u1sum = u1sum + (u1fast(1,i)/4)*delt; 
    end 
    if j == 5 
        x5sum = x5sum + x(5,i)*delt;  % integrating x5 to get total grams 
        u1slowsum = u1slowsum + (u1slow(1,i)/4)*delt; 
    end 
%PART OF SENSITIVITY    
%     if ((x(j,i+1) < bxmin(j)) & (i >= btlo) & (i <= bthi));   % behavior: finding low of state   
%        bxmin(j) = x(j,i+1);  tbxmin(j) = i+1 - btlo;  
%     end 
%     if ((x(j,i+1) > bxmax(j)) & (i >= btlo) & (i <= bthi)); % behavior: finding high of state 
%        bxmax(j) = x(j,i+1);  tbxmax(j) = i+1 - btlo;  
%     end 
%     if (i == bt1)            % behavior at t1 
%        bxt1(j) = x(j,i+1); 
%     end 
%     if (i == bt2)            % behavior at t2 
%        bxt2(j) = x(j,i+1); 
%     end 
%     if (i == bt3)            % behavior at t3 
%        bxt3(j) = x(j,i+1); 
%     end 
  end 
  x1d = (x(1,i+1) - x(1,i))/delt; 
  for ii = 1 : idel-1 
    x6(idel-ii+1) = x6(idel-ii);    % shifting for time delay 
  end 
  x6(1) = x(6,i+1); 
  
end     
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u1 = u1fast + u1slow; 
%FIGURE 1: 1) INPUT CURVES 2) X1 (BLOOD GLUCOSE)WITH THRESHOLD LINES 
%           3) TISSUE GLUCOSE, MUSCLE AND NON-MUSCLE (X2, X3) AND  
%               4) GLUCAGON AND INSULIN CONTROLLERS 
% 24 HOUR SIMULATION 
figure(1); set(2,'Color',[1 1 1]); 
hold on; 
 %tp = t(250:550);    up = u(:,250:550);    xp = x(:,250:550);   % ONE APPROACH: NEW VECTORS FOR PLOTTING 
 tpbeg = 0; tpend = 24;                                                                      % USE AXIS() 
TO PLOT PART OF T VECTOR (EASIEST?) 
subplot(5,1,1)                % Meal input, stomach state x4:         
  plot(t,u1(1,:),'k',t,x(4,:)*4,'r',t,u(3,:),'-.',t,u(4,:),'-',t,GG(5,:),':','LineWidth',1.5); hold on;    
  plot(t,x(5,:)*4,'g',t,x(10,:)*4,'b') 
  ylabel('G-Flow (Kcal/hr)','FontWeight','bold')  
  axis([tpbeg tpend 0 1200]) 
subplot(5,1,2)                          % Glucose states: 
   winl = [70*ones(1,length(t))];        % low glucose line  
   winh = [150*ones(1,length(t))];       % somewhat high glucose line 
   winhh = [200*ones(1,length(t))];      % very high glucose line, intol and/or to fat 
  plot(t,x(1,:),'r','LineWidth',1.5); hold on;  
  plot(t,winl,':',t,winh,':',t,winhh,':'); hold on; 
  ylabel('Gluc Bl (mg/dl)','FontWeight','bold') 
  axis([tpbeg tpend 40 280]) 
  
subplot(5,1,3)                          % Insulin input, states: 
 [hAx,hLine1,hLine2] = plotyy(t,x(6,:),t,x(8,:)); hold on;    % ,t,u(2,:),':',t,x(7,:),':' 
 set(hLine1,'LineStyle','-','LineWidth',1.5) 
 set(hLine2,'LineStyle','--','LineWidth',1.5) 
 ylabel(hAx(1),'Insulin (mU/dl)','FontWeight','bold') % left y-axis 
 axis(hAx(1),[tpbeg tpend 0 5])  % NEW, CAN COMMENT OUT 
 ylabel(hAx(2),'Glucagon (pg/dL)','FontWeight','bold') % right y-axis 
 axis(hAx(2),[tpbeg tpend 0 1.2]) % NEW, CAN COMMENT OUT 
 hold on; 
subplot(5,1,5) 
 plot(t,u(2,:),'r',t,x(9,:),'g',t,x(7,:)),'m'; hold on; 
ylabel('Exogenous Insulin') 
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 xlabel('Time (hours)','FontWeight','bold') 
 axis([tpbeg tpend 0 20]) 
  subplot(5,1,4)                          % Meal input, stomach state x4:         
   plot(t,x(2,:),':',t,x(3,:));    
   ylabel('Tissue','FontWeight','bold') %ADD MITOCHONDRIAL STATE HERE? SAME UNITS G/KG 
   axis([0 tmax 0 50]) 
  
   %plot GG HILL FUNCTIONALS  
% figure(2) 
% subplot(3,2,1) 
% plot(u(2,:), GG(10,:)) %RATE OF EXOGENOUS INFUSION 
% subplot(3,2,3) 
% plot(u(2,:), GG(11,:))  %MAGNITUDE OF EXOGENOUS INFUSION 
% subplot(3,2,4) 
% plot(t,GG(8,:), t,GG(9,:)) %FINAL DIGESTIVE AND SLOW DIGESTIVE 
% axis([tpbeg tpend 0 10]) 
% subplot(3,2,5) 
% plot(x(4,:),GG(8,:),'+') %FINAL DIGESTIVE AND INPUT 
% subplot(3,2,6) 
% plot(x(5,:),GG(9,:),'+') %SLOW DIGESTIVE AND INPUT 
  
  
%INSULIN STATES  
%figure(3); 
%subplot (2,1,1) 
%plot(t,x(6,:)) 
%ylabel('Plasma Insulin') 
%subplot (2,1,2) 
%plot(t,x(7,:)) 
%ylabel('Exogenous Insulin') 
%xlabel('Time (hours)') 
  
%PLOT MITOCHONDRIAL STATE 
% figure(4) 
% plot(t,x(10,:)); 
% ylabel('Mitochondrial State (g/kgmito/hr)') 
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%DEMONSTRATE HR CODE AND INFORMING U3 
% figure(6) 
% subplot(4,1,1) 
% plot(t, u(5,:)) 
% title('Heart Rate') 
% axis([5 10 0 200]) 
% subplot(4,1,2) 
% plot((t),deltu3) 
% title('Delt U3') 
% axis([5 10 -200 200]) 
% subplot(4,1,3) 
% plot(t,u(3,:),'g') 
% plot(t,u(4,:),'r') 
% title('U3 and U4') 
% axis([5 10 0 800]) 
% subplot(4,1,4) 
% plot(t,x(1,:),'k', t, x(2,:),'r', t, x(3,:),'b') 
% title('BG and Tissue') 
% axis([5 10 0 800]) 
  
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
%END OF SENSITIVITY ANALYSIS  
%    bx_min(isens,1:8) = bxmin(1:8);  bx_tmin(isens,1:8) = tbxmin(1:8);  % getting min behaviors 
%    bx_max(isens,1:8) = bxmax(1:8);  bx_tmax(isens,1:8) = tbxmax(1:8);  % getting max behaviors 
%    bx_t1(isens,1:8)  = bxt1(1:8);   bx_t2(isens,1:8) = bxt2(1:8);  bx_t3(isens,1:8) = bxt3(1:8);    % 
getting magn at times behaviors 
%    
%    switch (isens-1)    % switch back, after run 
%       case 1;   Ki     = saloM1*Ki;        case 2;   Ki     = sahiM1*Ki; 
%       case 3;   Cia    = saloM1*Cia;       case 4;   Cia    = sahiM1*Cia; 
%       case 5;   Cib    = saloM1*Cib;       case 6;   Cib    = sahiM1*Cib; 
%       case 7;   Cga    = saloM1*Cga;       case 8;   Cga    = sahiM1*Cga; 
%       case 9;   Kgt    = saloM1*Kgt;       case 10;  Kgt    = sahiM1*Kgt; 
%       case 11;  Kugs   = saloM1*Kugs;      case 12;  Kugs   = sahiM1*Kugs; 
%       case 13;  Grefi  = saloM1*Grefi;     case 14;  Grefi  = sahiM1*Grefi; 
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%       case 15;  Grefg  = saloM1*Grefg;     case 16;  Grefg  = sahiM1*Grefg; 
%       case 17;  Greft  = saloM1*Greft;     case 18;  Greft  = sahiM1*Greft; 
%       case 19;  Gbt    = saloM1*Gbt;       case 20;  Gbt    = sahiM1*Gbt; 
%       case 21;  wratm  = saloM1*wratm;     case 22;  wratm  = sahiM1*wratm; 
%       case 23;  wratt  = saloM1*wratt;     case 24;  wratt  = sahiM1*wratt; 
%       case 25;  Kg2Max = saloM1*Kg2Max;    case 26;  Kg2Max = sahiM1*Kg2Max; 
%       case 27;  kmxex  = saloM1*kmxex;     case 28;  kmxex  = sahiM1*kmxex;  %new pars 
%       case 29;  kse    = saloM1*kse;       case 30;  kse    = sahiM1*kse;  %new pars 
%       case 31;  ksds   = saloM1*ksds;      case 32;  ksds   = sahiM1*ksds;  %new pars  
%       case 33;  Kmintol= saloM1*Kmintol;   case 34;  Kmintol= sahiM1*Kmintol;  %new pars 
%       case 35;  insulindel= saloM1*insulindel; case 36;  insulindel  = sahiM1*insulindel;  %new pars 
%       case 37;  Kid= saloM1*Kid; case 38;  Kid  = sahiM1*Kid;  %new pars 
%    end  
%  
% end   % Param Sens Anal Loop (isens) 
% sens_xmin = zeros(nsens,8); sens_txmin = zeros(nsens,8); 
% sens_xmax = zeros(nsens,8); sens_txmax = zeros(nsens,8); 
% sens_xt1  = zeros(nsens,8); sens_xt2   = zeros(nsens,8); sens_xt3   = zeros(nsens,8); 
% for i = 1 : nsens 
%     sens_xmin(i,:)  = ((bx_min((2*i)+1,:)-bx_min(2*i,:))./bx_min(1,:))/sadiff;     
%     sens_xmax(i,:)  = ((bx_max((2*i)+1,:)-bx_max(2*i,:))./bx_max(1,:))/sadiff;     
%     sens_txmin(i,:) = ((bx_tmin((2*i)+1,:)-bx_tmin(2*i,:))./bx_tmin(1,:))/sadiff; 
%     sens_txmax(i,:) = ((bx_tmax((2*i)+1,:)-bx_tmax(2*i,:))./bx_tmax(1,:))/sadiff; 
%     sens_xt1(i,:)   = ((bx_t1((2*i)+1,:)-bx_t1(2*i,:))./bx_t1(1,:))/sadiff;  
%     sens_xt2(i,:)   = ((bx_t2((2*i)+1,:)-bx_t2(2*i,:))./bx_t2(1,:))/sadiff; 
%     sens_xt3(i,:)   = ((bx_t3((2*i)+1,:)-bx_t3(2*i,:))./bx_t3(1,:))/sadiff; 
% end 
% sens_all = [ sens_xmin' ; sens_txmin' ; sens_xmax' ; sens_txmax' ; sens_xt1' ; sens_xt2'; sens_xt3' ]; 
  
%~~~~~~HILL FUNCTION CODE~~~~~ 
%   function [dfh] = fhill(df,kmax,ks,nh) 
%     dfh = (kmax.*(df^nh))./((ks^nh) +(df^nh)); 
%   end 
%    
%     function [dfh] = fhillp1(df,kmax,ksp1,nh) 
%   ks = (9*(ksp1.^(nh))).^(1/nh);    % mapping 10% to 50% for any nh 
%   dfh = (kmax.*(df^nh))./((ks^nh) +(df^nh)); 
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%     end 
%    
%       function [dfh] = fhillr(df,kmax,ks,nh) 
%     dfh = (kmax.*(ks^nh))./((ks^nh) +(df^nh)); 
%       end 
%    
%  function [dfh] = fhillrp1(df,kmax,ksp1,nh) 
%   ks = ((1/9)*(ksp1.^(nh))).^(1/nh);    % mapping 10% to 50% for any nh 
%   dfh = (kmax.*(ks^nh))./((ks^nh) +(df^nh)); 
%   end 
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
%LITERATURE PLOTTING CODE% 
%u(3,:) = u3new; 
%Import Literature Data 
%t_moh = xlsread('Ins_clindata.xlsx', 'GI_avg', 'A3:A11'); 
%moh_gluc_potato = xlsread('Ins_clindata.xlsx', 'GI_avg','M3:M11'); %GI 41 
%moh_gluc_bread = xlsread('Ins_clindata.xlsx', 'GI_avg','N3:N11'); % GI 25 
%moh_gluc_spag = xlsread('Ins_clindata.xlsx', 'GI_avg','P3:P11');% GI 46 
%moh_gluc_bar = xlsread('Ins_clindata.xlsx', 'GI_avg','Q3:Q11'); %GI71 
%moh_gluc_juice = xlsread('Ins_clindata.xlsx', 'GI_avg','O3:O11');%GI 83 
  
%figure(1) 
%% %Mohammed et. al. GI 
%plot(t_moh,moh_gluc_potato); hold on; 
%plot(t_moh,moh_gluc_bread); hold on; 
%plot(t_moh,moh_gluc_spag); hold on; 
%plot(t_moh,moh_gluc_bar); hold on; 
%plot(t_moh,moh_gluc_juice); hold on; 
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
%%Aronoff, Blood Glucose, Insulin, and Glucagon, for normal and T1D 1) 
%%before injection and 2) after 
% aro_time_norm = xlsread('Ins_clindata.xlsx', 'Aronoff','A5:A17');  
% aro_norm_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','B5:B17'); %mg/dL 
% aro_norm_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','C5:C17'); %microU/mL 
% aro_norm_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','D5:D17'); %pg/mL 
%  
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% aro_time_T1D = xlsread('Ins_clindata.xlsx', 'Aronoff','F5:F16');  
% aro_T1Dinj_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','G5:G16'); %mg/dL 
% aro_T1Dinj_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','H5:H16'); %microU/mL 
% aro_T1Dinj_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','I5:I16'); %pg/mL 
%  
% aro_time_T1D2 = xlsread('Ins_clindata.xlsx', 'Aronoff','O5:O14');  
% aro_T1Dninj_BG = xlsread('Ins_clindata.xlsx', 'Aronoff','K5:K16'); %mg/dL 
% aro_T1Dninj_ins = xlsread('Ins_clindata.xlsx', 'Aronoff','L5:L16'); %microU/mL 
% aro_T1Dninj_gluc = xlsread('Ins_clindata.xlsx', 'Aronoff','P5:P14'); %pg/mL 
%  
% subplot(3,3,1) 
% plot(aro_time_norm, aro_norm_BG) 
% title('Aronoff Normal BG') 
% ylabel('mg/dL') 
% subplot(3,3,2) 
% plot(aro_time_norm, aro_norm_ins) 
% title('Aronoff Normal Ins') 
% ylabel('microU/mL') 
% subplot(3,3,3) 
% plot(aro_time_norm, aro_norm_gluc) 
% title('Aronoff Normal Glucagon') 
% ylabel('pg/mL') 
%  
% subplot(3,3,4) 
% plot(aro_time_T1D, aro_T1Dinj_BG) 
% title('Aronoff T1D BG after Inj') 
% subplot(3,3,5) 
% plot(aro_time_T1D, aro_T1Dinj_ins) 
% title('Aronoff T1D Ins after Inj') 
% subplot(3,3,6) 
% plot(aro_time_T1D, aro_T1Dinj_gluc) 
% title('Aronoff T1D Gluc after Inj') 
%  
% subplot(3,3,7) 
% plot(aro_time_T1D, aro_T1Dninj_BG) 
% title('Aronoff T1D BG before Inj') 
% subplot(3,3,8) 
% plot(aro_time_T1D, aro_T1Dninj_ins) 
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% title('Aronoff T1D Ins before Inj') 
% subplot(3,3,9) 
% plot(aro_time_T1D2, aro_T1Dninj_gluc) 
% title('Aronoff T1D Gluc before Inj') 
%~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
%%Yamamoto Subcutaneous vs. Intravenous (from Sekigami) Insulin Effect--Not sure how I feel about this 
data; 
%the source does not match what is presented and for children only 
% t_yam_sub = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','A4:A16'); 
% t_yam_iv = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','C4:C11'); 
% sub_ins_eff = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','B4:B16'); 
% iv_ins_eff = xlsread('Ins_clindata.xlsx', 'Yamamoto_ins','D4:D11'); 
% plot(t_yam_sub, sub_ins_eff);hold on; 
% plot(t_yam_iv, iv_ins_eff); 
% ylabel('Subcutaneous vs. Intravenous Ins Effect (/min)'); 
  
% %~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
% %Shimoda Peripheral Venous Insulin at 0.1 U/kg and Plasma Insulin Response 
% t_pvi =  xlsread('Ins_clindata.xlsx', 'Shimoda1','A4:A12'); 
% ins_conc = xlsread('Ins_clindata.xlsx', 'Shimoda1','B4:B12'); 
% plot(t_pvi, ins_conc) 
% title('Insulin Concentration (pmol/l)')
235 
 
 
 
 
